VISUALIZATION OF ULTRASOUND INDUCED CAVITATION BUBBLES USING SYNCHROTRON ANALYZER BASED IMAGING by Izadifar, Zahra
VISUALIZATION OF ULTRASOUND INDUCED CAVITATION BUBBLES USING 
SYNCHROTRON ANALYZER BASED IMAGING 
 
 
 
 
A Thesis Submitted to the College of 
Graduate Studies and Research 
In Partial Fulfillment of the Requirements 
For the Degree of Doctor of Philosophy 
In the Division of Biomedical Engineering 
University of Saskatchewan 
Saskatchewan 
 
By 
 
ZAHRA IZADIFAR 
 
 
 
 
 
 
 
 Copyright Zahra Izadifar, December, 2016. All rights reserved. 
 i 
 
 
PERMISSION TO USE 
In presenting this thesis in partial fulfilment of the requirements for a Postgraduate degree from 
the University of Saskatchewan, I agree that the libraries of this University may make it freely 
available for inspection.  I further agree that permission for copying of this thesis in any manner, 
in whole or in part, for scholarly purposes may be granted by the professor or professors who 
supervised my thesis work or, in their absence, by the Head of the Department or the Dean of the 
College in which my thesis work was done.  It is understood that any copying or publication or 
use of this thesis or parts thereof for financial gain shall not be allowed without my written 
permission.  It is also understood that due recognition shall be given to me and to the University 
of Saskatchewan in any scholarly use which may be made of any material in my thesis. 
Requests for permission to copy or to make other use of material in this thesis in whole or 
part should be addressed to: 
 
 Head of the Division of Biomedical Engineering 
 57 Campus Drive, University of Saskatchewan 
 Saskatoon, Saskatchewan S7N 5A9 
Canada 
 
 
 
 ii 
 
 
ABSTRACT 
Ultrasound is recognized as the fastest growing medical modality for imaging and therapy. Being 
noninvasive, painless, portable, X-ray radiation-free and far less expensive than magnetic 
resonance imaging, ultrasound is widely used in medicine today. Despite these benefits, 
undesirable bioeffects of high-frequency sound waves have raised concerns; particularly, 
because ultrasound imaging has become an integral part of prenatal care today and is 
increasingly used for therapeutic applications. As such, ultrasound bioeffects must be carefully 
considered to ensure optimal benefits-to-risk ratio. In this context, few studies have been done to 
explore the physics (i.e. ‘cavitation’) behind the risk factors. One reason may be associated with 
the challenges in visualization of ultrasound-induced cavitation bubbles in situ. To address this 
issue, this research aims to develop a synchrotron-based assessment technique to enable 
visualization and characterization of ultrasound-induced microbubbles in a physiologically 
relevant medium under standard ultrasound operating conditions.  
The first objective is to identify a suitable synchrotron X-ray imaging technique for visualization 
of ultrasound-induced microbubbles in water. Two synchrotron X-ray phase-sensitive imaging 
techniques, in-line phase contrast imaging (PCI) and analyzer-based imaging (ABI), were 
evaluated. Results revealed the superiority of the ABI method compared to PCI for visualization 
of ultrasound-induced microbubbles. 
The second main objective is to employ the ABI method to assess the effects of ultrasound 
acoustic frequency and power on visualization and mapping of ultrasound-induced microbubble 
patterns in water. The time-averaged probability of ultrasound-induced microbubble occurrence 
along the ultrasound beam propagation in water was determined using the ABI method. Results 
showed the utility of synchrotron ABI for visualizing cavitation bubbles formed in water by 
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clinical ultrasound systems working at high frequency and output powers as low as used for 
therapeutic systems. It was demonstrated that the X-ray ABI method has great potential for 
mapping ultrasound-induced microbubble patterns in a fluidic environment under different 
ultrasound operating conditions of clinical therapeutic devices. 
 Taken together, this research represents an advance in detection techniques for 
visualization and mapping of ultrasound-induced microbubble patterns using the synchrotron X-
ray ABI method without usage of contrast agents. Findings from this research will pave the road 
toward the development of a synchrotron-based detection technique for characterization of 
ultrasound-induced cavitation microbubbles in soft tissues in the future. 
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Chapter 1 Introduction 
Ultrasound, which is high-frequency sound waves inaudible to humans, has been a fast growing 
tool useful for imaging and therapy in modern medicine. Diagnostic ultrasound, so called 
‘sonography’, is the most widely used non-ionizing medical imaging technique. Sonography 
offers several distinct advantages including being noninvasive and painless for patients, accurate 
for most cases without X-ray radiation, portable, and far less expensive than magnetic resonance 
imaging (MRI). Ultrasound has been useful for therapy over the past 50 years. Since the 1950s, 
when low power ultrasound (1 MHz) was first used for tendinitis or bursitis, the use of 
ultrasound has been dramatically extended to different areas such as mechanically resolving 
kidney stones using high pressure-amplitude shockwaves, so called ‘lithotripsy’, uterine fibroid 
ablation, cataract removal, surgical tissue cutting, transdermal drug delivery and bone fracture 
healing [1]. 
Despite all benefits of ultrasound, undesirable bioeffects may occur during ultrasound therapy 
and imaging. Typical benefits and risks of therapeutic ultrasound are well-known to clinicians. 
Typical safety problems such as burns for ultrasound thermal-based therapy and hemorrhage for 
lithotripsy are known and relatively tractable [1]. In terms of diagnostic ultrasound, most of 
epidemiologic investigations are in favour of the safety of ultrasound imaging; however, there 
have been some reports that indicate a relationship between prenatal ultrasound exposure and 
adverse effects such as growth restrictions, delayed speech, and dyslexia [2]. These reports 
indicate that the diagnostic ultrasound safety information can be scattered, confusing or subject 
to commercial conflicts of interest [1]. In particular, the safety and risk of ultrasound imaging is 
of great importance because the use of diagnostic ultrasound has become such an integral part of 
today’s prenatal care. For all ultrasound applications, but especially for prenatal care and 
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diagnosis, minimization of side effects must be taken carefully into consideration to ensure an 
optimal risk to benefit ratio of the ultrasound [1]. 
While investigations are mostly concerned about clinically relevant variables such as acoustic 
output, exposure time, number of exposures per subject, and the timing during the pregnancy for 
ultrasound risk assessments, little attention has been paid to exploring the physics behind safety 
issues, such as ‘cavitation’ [2]. One reason may be the difficulties associated with the 
visualization and characterization of ultrasound-induced cavitation process. Thus, continued 
research is required to develop technique(s) and protocol(s) for assessing ultrasound-induced 
cavitation in physiologically relevant media (in-vitro studies), tissue mimicking phantoms (ex-
vivo studies) and animal models (in-vivo studies).  
To draw a road map toward defining the objectives of this research, this chapter aims to provide 
an overview of ultrasound medical applications, ultrasound-induced cavitation process and its 
safety concerns and detection methods, and synchrotron X-ray imaging as a potential detection 
technique for characterization of cavitation microbubbles. 
1.1. Therapeutic applications of ultrasound       
Acoustic waves are categorized into three categories of infrasound, sound, and ultrasound based 
on the three frequency bands in an overall spectrum of acoustic waves. Acoustic waves lower 
than 20 Hz are called infrasound, between 20 Hz and 20 kHz are called sound (audible sound), 
and greater than 20 kHz are called ultrasound. At frequency range between 1 and 20 MHz, 
practical application is made out of ultrasound in clinical medicine for diagnosis and therapeutic 
purposes. The biological effects associated with high frequency sound wave energy have been 
used for therapeutic purposes in medicine for many years. While the ultrasound bioeffects must 
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be minimized in diagnostic applications, they have been employed for therapeutic purposes 
including physical therapy, lithotripsy, targeted ultrasound drug delivery, trans-dermal 
ultrasound drug delivery, ultrasound hemostasis, cancer therapy, and ultrasound assisted 
thrombolysis [3, 4]. In particular, the ability to precisely focus ultrasonic energy onto targets of 
millimetre dimensions has brought a significant milestone in the development of focused 
ultrasound therapeutic applications. Focused ultrasound has shown promise for non-invasive 
thermal ablation of tumors in several organs, and is a promising alternative to standard treatment 
options including surgery, radiotherapy, gene therapy and chemotherapy. High intensity focused 
ultrasound (HIFU) has been used for the treatment of different types of solid malignant tumors 
such as pancreas, liver, kidney, bone, pancreas, prostate, breast, uterine fibroids, and soft-tissue 
sarcomas [5].  
Ultrasonic biological effects can be induced through heating (e.g. tumor ablation), nonthermal 
(e.g. acoustic cavitation, gas body activation, mechanical stress) and/or undetermined nonthermal 
mechanisms [6]. While ultrasound-induced cavitation is undesired for the heat-based ultrasound 
treatments, some therapeutic applications such as extracorporeal shock wave lithotripsy (ESWL), 
intracorporeal lithotripsy, and surgical ultrasonic instruments are based on the ultrasound-
induced cavitation. In contrast, HIFU takes advantage of both ultrasound-induced thermal effects 
and cavitation to induce required bioeffects for therapy. However, the timing, pattern and 
location of formation of cavitation bubbles are not well understood and remain unpredictable 
during therapeutic procedures. As such, continued studies are crucial for a better insight into the 
cavitation process. More specifically, the formation and collapse of the ultrasound-induced 
cavitation microbubbles under ultrasonic therapeutic procedures may need to be re-standardized, 
in terms of safety risks, for a range of therapeutic and diagnosis applications. 
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1.2. Ultrasound-induced cavitation (non-thermal) effects 
Cavitation is defined as the formation of bubbles (cavities) in a liquid  due to the strong negative 
pressure induced by the propagating acoustic waves through the fluidic environment [4]. The 
term ‘cavitation process’ refers to the events in which vapour- or gas- filled cavities are formed 
and then collapsed (implosion) in the ultrasound-exposed host medium. When an ultrasound 
wave is applied to a liquid (or a fluidic environment), the molecular structure of the medium 
goes through alternative expansion and compression cycles. As the cyclic expansions 
(rarefaction) and compressions travel through the medium, the rarefaction pulls molecules apart 
and the compression pushes them together. If the ultrasound wave is strong enough, the 
expansion cycle can overcome intermolecular binding forces and leads to a sudden pressure drop 
and creation of bubbles filled with gaseous substances (vapour) in the medium. These bubbles 
grow in size with the following expansion cycles of ultrasound until they reach an unstable size 
and then violently collapse. In succeeding cavitation processes, the cavities can grow and 
collapse violently with the release of enormous amounts of energy in the form of an acoustic 
shock wave, elevation in temperature, increased pressure, and release of visible light [5]. 
Multiple physical effects are associated with the growth and violent collapse of cavitation 
bubbles including direct physical phenomena such as luminescence, free radical formation, very 
high-pressure shock wave emissions, shear stress and high speed microjet production.   
1.3. Safety concerns of ultrasound applications  
Cavitation can cause substantial injury to cells due to the microexplosions associated with the 
high frequency expansion and collapse of the ultrasound induced microbubbles adjacent to the 
cells. Extreme temperature and pressure can be generated as a result of the serial ultrasound-
induced microbubble explosions. When a microbubble collapses, high-speed liquid jets are 
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produced and driven into the surface of the surrounding cells at a high speed of about 400 km/h, 
which causes serious damage in the impact zones and create newly exposed surfaces susceptible 
to damage [6]. Moreover, the high temperatures and pressures generated within the bubbles can 
generate highly reactive radical species from any contained vapour that can then chemically 
attack the surface.  In ultrasound therapy (i.e. HIFU), gas generation, caused by cavitation, 
suddenly changes the pattern of heat transfer induced by ultrasound, which consequently extends 
the margin of the lesion from the targeted area to surrounding healthy tissue [7].  
Furthermore, based on the fact that the ultrasound imaging is widely used in obstetrics and has 
become an integral part of prenatal care today, the safety risk assessments associated with the 
ultrasound-induced cavitation is of a great importance. In particular, the increasing trend of the 
use of ultrasound combined with microbubbles, as contrast agents for diagnostic imaging and 
drug/gene delivery vehicles, raises additional concerns. The ultrasound safety risks attributed to 
cavitation become a serious concern when it applies to prenatal care. Samuel and Eugenie (2001) 
recorded sound via a miniature hydrophone placed in a woman’s uterus during a standard 
sonography and described the sound “as loud as a subway train coming into the station” [8]. This 
might explain why ultrasound operators have to keep re-positioning the ultrasound transducer 
over the part of the fetus which they try to visualize; because the fetus moves away from the 
sound wave stream probably due to the induced heat, vibration or both [9]. In addition, there has 
been an increasing interest in the use of higher ultrasound frequencies and acoustic power for 
improved imaging resolution [10]. As the sound wave power increases, the potential cavitation 
hazard to the local tissue including cell damage and hemorrhage of blood vessels is elevated 
[11]. When the frequency increases, an inhomogeneous periodic field around the bubble can 
produce a small steady flow of fluid that is known as microstreaming [12], resulting in extremely 
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high shear stresses near the bubble surface. Cell membrane destruction and temporary alteration 
in permeability may be associated with this high shear stress [13] (e.g. at frequency range 
between 20 kHz and 2 MHz).  
1.4. Safety assessment detection techniques 
Over the past decades, different techniques have been investigated for detecting and mapping 
microbubbles. These techniques mainly include optical, acoustic, and scattering methods. Optical 
methods include high-speed photography, sonoluminescence, sonochemiluminescence, acoustic 
methods including active cavitation detection (ACD) and passive cavitation detection (PCD), and 
the Doppler method. Scattering methods include laser and synchrotron based X-ray methods. 
Each of these techniques has specific strengths and weaknesses for detection and mapping 
microbubbles. These signatures can be used to detect the microbubbles through physical and 
chemical techniques. There are a couple of techniques by which either exogenous microbubble 
or endogenous cavitation bubbles can be measured. Most published studies of visualization and 
detection of microbubbles come from in vitro experiments. There have been few attempts to 
detect microbubbles in animals [14, 15]. One challenge for in-vivo detection of the cavitation 
microbubbles is attributed to the high attenuation and inhomogeneous nature of tissues which 
affect the sound wave propagation and consequently the behavior of the ultrasound-induced 
microbubbles in-situ. 
The presence of cavitation can be indirectly assessed through a variety of physical and chemical 
methods [16]. These methods rely on the detection and measurement of free radicals, 
sonoluminescence, and acoustic emission created from cavitation bubbles [17]. In order to 
improve the efficiency of cavitation and microbubble application in clinical use, it has been 
attempted to optically observe the microbubbles and cavitation process as well as the interaction 
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between microbubbles and cell membranes. Different imaging systems, such as electron 
microscopy, flow cytometry [18], atomic force microscopy [19, 20], home-made instruments 
based on white light illumination [21], and ultra-high speed imaging with the Brandaris camera 
have been investigated for studying the interaction of pre-made microbubbles with ultrasound 
and membranes of artificial cells in-vitro. In in-vitro studies, high-speed cameras have been used 
for observing cavitation bubble behaviors [22-25]. Fluorescence microscopy imaging combined 
with high speed photography has been also used for studying the dynamic interaction between 
microbubbles and cell membranes. Another method of detecting and characterizing cavitation 
microbubbles is based on laser scattering of individual bubbles, in which the dynamics of the 
formation of spherically-shaped bubbles can be individually and precisely measured [26]. 
Acoustic detection of bubbles, either as active cavitation detection (ACD) or passive cavitation 
detection (PCD), is another technique with potential application for in in-vivo studies.  
Each imaging technique has its own advantages and disadvantages for studying microbubble 
behaviour. However, the potential of each technique for in-vivo studies and particularly for deep 
tissue monitoring of the microbubbles in the human body is considered as an important aspect of 
the detection method for future clinical study. 
1.5. Synchrotron detection technique 
Synchrotron radiation provides a highly coherent, collimated and brilliant light which offers 
potential for studying and directly visualizing microbubbles or ultrasound induced cavitation 
bubbles. Synchrotron X-rays are generated from electron charged particles accelerating in a 
storage ring. The electrons are ejected from an electron gun by a strong electric field and 
accelerated in a linear accelerator. The particles then enter a booster ring and are further 
accelerated to near the speed of light before being directed to the storage ring. In the storage ring, 
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the trajectory of the electron is changed by applying magnetic fields as the electrons travel 
through bending magnets. As a result, the electron velocity vector is changed, electrons are 
accelerated, and synchrotron light is radiated from the bending magnets. The benefits of 
synchrotron X-ray are high photon flux over a large range of energies, high brilliance, small 
angular beam divergence and high level of coherence. In addition, synchrotron X-ray enables us 
to use monochromatic X-rays for implementation of unique synchrotron-based imaging 
techniques such as K-edge subtraction and phase-based imaging techniques [27, 28]. 
Synchrotron radiation has led to the development of several biomedical imaging techniques [29-
32] with outstanding imaging capabilities, among which X-ray Phase Contrast Imaging (PCI) 
and analyser based imaging (ABI) have shown potential for the detection of microbubbles.  
Analyzer based imaging (ABI) is a phase sensitive imaging technique in which a monochromatic 
beam is prepared using a double crystal monochromator. The monochromatic X-ray wave field 
irradiates the object of study and is subsequently diffracted by an analyzer crystal. Depending on 
the refractive index of different features of the sample, X-ray diffraction takes place as X-rays 
travel through the sample. Based on properties of the analyzer crystal, the diffracted X-rays at or 
near the crystal’s Bragg angle are filtered and ultimately passed on to the detector, accentuating 
microstructural features of different components of the object. Due to the significant difference 
of refractive index between microbubbles and their surrounding medium (fluid), X-ray 
diffraction at the bubble-medium interface presents high contrast, making the ABI method a 
potential technique for visualizing ultrasound-induced microbubbles.  
1.6. Research objectives  
Overall, this thesis work aims to develop a synchrotron based X-ray imaging technique for 
detection and better understanding of the spatial distribution of ultrasound induced cavitation 
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bubbles to help optimize clinical ultrasound applications. The hypothesis of this research is that 
specific synchrotron phase-based X-ray imaging techniques such as Analyzer based imaging and 
phase contrast imaging techniques could visualize and provide further information regarding the 
presence and characteristics of ultrasound induced cavitation bubbles. Accordingly, the main 
objectives of this research are as follows: 
 To develop a refraction based synchrotron X-ray imaging technique for visualization of 
ultrasound-induced microbubbles in water  
 To characterize the ultrasound induced cavitation bubbles by observing the distribution 
of cavitation bubbles in terms of bubble distribution, location and density of cloud 
cavitation in water at different levels of ultrasound operating conditions.  
 To employ the ABI method for assessing the effects of ultrasound acoustic frequency 
and power on visualization and mapping the ultrasound-induced microbubble patterns in 
the water. 
 To identify the threshold ultrasound parameters causing bubble formation and collapse at 
different levels of frequencies and intensities. These findings may improve standards of 
ultrasound safety for a range of diagnostic and therapeutic applications, toward 
improving the biosafety of ultrasound applications in clinics. 
This dissertation has been organized into 8 chapters, including this introductory chapter. A series 
of comprehensive literature reviews are presented in chapters 2 to 5 as follow: Literature review 
on current trends and future applications and safety of therapeutic ultrasound in chapter 2 
(submitted to the Journal of Clinical Research), review on principles, devices, and clinical 
applications of high intensity focused ultrasound in chapter 3 (submitted to the Journal of 
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RadioGraphics), review on mechanical and biological effects of ultrasound in chapter 4 
(submitted to the Journal of Ultrasound in Medicine and Biology), and review on detection 
techniques of ultrasound cavitation and microbubble contrast agents are presented in chapter 5 
(Submitted to the journal of Measurement Science and Technology). Chapters 6 presents a novel 
synchrotron X-ray Analyzer Based Imaging technique for visualization of ultrasound induced 
cavitation bubbles and identifying the threshold ultrasound parameters causing cavitation bubble 
formation (published in the journal of Physics in medicine and Biology). The Analyzer Based X-
ray Imaging (ABI) technique was applied to detect ultrasound induced cavitation bubbles from a 
physical therapy unit and results were presented in chapter 7 (published in the journal of 
Biomedical Engineering Online). Finally, Chapter 8 concludes this dissertation by presenting the 
general conclusions drawn from this research. 
1.7. Contributions of the primary investigator 
The manuscripts included in this thesis are co-authored; however, it is the mutual understanding 
of all authors that Zahra Izadifar, as the first author, is the primary investigator of the research 
work. The contributions of other authors are greatly appreciated in this thesis.  
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Chapter 2 Applications and safety of therapeutic ultrasound: current 
trends and future potential 
This chapter has been submitted as “Zahra Izadifar, Paul Babyn, Dean Chapman, 2016, 
Applications and safety of therapeutic ultrasound: current trends and future potentials, Clinical 
Research (Under Review)” According to the Copyright Agreement, "the authors retain the right 
to include the journal article, in full or in part, in a thesis or dissertation".
 
2.1 Abstract 
The ability of ultrasound to penetrate deep into tissue and interact with human tissues via thermal 
and mechanical mechanisms has expanded its various therapeutic applications. In the 1950s, low 
power (1 MHz) ultrasound began being used for physical therapy of tendinitis or bursitis. In the 
1980s, high pressure amplitude shockwaves were used for kidney stone destruction in lithotripsy. 
Since then, ultrasound therapy has expanded significantly and is rapidly replacing surgery in 
clinics. Several major benefits of ultrasound derive from its minimally invasive nature compared 
to conventional open surgeries that disturb the overlying tissues. The minimally invasive 
therapeutic procedures have resulted in shortened recovery times and hospital stays as well as 
lowered risk of complications and cost. Ultrasound therapy may require local anesthesia or 
sedation, which is highly preferred over general anesthesia, especially for elderly patients. Some 
ultrasonic therapy techniques, such as cataract removal, surgical tissue cutting and hemostasis, 
transdermal drug delivery, and bone fracture healing, have been approved for widespread use. 
Other minimally invasive therapy techniques, such as focused ultrasound beam therapy for 
coagulating tissue, are on the verge of clinical approval. Therapeutic ultrasound methods work 
based on thermal and/or non-thermal (e.g., mechanical) mechanisms, with well-defined benefits 
and risks that include complications to the patient. Ensuring the benefits and minimizing 
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unwanted side effects depends on a clear understanding of the thermal and non-thermal 
biological effects of ultrasound as well as more accurate guidance of the ultrasound beam. In this 
chapter the basic principles behind thermal and non-thermal (cavitation) biological effects of 
ultrasound, as well as general information and safety considerations for a wide range of 
therapeutic ultrasound methods either under study or in clinical use are reviewed.  
2.2 Introduction 
Ultrasound can be employed in many therapeutically beneficial applications. In therapeutic 
ultrasound procedures, energy is deposited in tissue to bring about different biological effects for 
therapeutic benefit [1, 2]. The very first large-scale use of ultrasound for therapeutic benefit was 
in the 1930s [3] [4]; during World War II, people realized that the high-intensity ultrasound 
waves used to navigate submarines were heating and killing fish and the first therapeutic 
ultrasound mechanism of tissue heating and healing was envisioned [5]. This led to research 
using a focused ultrasound beam as an alternative to ablative procedures. As early as the 1940s, 
researchers tried to focus the ultrasound beam, strengthen the mechanism of heating at the focal 
point, and ablate tissue [6-9]. In the ensuing decades, the application of ultrasound for 
destruction of tissue in the brain for Parkinson’s disease treatment and of the vestibular nerve for 
Meniere’s disease treatment was explored [10, 11]. The use of ultrasound was also established by 
the 1970s in physiotherapy because of its ability to speed up the healing process (by giving rise 
to blood flow in the treated area), decrease pain, and gently massage muscles, tendons, and 
ligaments; research also continued into further applications related to neurosurgery [12] and 
cancer treatment [13]. In the 1980s, the use of ultrasound in high-pressure amplitude shockwaves 
for mechanical destruction of calculi such as kidney stones and gallstones into fragments small 
enough to be passed from the body (lithotripsy) came into use and replaced surgery [3]. In the 
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last two decades, advances in the fields of imaging, physics, and engineering have expanded 
ultrasound use to various applications in medicine, including dentistry (for dental cleaning and 
disinfection) [14], cataract treatment (for ultrasound phacoemulsification cataract surgery) [15], 
acoustic targeted drug delivery (for delivering drug to different tissues) [16], lipectomy (for 
internal and external ultrasound-assisted liposuction) [17-19], and high-intensity focused 
ultrasound (HIFU) and magnetic resonance guided focused ultrasound (MRgFUS) treatment (for 
non-invasive ablation of soft tissue in the area of cancer therapy and surgery) [20-24]. The 
purpose of this review is to briefly outline the common and recent developed therapeutic 
applications of ultrasound, together with general information and safety considerations for a 
wide range of therapeutic ultrasound methods either under study or in clinical use. The basic 
principles behind thermal and non-thermal (cavitation) biological effects are discussed. This is 
followed by the description of a wide range of ultrasound treatment methods using heating, 
cavitation, or combined mechanisms of action. Prospective new therapeutic ultrasound methods 
are also presented.  
2.3 Basic principles of ultrasound tissue interaction 
Ultrasound can interact with biological tissues through heating as well as through non-thermal 
mechanisms, including acoustic cavitation, gas body activation, mechanical stress, or other 
unknown non-thermal processes [25]. As the ultrasound beam travels through tissue, the 
amplitude of the original signal is attenuated due to absorption, reflection, or scattering at 
interfaces. When ultrasound passes through soft tissue, about 80% of the attenuation (energy 
loss) of the sound wave occurs through absorption. The amount of attenuation depends on the 
type of tissue. Table 2-1 shows the attenuation coefficient of different tissues, measured in 
decibels per centimeter at a frequency of 1 MHz. A higher attenuation coefficient means more 
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energy loss; the highest attenuation coefficient is for bone, which means bone particularly limits 
beam transmission [26]. 
Table 2-1 Ultrasound attenuation coefficients of different body tissues at a frequency of 1 
MHz [26] 
Type of body tissue Attenuation coefficient (dB/cm at 1 MHz) 
Water 0.002 
Blood 0.18 
Fat 0.63 
Liver 0.5-0.94 
Kidney 1.0 
Muscle 1.3-3.3 
Bone 5.0 
The attenuation coefficient is also directly affected by the applied frequency of the ultrasound 
wave and the distance the ultrasound wave travels in the body. Higher frequency waves are 
associated with higher attenuation and therefore limited penetration in tissue; in contrast, lower 
frequency waves have a lower tissue attenuation and therefore higher penetration depth [26]. For 
example, the attenuation of ultrasound waves by muscle, liver, and blood increases linearly with 
frequency, considering that muscle has a higher attenuation than liver, and liver has a higher 
attenuation than blood [26].  
The frequency and intensity of ultrasound waves are determined based on the particular 
therapeutic application being considered and the penetration distance into the body required to 
reach the target area. For example, in physical therapy applications ultrasound  is applied at a 
relatively low frequency so as only to generate enough heat for pain relief and to speed healing 
in injured joints or muscle tissue. At frequencies of 1, 3, and 5 MHz, the ultrasound penetrates up 
to 4, 2, and 0.5 cm into the body and generates tissue temperatures of up to 40, 42, and 44 °C, 
respectively [27, 28]. Different therapeutic applications of ultrasound and a comparison between 
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ultrasound frequency, therapeutic outcome, and related bioeffect mechanism are given in Table 
2-2. 
Table 2-2 Different therapeutic applications of ultrasound and a comparison between 
ultrasound frequency, therapeutic outcome, and related bioeffect mechanism (thermal or 
non-thermal) (table design based on [3]). 
Ultrasound 
Therapy 
Application 
Therapeutic Outcome 
Bioeffect 
Mechanism 
Frequency Reference 
Physical 
therapy 
Therapy of sports injuries, 
chronic inflammation, 
arthritis, and trauma 
heating 1 MHz Newman [28] 
Physical 
therapy 
Bone fracture healing unknown 1.5 MHz Gebauer et al. [29] 
Physical 
therapy 
Treatment of the most 
superficial of tendon injuries 
heating 3 MHz Draper et al. [27] 
Physical 
therapy 
Skin & facial rejuvenation, 
fat removal, cellulite, scars & 
scar tissue, sunburn, bruises, 
superficial cuts & scrapes 
heating 5 MHz Newman [28] 
Physical 
therapy 
Bone growth stimulation heating 1.5 MHz Szaboo [30] 
Hyperthermia Cancer therapy heating 1-3.4 MHz Samulski et al. [31] 
HIFU Uterine fibroid ablation thermal lesion 0.5-2 MHz Tempany et al. [32] 
HIFU Glaucoma relief thermal lesion 4.6 MHz Burgess et al. [33] 
HIFU Laparoscopic tissue ablation thermal lesion 4 MHz Klingler et al.[34] 
HIFU Laparoscopic or open surgery thermal lesion 3.8-6.4 MHz Ninet et al. [35] 
Focused 
ultrasound 
Skin tissue tightening thermal lesion 4.4-7.5 MHz Alam et al. [36] 
Extracorporeal 
lithotripsy 
Kidney stone destruction 
mechanical 
stress; 
cavitation 
~150 kHz Weizer et al.[37] 
Intracorporeal 
lithotripsy 
Kidney stone comminution 
mechanical 
stress; 
cavitation 
25 kHz 
Lowe and Knudsen 
[38] 
Extracorporeal 
shock wave 
therapy 
Plantar fasciitis epicondylitis unknown ~150 kHz Haak et al. [39] 
Phacoemulsifi
cation 
Lens removal 
vibration; 
cavitation 
40 kHz Packer et al. [40] 
Ultrasound-
assisted 
liposuction 
Fat tissue removal 
fat 
liquefaction; 
cavitation 
20-30 kHz Mann et al. [41] 
Cutting tissue Laparoscopic or open surgery thermal lesion 55.5 kHz Koch et al. [42] 
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and scaling 
vessel 
and vibration 
Intravascular 
ultrasound 
Thrombus dissolution 
gas body 
activation; not 
clear 
2.2 MHz Parikh et al. [43] 
Skin 
permeabilizati
on 
Transdermal drug delivery 
mechanical 
effect 
55 kHz Smith [44] 
Focused 
ultrasound 
Microbubble-aided gene 
delivery 
cavitation 
20 kHz-2 
MHz 
Porter and Xie [45] 
Ultrasound waves can distort and lead to a discontinuity or shock in the waveform as the 
pressure amplitude, the frequency, or the propagation length rises [3]. Decreasing frequency 
raises the probability of cavitation and gas body activation. Enhancing power or intensity tends 
to raise the probability and magnitude of all types of bioeffect mechanisms [3]. When ultrasound 
waves are transmitted into tissue, the acoustic pressures can become very large compared with 
the ambient pressure, with rarefactional pressure amplitudes of several megaPascals (MPa). This 
tensile stress is supported by the medium; for example, a diagnostic ultrasound scanner with a 
rarefactional pressure of 2 MPa has a negative tension that is 20 times atmospheric pressure (i.e., 
0.1 MPa) [3]. Fluid and tissue can withstand acoustic pressures greater than one atmosphere 
because of their cohesive molecular forces; however, their strength in this regard is limited. For 
longer times associated with ultrasonic frequencies at the lower end of the spectrum (e.g. 
approximately 20 kHz) and at high acoustic pressures (e.g. greater than 20 MPa), the fluid may 
form small gas bubbles [46], a phenomenon termed cavitation (described in the next section).  
Other biological effects of ultrasound can be considered the direct action of compressional, 
tensile, and shear stresses, and second-order phenomena include radiation pressure, forces on 
particles, and acoustic streaming [3]. Furthermore, secondary physical, biological, and 
physiological mechanisms such as vasoconstriction, ischemia, extravasation, reperfusion injury, 
and immune responses [47-49] can cause further effects. Sometimes the impacts of these 
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secondary effects are greater than the initial direct insult of ultrasound treatment [3]. The 
beneficial effects of therapeutic ultrasound include thermal and non-thermal effects. Thermal 
effects are due to the absorption of ultrasound energy, and non-thermal effects are due to 
cavitation, microstreaming, and acoustic streaming [1]. The ability to focus ultrasound waves 
enhances both thermal and non-thermal effects to a specific area of the body and has led to 
additional applications of focused ultrasound or high-intensity focused ultrasound for various 
therapeutic purposes. Thermal and non-thermal effects along with their related therapeutic 
applications are reviewed below. 
2.4 Cavitation effect 
Cavitation is defined as the creation or motion of very small gas bubbles that are produced in 
tissue due to the alternating expansion and compression of tissue as an ultrasound wave 
propagates through it. These bubbles are produced in two fashions, either inertial and non-
inertial (stable) cavitation [50]. Once the cavitation bubbles are produced, they may undergo 
nonlinear oscillations during many cycles of the acoustic wave, called “non-inertial cavitation”, 
or they may grow and collapse more or less violently,  called “inertial cavitation”[51]. When 
low-pressure acoustic ultrasound is applied, non-inertial cavitation bubbles oscillate in size but 
do not collapse. This oscillating motion causes the rapid movement of fluid near the cavitation 
bubble that is called “micro-streaming”. This micro-streaming can generate high shear forces 
that can lead to transient damage to cell membranes. This effect of non-inertial cavitation 
bubbles plays an important role in ultrasound-enhanced drug or gene delivery [52].  
As opposed to non-inertial cavitation, inertial cavitation occurs due to violent oscillation, rapid 
bubble growth during the rarefaction cycle of the acoustic wave, and then violent collapse and 
destruction of the bubble. This collapse generates a very high pressure shock wave (20000-30000 
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bars) and high temperatures (2000-5000 K) in the immediate microenvironment [50]. In addition, 
bubbles that collapse close to a cell wall or solid surface produce a very high-speed (~111 m/s) 
liquid jet that drives into the surface and results in pitting of the surface or cell wall [53].   
This cavitation activity can be initiated in tissue when suitable cavitation nuclei are present or 
can be induced directly by pulsating pre-existing gas bodies, such as in the lung or intestine, or 
those introduced via ultrasound contrast agents. This causes local tissue injury (including cell 
death and hemorrhage of blood vessels) in the immediate vicinity of the cavitation activity [3]. 
2.5 Cavitation-based applications of ultrasound 
Therapeutic applications of ultrasound based on cavitation include extracorporeal shock wave 
lithotripsy (ESWL), intracorporeal lithotripsy, and surgical ultrasonic instrumentation. The non-
thermal effects of ultrasound in the human body are the basis for ESWL [37, 54] for kidney stone 
destruction. The mechanism behind ESWL is that ultrasound waves focused over the kidney 
stone create shear waves that fracture the stone from within. The stone is shaved away from the 
outside through cavitation, resulting in cracks that are amplified by dynamic fatigue and further 
break the stone down [55]. To pulverize the stone to pieces less than 2 mm in size, which can 
pass naturally in urine, about 3000 ultrasound shock waves are triggered at a frequency of 2 Hz 
repetition rate at the stone location [3]. Shockwaves have also been used for gall stone 
destruction, but this technique is not yet in widespread use [3]. Some other orthopedic 
applications for conditions such as plantar fasciitis and epicondylitis have a similar basis as 
lithotripsy and have been approved and marketed [39]. The biological side effects of lithotripsy 
affect virtually all patients [56]. The technique breaks blood vessel walls and leads to bleeding 
into the connective tissue and interstitium. This can cause bruising of the parenchyma or 
formation of massive subcapsular hematomas [3]. Permanent loss of kidney mass then ensues as 
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result of inflammation and scar formation [57]. In addition, the lithotripsy-induced injury causes 
systemic blood pressure increases, kidney function decreases, establishment of hypertension, and 
an increased rate of stone return, and also exacerbates the problem of stone disease [3, 58]. 
Krambeck et al. [59] demonstrate a link between lithotripsy and diabetes mellitus. Furthermore, 
severe skin injury (second-degree skin burns) after ESWL have also been reported [60, 61]. Such 
challenging clinical side effects can result from the generation of cavitation bubbles in the 
coupling gel (due to poor gel quality) or a lack of probe surface uniformity.  
In intracorporeal lithotripsy, a rigid ultrasonic probe may be percutaneously manipulated and 
applied via the ureter for treatment of very large stones. In this technique, the stone is imaged by 
external ultrasound or fluoroscopy, or by ureteroscopy, endoscopy, or laparoscopy [3]. 
Hemorrhage, ureteral perforation, urinary tract trauma, and infection are considered risks of 
intracorporeal lithotripsy [3].  
Although the benefits of lithotripsy to patients are many, the considerable risks require more 
investigations toward safer devices as well as optimization of the therapeutic ultrasound safety 
standards.  
In biological research, frequencies as low as 20 to 90 kHz are applied to break up cells and 
tissues using a sonicator device [3]. Ultrasound-induced cavitation at low frequencies causes the 
break-up of cell walls and results in cell death. This is the basis behind ultrasound-assisted 
liposuction, a procedure in which excessive fat tissue is removed [41]; however, this procedure 
can result in bleeding, scarring, and infection [3]. 
Ultrasonic cavitation close to the probe tip can be used for very precise cutting in surgery. The 
ability of ultrasound to break up cells in the kHz frequency regime (e.g., a sonochemistry 
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device), has found wide applications in biological research for destroying cells for extraction and 
other reasons. Ultrasound devices working in kHz frequency regimes are routinely used in 
clinical surgeries. Some advanced surgical procedures operating at frequencies of 20 to 90 kHz 
for tissue cutting, hemostasis, and tissue removal are routinely applied in clinics [3]. In 
ophthalmology, the lens of the eye is removed using an ultrasound probe working at kHz 
frequency during eye surgery for phacoemulsification for cataracts [40]. Another application of 
kHz-frequency ultrasound probes are as “harmonic scalpels” to rapidly stop bleeding by 
coagulating blood due to localized frictional heating [42]. 
2.6 Heating effect of ultrasound 
Absorption of ultrasonic energy can lead to heating of tissues [3]. Ultrasonic-induced heating 
response in vivo is modified by the presence of bone, gas, and fluid. Sites in the body with higher 
absorption experience greater heating than surrounding tissues. For example, a calcified bone 
surface strongly absorbs ultrasound energy. Fetal bones absorb more energy compared to the 
surrounding fetal soft tissue, and the difference becomes greater as bone mineralization proceeds 
[46].  
Ultrasound is usually generated from a piezoceramic crystal in very short cycle pulses (i.e., 1- to 
5-cycle). Diagnostic ultrasound typically operates in the range of 2 to 12 MHz. Current 
diagnostic ultrasound equipment is unlikely to cause a temperature rise in tissue outside the 
normal physiological range [3]. Temperature elevation and potential bioeffects are kept 
negligible [62] by applying finite temporal average intensities and short exposure time principles 
[3]. However, hazardous temperature increases in tissue can occur during the use of 
physiotherapy ultrasound equipment. The heating caused by ultrasound is highly localized and 
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limited to the region of the ultrasonic beam. It is possible to expose and so heat the whole of the 
uterus at the very early stages of a human pregnancy [46]. 
2.7 Heating-based applications of ultrasound  
Heating is generated during therapeutic application of ultrasound either in the form of an 
unfocused beam with longer durations or focused ultrasound with a higher intensity than 
diagnostic ultrasound [3]. For example, in physical therapy the unfocused beam is utilized to 
treat tissues such as bone or tendon and enhance healing without injury; in contrast, a focused 
beam is utilized to concentrate the heat until tissue coagulates for purposes such as tissue 
ablation. Depending on the heat generated during ultrasound exposure, the effects can result 
from moderate heat, coagulative necrosis, tissue vaporization, or all three [3]. Therapeutic 
application of ultrasound based on heating can be subdivided into three categories: physical 
therapy, hyperthermia, and high intensity focused ultrasound.  
2.7.1 Ultrasound for physical therapy 
Physical therapists often use “therapeutic ultrasound”, which features an unfocused beam applied 
with coupling gel to warm tendons, muscles, and other tissues to treat conditions such as bursitis 
of the shoulder or tendonitis. This method of treatment uses sound waves to treat pain, 
inflammation, and muscle spasm. The purpose is to stimulate the tissue beneath the skin’s 
surface [63], improve blood flow, and accelerate healing [3]. Another application of ultrasound is 
sonophoresis or phonophoresis, in which ultrasound is used to assist transport of a compound 
into the skin [64]. As reported by Miller et al. [3], these techniques have a modest level of 
efficacy and patient benefit and a low level of risk. Ultrasound waves are applied to tissue by a 
round-headed transducer that can come in different shapes (Figure 2-1) to stimulate joints, 
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ligaments, tendons, muscles, and other tissues. The gel is used on the skin to decrease friction 
and act as a conductor of the ultrasonic waves [63].  
 
Figure 2-1 The different shapes of physical therapy ultrasound transducers widely used in 
clinics. 
The ultrasonic waves pass through the skin and, through vibration and cavitation, cause deep 
local heating of tissues, soothe inflammation, and relieve pain. This heating increases blood 
flow, causes tissues to relax, and helps decrease local swelling and chronic inflammation. The 
increase in blood flow also delivers more oxygen and a nutrient to the tissue, eliminates cell 
waste, and aids healing. Ultrasound can decrease the sensitivity and pain related to muscular 
trigger points. Physical therapy ultrasound can also be used to increase the delivery of applied 
drugs by enhancing the absorption of analgesics and anti-inflammatory agents to tissue through 
ultrasound waves.  
Physical therapy ultrasound is conducted at low frequency ranges that depend on the deepness of 
the target area for treatment in the body. The ultrasonic frequency is the inverse of the ultrasound 
wavelength and its penetration in the body, meaning a lower frequency results in a larger 
wavelength and deeper penetration, and vice versa. The amount of energy released to the target 
area depends on the frequency, power, and absorption coefficient of the substance through which 
the sound waves travel. Table 2-3 shows the typical frequencies used in physical therapy 
ultrasound units and related wavelengths, temperatures generated, and target organs. 
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Table 2-3 Typical frequencies used in physical therapy ultrasound units and their 
associated wavelengths, temperatures generated, and target organs. 
Frequency 
Ultrasound 
wavelength 
Penetration 
depth into 
the skin 
Temperatur
e generated  
Therapeutic 
outcome 
Reference 
1 MHz 1.6 mm 4 cm 
40 °C 
 (104 °F) 
Treatment of acute 
or chronic injuries 
and pain, bone 
injuries and 
arthritis treatment, 
nerve, muscle, 
tendon injuries and 
pain, arthritis, 
bursitis, wound 
care, exercise 
recovery; beauty-
related applications  
Newman [28]; 
Draper et al. [27]; 
Enwemeka [65]; 
Ebenbichler et al. 
[66, 67]; 
Langford [68] 
3 MHz 0.53 mm 2 cm 
42 °C 
 (106 °F) 
Treatment of 
superficial tendon 
injuries; beauty-
related applications 
for facial 
treatments such as 
cheeks, forehead, 
chin 
Draper et al. [27]; 
Newman [28]; 
Langford [68] 
5 MHz 0.3 mm 0.5 cm 
44 °C  
(108 °F) 
Beauty-related 
applications for 
facial treatment 
such as eye area 
Draper et al. [27];  
Newman [28]; 
Langford [68] 
 
2.7.2 Hyperthermia 
Another heat-based application of ultrasound is hyperthermia (also called thermal therapy or 
thermotherapy), in which ultrasound is used to heat a relatively large amount of tissue to about 
42 °C for reducing tumor growth in cancer therapy [69]. In hyperthermia, multi-element 
applicators are used at a frequency range of 1 to 3.4 MHz [70, 71]. Hyperthermia is almost 
always applied in conjunction with other cancer therapies, such as chemotherapy or radiation 
therapy [72, 73]. Many clinical trials have focused on such combined applications and many 
have shown a considerable reduction in tumor size [72, 73]. However, increased survival in 
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patients was not always observed [73, 74]. Research has shown that high temperatures damage 
and kill cancer cells. High temperatures damage proteins and structures within cells [75], cause 
less blood flow to the tumor by damaging blood vessels, and ultimately result in the death of 
cancer cells. However, the moderate heat produced in hyperthermia has not advanced to other 
clinical applications and has been replaced by high-intensity focused ultrasound [3].  
2.7.3 High-intensity focused ultrasound 
HIFU is one of the more active and developed research areas among all non-ionizing-energy 
methods, which include radiography, lasers, and microwaves [3]. The first application of HIFU 
was for thermal ablation of inoperable tissue related to Parkinson’s disease [10, 76]. This non-
invasive thermal ablation technique has been used for treatment of tumors in several organs and 
is on the verge of becoming an alternative to the standard treatment options of surgery, 
radiotherapy, gene therapy, and chemotherapy in future oncology practice. HIFU has been used 
for clinical treatment of different types of solid malignant tumors, such as those in the pancreas, 
liver, kidney, bone, pancreas, prostate, and breast, as well as uterine fibroids and soft-tissue 
sarcomas. The HIFU technique has FDA approval for clinical use in the USA for the treatment 
of uterine fibroids [32], cardiac ablation [35], visceral soft tissue ablation [34], and aesthetic 
treatment to lift the eyebrow [36, 77]. Other HIFU-based therapies are under study for clinical 
applications such as modulation of nerve conductance [78], benign prostate hyperplasia, and 
prostate cancer, but do not yet have FDA approval. HIFU has also been utilized in methods for 
curing glaucoma [33]. Other HIFU-based therapeutic techniques for the treatment of benign 
prostatic hyperplasia (BPH), prostate cancer [79, 80], hepatic cancer, and pancreatic cancer are 
still under investigation.  
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The HIFU technique focuses the ultrasound beam in a small area and generates a tissue lesion 
typically a few mm in diameter and in length. The absorbed energy raises the tissue to a lethal 
temperature, with very sharp thermal gradients so that the boundaries of the volume under 
ablation are clearly confined without damaging the overlying tissues [81]. In a HIFU system, a 
signal generator connected to a focusing transducer generates very high local intensities (greater 
than 1 kW/cm
2
 at the focal point) at frequencies ranging between 0.5 and 7 MHz [3]. In this 
method of treatment, the ultrasound beam is focused several millimetres to centimeters away 
from the transducer plane. In order to determine the location of the treatment zone and also 
monitor tissue changes in the target area, two image guidance and treatment monitoring methods 
are applied: magnetic resonance imaging (MRI) and ultrasound imaging. The related treatment 
techniques are called magnetic resonance guided focused ultrasound (MRgFUS) and ultrasound 
guided focused ultrasound (USgFUS), respectively. USgFUS systems incorporate both treatment 
and imaging modalities in one system. The ultrasound-based monitoring in HIFU treatment is 
based on a combination of sound velocity, attenuation, stiffness, and vapor content variation in 
the target area [82]. HIFU guided by ultrasound has limited target definition and monitoring 
capability of the ablation process. MRgFUS provides more accurate targeting and real-time 
temperature monitoring. MRgFUS surgery is a non-invasive thermal ablation technique in which 
MRI is used for target definition, treatment planning, and closed-loop control of energy 
deposition. In fact, MRgFUS as a therapy system allows targeting, localizing, and monitoring in 
real time without damaging normal structures. This precision has made MRgFUS an attractive 
method for surgical resection or radiation therapy of benign and incurable tumors. MRgFUS has 
been approved for treatment of uterine fibroids, and is undergoing clinical trials for the treatment 
of breast [83, 84], liver [85, 86], prostate [87-89], and brain cancer [90, 91] as well as to relieve 
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and lessen pain in bone metastasis [92-94]. Because MRI is capable of providing the temperature 
variation within the treatment zone [95], generating detailed images of soft tissues in the body, 
discovering a wide spectrum of space-occupying soft-tissue lesions, and creating real-time 
images and thermographic guidance during the procedure, MRgFUS has become a novel and 
non-invasive method of treatment. MRgFUS plays an important role in the development of 
neurotherapeutics and brain-based disorders and has been proposed as an alternative to open 
neurosurgical procedures for a wide variety of indications. Specialized MRgFUS systems have 
ultrasound therapy sub-systems integrated into MR-imagers. Such systems are employed in the 
treatment of uterine fibroids [32], breast cancer [96], and prostate cancer [97]. 
All of the above HIFU techniques are applied by external devices; however, natural orifices are 
also employed, such as in transrectal treatment of prostate cancer [98] and endoscopy via an 
intraductal probe for bile duct tumors [99].  
Non-invasive aesthetic applications of HIFU will provide a safer alternative to liposuction for 
cosmetic applications [100]. The exposure of superficial tissue to HIFU leads to a contraction of 
the dermis or to demolition of fatty tissue [77, 101]. In this technique, both thermal as well as 
non-thermal mechanisms of ultrasound are involved.  
HIFU has also been utilized to treat atrial fibrillation by tissue ablation to achieve pulmonary 
vein isolation [3].  
During HIFU applications, undesired tissue injury, unwanted burns, and pain can occur as 
significant ultrasound energy is delivered to a localized area of tissue [3]. In addition, HIFU can 
cause vasospasm and hemorrhaging when concomitant cavitation is also generated in the tissue 
[102], impotence and incontinence during prostate cancer treatment [103], or creation of an 
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atrial-esophageal fistula during atrial fibrillation treatment [104]. Furthermore, fistula formation 
and rib necrosis with delayed rib fracture [105] are also considered to be serious complications 
that can occur following hepatic and pancreatic cancer treatment [3].  
2.8 Therapeutic applications of ultrasound based on combined mechanisms 
Other therapeutic techniques involve multiple mechanisms of ultrasound. In intravascular 
catheters, a MHz-frequency transducer is placed near the tip for increasing dissolution of thrombi 
[43]. When the catheter is placed into a deep vein thrombus, the ultrasound is targeted radially 
into the thrombus or an infusion of a thrombolytic drug, such as tissue plasminogen activator, is 
delivered into the thrombus [3]. Ultrasound-assisted drug delivery significantly decreases 
treatment time by increasing the permeability of cell walls and the infusion of drugs into cells.  
Another application of ultrasound is skin permeabilization, which may replace multiple use of 
needles for drug delivery through the skin for medicines such as heparin and insulin [44]. Drug 
diffusion through the stratum corneum is difficult for molecules with a molecular weight greater 
than 500 Da [106]. Using low-frequency ultrasound (<100 kHz), the permeability of the stratum 
corneum (which is considered a protein diffusion barrier) increases [107] and the drug can pass 
and reach the inner layers and finally the capillary vessels where it is absorbed [108]. 
The use of low-intensity pulsed ultrasound (about 1.5 MHz) for accelerating the healing of bone 
fractures for cases such as non-union and non-healing fractures is another therapeutic action of 
ultrasound [3]. The biophysical mechanism behind this therapeutic action is not yet clear. 
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2.9 New research areas for therapeutic applications of ultrasound  
Several streams of research are investigating other therapeutic applications of ultrasound. These 
new methods mostly rely on low frequency and power ultrasound aided by microbubbles or very 
high power ultrasound for the production of vigorous cavitation [3].  
The application of low-frequency ultrasound for direct sonothrombolysis for treatment of 
thrombotic disease such as stroke is a new strategy [109]. However, this method showed 
increased brain hemorrhage in a clinical trial [110]. Microbubbles play an important role in 
increasing thrombolysis and improving stroke therapy [111].  
Another potential use of ultrasound is to produce cortical and hippocampal stimulation in mice 
[112]. Non-thermal mechanisms have been hypothesized to be responsible for the neuronal 
effects in this method, as the temperature gradients were very small (<0.01 °C) [3]. 
Ultrasound-aided drug delivery is another area of study. This technique is based on microbubbles 
and is under study for direct and targeted therapies that release drugs at a specific location within 
the body (such as a cancerous area) without affecting the rest of the body. It can also be used to 
force drug flow from a vessel out into the surrounding tissue and to increase intracellular 
delivery [3]. The advantage of ultrasound microbubble techniques over other techniques such as 
nanoparticle or liposome delivery systems is the capacity for external control [3]. DNA transfer 
in gene therapy applications has also been under extensive study [113].  
Histotripsy, equivalent to lithotripsy but at a higher frequency and with very high amplitude 
pulses, uses only the cavitation mechanism for tissue ablation [114] to homogenize targeted 
tissue, such as tumors, with little heating [115].  
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2.10 Summery 
Both thermal and non-thermal (cavitation) effects play very important roles in all therapeutic 
applications of ultrasound. These effects can be hazardous biologically, and are therefore 
avoided in diagnostic applications of ultrasound but used in therapeutic applications of 
ultrasound. The application of ultrasound at high levels of exposure has well-recognized adverse 
biological effects, which are harnessed for therapeutic purposes in most therapeutic devices. The 
use of therapy ultrasound devices comes with the risk of affecting healthy organs and causing 
substantial bioeffects. The benefits and potential risks associated with each therapeutic device 
should be considered and explained to patients. For example, non-invasive lithotripsy has 
tremendous benefits compared to conventional surgical treatment even though it has an increased 
risk of hemorrhage and longer-term kidney injury.  
Although measures and guidelines are in place to avoid unwanted bioeffects and deliberate 
caution on the part of the operator of the device can help decrease the risk of injury, safe and 
accurate use of ultrasound devices is essential to minimize the risks.  
The cavitation mechanism that is exploited to ablate tissue, disrupt cells, destroy kidney and 
bladder stones, and treat thrombolysis, among many other applications, is secondary to the 
ultrasound exposure. Microbubble-based therapeutic strategies are still under investigation for 
direct and targeted therapeutic purposes. The problems of dosimetry and control of cavitation 
and microbubbles are challenging. Researchers studying cavitation are endeavoring to 
understand medium and cavitation nuclei, the ultrasound field, and when cavitation occurs [3]. 
Understanding the connection between the cavitation threshold and the medium and cavitation 
nuclei is desired and understanding the ultrasound field requires accurate measurement of the 
ultrasound beam area. Knowing when cavitation occurs requires the direct observation or 
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indirect monitoring of cavitation events. Different detection techniques can quantify an 
ultrasound field [116, 117] and measure cavitation through the noise of bubble collapse [118]. 
However, considering the rapid development of therapeutic ultrasound techniques that mostly 
work based on cavitation and microbubbles, the emergence of more accurate and new cavitation 
detection methods is essential to monitor and control cavitation for optimum patient safety. 
Repeating treatments can serve to accumulate unwanted bioeffects and damage already 
compromised organs (e.g., the kidney in lithotripsy) and lead to permanent loss of organ 
function. Therefore, defining the cumulative dose and anticipating the level of bioeffects after 
each treatment is also required.  
Therapeutic applications of ultrasound directly depend on the interaction of the sound field with 
the tissue to induce the desired beneficial bioeffect. The exposure parameters used for ultrasound 
therapies are often noticeably different. This requires sufficient knowledge of acoustic 
mechanisms with respect to the interaction of ultrasound with tissue to improve the safety of 
ultrasound use and to facilitate the design of new therapeutic applications of biomedical 
ultrasound. Safety improvements in therapeutic ultrasound devices need to be pursued and more 
research should be dedicated to this issue. Exposimetry, dosimetry, and accurate and precise 
evaluation of acoustic fields in water and in situ should be done carefully and followed by animal 
studies to identify possible harmful bioeffects in humans. New accurate and more effective 
means of detection and monitoring of acoustic cavitation should be in place to continually 
regulate the acoustic output levels of therapeutic and diagnostic devices for their safe operation. 
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Chapter 3 High Intensity Focused Ultrasound: a Review of Principles, 
Devices, and Clinical Applications 
This chapter has been submitted as “Zahra Izadifar, Paul Babyn, Dean Chapman, High Intensity 
Focused Ultrasound: a Review of Principles, Devices, and Clinical Applications, RadioGraphics 
(Under Review)” According to the Copyright Agreement, "the authors retain the right to include 
the journal article, in full or in part, in a thesis or dissertation". 
3.1 Abstract 
The ability of ultrasound to penetrate deep into tissue and interact with human tissue via thermal 
and mechanical mechanisms has expanded its various therapeutic applications. The ability to 
focus the ultrasound beam and, as a result, ultrasound energy onto millimetre-size targets was a 
significant milestone in the development of therapeutic applications of focused ultrasound. 
Focused ultrasound is a non-invasive thermal ablation technique for treatment of tumors in 
several organs and is on the verge of becoming an alternative to the standard treatment options of 
surgery, radiotherapy, gene therapy, and chemotherapy in oncology practice. High-intensity 
focused ultrasound (HIFU) has been used for clinical treatment of different types of solid 
malignant tumors, including those in the pancreas, liver, kidney, bone, prostate, and breast as 
well as uterine fibroids and soft-tissue sarcomas. In addition, the capability of magnetic 
resonance imaging (MRI) to provide detailed images of soft tissues in the body and identify a 
wide spectrum of space-occupying soft-tissue lesions has accelerated the application of HIFU by 
providing real-time images and thermographic guidance during the procedure. Magnetic 
resonance guided focused ultrasound (MRgFUS) is a novel and non-invasive method of 
treatment that plays an important role in the development of neurotherapeutics and treatment 
options for brain-based disorders. MRgFUS has been proposed as an alternative to open 
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neurosurgical procedures for a wide variety of indications. The fundamental principles behind 
HIFU are the thermal absorption of ultrasound energy during transmission in tissue and the 
induced cavitation damage. This chapter briefly reviews heating and mechanical therapeutic 
applications of ultrasound along with an extensive review of the clinical applications of HIFU 
(MRgFUS). The clinical outcomes of HIFU ablation for tumor therapy, complications after 
treatment, and current challenges are also described. More recent developments in the 
application of HIFU for tumor treatment, HIFU-mediated drug delivery, vessel occlusion, 
histotripsy, movement disorders, and vascular, oncologic, and psychiatric applications are 
reviewed, along with potential future clinical applications of HIFU. 
3.2 Introduction 
Ultrasound can be employed in many therapeutically beneficial applications [1, 2] Medical 
therapeutic applications of ultrasound started in the 1930s [3]. The use of ultrasound for tissue 
heating represented an early clinical application of ultrasound [4]; this first therapeutic 
application of ultrasound was envisioned when people realized that the high intensity ultrasound 
waves used to navigate submarines during World War II were heating and killing fish [5]. As 
early as the 1940s, researchers tried to focus ultrasound waves on body tissues as an alternative 
to ablative procedures [6-9]. The application of ultrasound for destruction of tissue in the brain 
for treatment of Parkinson’s disease and of the vestibular nerve for treatment of Meniere’s 
disease was explored in the ensuing decades [10, 11]. The use of ultrasound for physiotherapy 
was established by the 1970s, and research continued into further applications related to 
neurosurgery [12] and cancer treatment [13]. In the 1980s, the application of ultrasound in high 
pressure-amplitude shockwaves for mechanical destruction of kidney stones (lithotripsy) came 
into use and replaced surgery [3]. In the last two decades, several advances in the fields of 
 42 
 
 
imaging, physics, and engineering led to the possibility of focusing ultrasound onto targets 
anywhere deep into body. Recently, high-intensity focused ultrasound (HIFU) and magnetic 
resonance-guided focused ultrasound (MRgFUS) in particular have proven effective as non-
invasive ablation modalities for soft tissue and been used to treat thousands of patients globally 
[14-18]. In fact, HIFU is the only completely non-invasive and extracorporeal method to treat 
primary solid tumors and metastatic disease. Scientific advances have facilitated the 
development and acceleration of a wide range of therapeutic methods now in use. Recent 
technical accomplishments have made MRgFUS a non-invasive and image-guided therapeutic 
approach that is proposed as an alternative to neurosurgical procedures for a wide variety of 
indications and brain disorders. This article begins by introducing the heating and mechanical 
(cavitation) effects of ultrasound in the body and briefly addresses their related therapeutic 
applications. HIFU therapy techniques are introduced and an overview of actual clinical 
activities in the field is given, including efficacy and safety measures. Clinical studies and 
outcomes of HIFU use for tumor therapy on different organs and related complications are 
presented. Recent investigations on intracranial MRgFUS in a range of clinical applications — 
from movement disorders, to vascular, oncologic, and psychiatric applications as well as brain-
based disorders — are also reviewed. The article concludes with a discussion of some potential 
future clinical applications for focused ultrasound as well as some prospective new research 
areas.  
3.3 High intensity focused ultrasound  
HIFU is one of the research areas that is more active and developed among all non-ionizing 
energy methods, which include radiography, lasers, and microwaves [3]. The lesion produced in 
the tissue due to HIFU is a few mm in diameter and in length [3]. The first application of HIFU 
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was for thermal ablation of inoperable tissue related to Parkinson’s disease [10, 19]. HIFU has 
also been used for treating uterine fibroids [20], cardiac ablation [21], visceral soft tissue ablation 
[22], and aesthetic treatment to lift the eyebrow [23, 24]. These methods have been approved by 
the Food and Drug Administration (FDA) for clinical use in the USA [3]. HIFU has also been 
utilized for curing glaucoma [25]. Other HIFU-based therapeutic techniques are under 
investigation for the treatment of benign prostatic hyperplasia (BPH) and prostate cancer [26, 
27], hepatic, and pancreatic cancer [28]. HIFU treatment is usually assessed, guided, and 
monitored by one of two image guidance methods: magnetic resonance imaging (MRI) or 
ultrasound imaging [29]. MRgFUS has proven to be an attractive modality for non-invasive 
thermal ablation of soft tissue. All of the above HIFU techniques are applied by external devices; 
however, natural orifices are also employed, such as in transrectal prostate cancer treatment [30] 
and endoscopy via an intraductal probe for bile duct tumor treatment [31]. Ultrasound 
monitoring in HIFU treatment is based on a combination of sound velocity, attenuation, stiffness, 
and vapor content variation in the target area [32].  
Energy-based thermal therapies apply various energy sources (e.g., radiofrequency currents, 
microwaves, laser, thermal conductor sources, and ultrasound) in clinical devices. Ultrasound 
provides several benefits over other competing technologies, including energy penetration to 
treat deep target areas, better focusing because of its small wavelengths, and precise control of 
energy deposition shape and location [33, 34]. HIFU with image guidance demonstrates the 
advantage of ultrasound energy and is increasingly being applied for tumor ablation [35].   
HIFU was developed in the 1940s as a permanent thermal tissue ablation approach [36]. The 
advantages of HIFU have recently expanded its clinical use to treatment of a variety of solid 
virulent tumors in a well-defined volume, including those in the pancreas, liver, prostate, and 
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breast, as well as uterine fibroids and soft tissue sarcomas. The advantage of HIFU with respect 
to conventional tumor/cancer treatment methods, such as chemotherapy, radiotherapy, and open 
surgery, is that HIFU is a non-invasive and non-ionizing treatment modality [36]. In fact, among 
tumor/cancer treatment modalities, HIFU is the only completely non-invasive and extracorporeal 
technique to treat primary solid tumors and metastatic diseases. Over 100,000 cases have been 
treated using HIFU, mainly in Asia and Europe, with great success [36]. The key to HIFU 
treatment is that the energy delivered is sufficient to increase the tissue temperature to a 
cytotoxic level very fast so that the tissue vasculature does not affect the extent of cell killing. 
Heat coagulation by HIFU is desired for cell reaction with chronic inflammation, with 
histological signs of fat necrosis in the surrounding normal fatty tissue [36]. The boundary width 
between totally disrupted cells and normal tissue is no more than 50 µm [37]. Deadly 
complications may develop if any vital blood vessels adjacent to the tumors are damaged. Large 
blood vessels are probably less vulnerable to HIFU damage compared to tumor tissue; however, 
this speculation is likely due to the fact that the blood flow dissipates the thermal energy from 
the vessel wall and results in safe ablation of the tumor. Surgical resection of a tumor is often 
contraindicated and may be dangerous when it is located close to major blood vessels [36]. HIFU 
has been widely applied in neurosurgery, ophthalmology, urology, gynecology, and oncology 
[26, 37, 38]. HIFU can pass through overlying skin and tissues without harming them and is 
focused to a localized tumor area with an upper size limit of approximately 3-4 cm in diameter 
for tumors; there is a very sharp boundary between dead and live cells when the tumor is ablated 
[36]. Figure 3-1 is a schematic of a HIFU transducer and the focused ultrasound beam it 
produces to pass through overlying skin and tissues and necrose a localized tumor region. The 
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tumor region may lie deep within the tissue. The affected area at the focal point that leads to 
lesion coagulative necrosis is shown in red in the figure. 
 
Figure 3-1 Schematic of high-intensity focused ultrasound for tumor therapy 
Many benefits justify further exploration of HIFU for additional future clinical applications: 
HIFU ablation results in reduced toxicity compared with other ablation techniques; it is non-
invasive and causes minimal pain; it is a low-cost procedure compared with surgery; it leaves no 
scars on the patient; recovery is faster compared with traditional surgery techniques; any 
bleeding that occurs during the procedure can be stopped by ultrasound; it has excellent 
repeatability as there is no dose limit; as it is guided by MRI or diagnostic ultrasound, as opposed 
to X-rays, there is no exposure to ionizing radiation; system maintenance costs are low; it causes 
very limited side effects to normal surrounding tissues [36]; patient comfort and safety are 
Transducer
Lesion of coagulative 
necrosis at focus
Skin
Tissue
Focused beam
Tumor
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maximized; undisturbed real-time visualization can occur during the procedure; and the 
technique is precise and easy to apply. In terms of limitations, HIFU treatment is sensitive to 
complications including metastasis, patient movement, and near-field heating, and the treatment 
time can be as long as several hours. 
3.4 Principles behind HIFU 
The basic principles of HIFU are coagulative thermal necrosis due to the absorption of 
ultrasound energy during transmission in tissue (thermal effect) and ultrasound-induced 
cavitation damage [36]. The heat generated by HIFU results in a rapid rise in temperature in the 
local tissue to more than 60 °C for 1 s, which leads to immediate and irreversible cell death in 
most tissues[36]. The highly focused ultrasound beam results in a very high intensity at the focal 
point of the beam within a small volume of about 1 mm in diameter and about 10 mm in length 
[36], which minimizes the potential damage to tissue outside the focal region. Thermal tissue 
damage due to high temperature exposure is dependent almost linearly on exposure time and 
exponentially on the temperature increase [39, 40]. A thermal dose of 43 °C for 120 to 240 
minutes coagulates cellular protein and tissue structure components, leading to immediate and 
irreversible vascular and immediate tissue destruction [33]. However, this threshold may vary 
with tissue type. The tissue at the border of the target area will die within 2-3 days [36]. 
Another mechanism involved in HIFU ablation is the mechanical effect. This mechanical effect 
including cavitation only occurs with high intensity acoustic pulses [36]. Cavitation can generate 
very high pressures and temperatures, high shear stress, and microstreaming jet liquids that can 
cause pitting of the cell wall. If the medium is mostly liquid and can freely move, then liquid 
movement can lead to the production of microscopic streaming, which can cause cell apoptosis 
[41].  
 47 
 
 
The nuclei of these apoptotic cells are self-destructed with quick degradation of 
deoxyribonucleic acid (DNA) by endonucleases. One of the delayed bioeffects in tissue exposed 
to HIFU can be apoptosis, especially in cells such as neurons that regenerate poorly [36]. 
3.5 HIFU devices for clinical applications  
The process of ablation can be monitored by ultrasound imaging (ultrasound guided high 
intensity focused ultrasound - USgFUS) as shown in Figure 3-2, or by MRgFUS as shown in 
Figure 3-3. 
There are three different ways to apply HIFU to the human body based on the accessibility of the 
targeted organ. When the organ is readily accessible, such as the kidney, HIFU is applied 
through an acoustic window on the skin by external or extracorporeal transducers. For cases like 
prostate cancer, however, a transducer is inserted into the body through the rectum (transrectal 
transducer) (Figures 3-4 and 3-5). Interstitial probes are being developed for the treatment of 
biliary duct and esophageal tumors and are inserted into the body through the mouth and placed 
close to the tumor (Figures 3-6 and 3-7). To focus the high-intensity ultrasound beam, a concave 
focusing transducer is used (Figure 3-1), or multiple piston transducers are arranged on the 
truncated surface of a spherical bowl (Figure 3-2), or a flat transducer is used with a fittingly 
designed acoustic lens (e.g., Model-JC, Chongqing HAIFU™, China) [36] (Figure 3-6). Because 
an extracorporeal device is used to distribute the incident energy over a large skin area, the 
device has a wide aperture and long focal length to decrease the acoustic intensity at the entry of 
the wave site to avoid skin burn. However, severe full skin burns following extracorporeal shock 
wave lithotripsy (ESWL) for renal calculi [42] or second-degree burns after shock wave 
lithotripsy [43] are often reported. Also, some patients face post-operative side effects, such as 
pain, vomiting, and wounds on their skin. For targets lying within the breast, abdomen, brain, or 
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limbs, an extracorporeal HIFU device is usually employed. The device couples the acoustic 
energy to the skin surface via a coupling gel or water balloon, with an appropriate entry window 
site on the skin so that the propagated focused beam is not interrupted by intervening gas. 
Transrectal and interstitial transducers usually operate at higher frequencies and lower powers so 
they can be applied at a closer distance to the target area. The devices developed for transrectal 
use have both therapy and imaging transducers incorporated into the head of the transducer probe 
with a fixed but adjustable focal point that can be mechanically moved to treat a larger tissue 
volume (Figures 3-2, 3-4, and 3-6). Prostate ablation is performed by creating lesions side by 
side and the ultrasound power is altered to adjust the lesion length (for the Ablatherm probe 
(Edap Technomed, France)). For thick prostates, deep lesions are achieved either by making 
separate lesions in two layers or by using a longer focal length [36]. For an interstitial transducer, 
instead of focusing the probe a plane transducer is usually applied and coagulation of the volume 
is achieved by rotating the probe [30]. When the probe is set in the body and 360° of rotation is 
achieved, then under fluoroscopic or MRI guidance the transducer is repositioned and another 
adjacent ring is produced. This device can be used for biliary and esophageal tumors or bloodless 
partial nephrectomy [36]. Interstitial devices can be derived from percutaneous, laparoscopic, or 
catheter-based ultrasound. Catheter-based ultrasound devices can be placed within or adjacent to 
the target volume directly to treat and coagulate a large volume of the target area, or they can be 
used as endoluminal and endovascular cardiac devices. The exposure time for catheter-based 
ultrasound devices is typically 10-30 min and the procedure is more invasive compared to 
external HIFU; however, this method has better energy localization [44]. Catheter-based 
ultrasound devices are under development for future clinical use for thermal therapy of cancer 
and benign tissue in the prostate, uterus (fibroids), liver, and bone. Devices for percutaneous 
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ablations have been successfully investigated in vivo (mostly in pigs) for organs such as the liver 
[45-47], prostate (in vivo studies mostly in pigs) [48, 49], brain (in vivo study in dogs) [50], and 
uterus (ex vivo trial on human uterine fibroids) [51]. To the best of our knowledge, no human 
trials of this device have been reported. Figures 3-2 and 3-3, respectively, show schematics of 
typical ultrasound- and MRI-guided focused ultrasound systems applied to the target through the 
skin for ESWL, extracorporeal shock wave therapy (ESWT), or HIFU.   
 
 
Figure 3-2 Schematic of the structure of an extracorporeal HIFU transducer, including 
both imaging and therapy probes, depicting an ultrasound-guided technique on a patient 
Ultrasound 
scanner
Ultrasound 
transducer
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Figure 3-3. Schematic of magnetic resonance-guided extracorporeal focused ultrasound 
system treatment technique 
Depending on the geometrical size and acoustic parameters of the transducers applied in a HIFU 
system, the beam size of a -6 dB HIFU system at its focal region is typically 1-3 mm in width 
and approximately 10 mm in length [36]. However, a 1-cm cancerous tumor is detectable and 
treatable with HIFU. The concern for inhomogeneity of tissue in abdominal-pelvic (such as in 
uterine fibroids and renal tumors) or transcranial usage that may cause distortion of the focal 
beam or a drop in focusing ability in deep-seated tissues is solved by application of the phase 
correction procedure in the HIFU system, as is done with ultrasound imaging systems [36]. 
When a larger volume is targeted for ablation, the transducers applied in the HIFU system are 
mechanically or electronically moved in discrete steps and fired at each point until the result is a 
confluent region of cell killing.  
Overall, the therapeutic ultrasound frequency depends on the application-specific treatment 
depth and the desired rate of heating required for treatment. Higher frequencies lead to lower 
penetration depths and lower frequencies lead to higher penetration depths. Frequencies as low 
Focused ultrasound transducer
MRI table Degassed water
MRI system
 51 
 
 
as 0.5 MHz have been used for deep treatments (such as transcranial applications) or high 
absorption situations and as high as 8 MHz for superficial treatments (such as prostate 
applications) [52]. Frequencies close to 1 MHz have been found to be the most useful for heat 
deposition and increasing temperature [36].   
In order to target and treat the desired region, the HIFU focus point needs to be scanned 
throughout the entire volume of tissue. Extracorporeal HIFU systems are guided by either 
ultrasound (USgFUS) or MRI (MRgFUS). MRI with high anatomical resolution and sensitivity 
for tumor detection offers accurate planning of the tissue to be targeted and treated. In addition, 
MR thermometry enables calculation of the thermal dose and also superimposes a representation 
on the anatomical image of the area in which the temperature reaches cytotoxic levels. It 
provides closed-loop control of energy deposition with a temperature accuracy of 1 °C, spatial 
resolution of 1 mm, and temporal resolution of 1 s during HIFU treatment [36]. Within seconds 
of HIFU exposure, MRI can provide temperature data and is superior to sonography for 
overweight patients [53] as it is not sensitive to fat tissue [54]. However, MRI is expensive, 
labor-intensive, and its temporal and spatial effects lead to underestimation of temperature. For 
example, the MRI-measured temperature by water proton resonance frequency of a voxel 
reached a maximum of only 73 °C after 7 s of continuous HIFU exposure after boiling started; 
however, the theoretical simulation predicted 100 °C after 7 s of exposure and an average 
temperature field of 73 °C in the volume of the MRI voxel (0.3 mm
8
 × 0.5 mm
8
 × 2 mm), which 
agreed with the MR thermometry measurement [55]. In comparison with MRgFUS, ultrasound 
imaging is more convenient and mechanically compatible, and provides the same form of energy 
for imaging as used for therapy. It provides the benefit of verifying the acoustic window with 
sonography in real time, which means that if the target region is not visualized by ultrasound 
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imaging before or during HIFU therapy, then it is unlikely that HIFU therapy will be effective in 
that specific region. The ablated target region is not visualized on standard B-mode images 
unless the gas bubbles produced in that focal region work as hyperechoic spots and appear in the 
image [36].   
Overall, both USgFUS and MRgFUS have benefits and drawbacks. USgFUS is good for 
preprocedural positioning of the target tumor, but not for intraprocedural evaluation of 
therapeutic boundaries [36]. MRgFUS is good for measuring the temperature that is temporally 
generated in the tissue, but not for measuring the mortal thermal dose [54]. Recently, sensitive 
microbubbles have been explored for raised ultrasound imaging [56]. MRgFUS as an integrated 
HIFU therapy system has recently become an attractive method for surgical resection or 
radiation therapy of benign and incurable tumors. MRgFUS has already been approved for the 
treatment of uterine fibroids, and is undergoing clinical trials for the treatment of breast [57, 58], 
liver [59, 60], prostate [61-63], and brain cancer [64, 65] and also to relieve and lessen pain in 
bone metastasis [66-68].  
Non-invasive aesthetic applications of HIFU will provide a safer alternative to liposuction for 
cosmetic applications [69]. The exposure of superficial tissue to HIFU leads to a contraction of 
the dermis or to demolition of fatty tissue [23, 70]. In this technique, both thermal as well as non-
thermal mechanisms of ultrasound are involved.  
HIFU has also been utilized to treat atrial fibrillation by tissue ablation to achieve pulmonary 
vein isolation [3].  
During HIFU applications, undesired tissue injury, unwanted burns, and pain can occur as 
significant ultrasound energy is delivered to a localized area of tissue [3]. In addition, HIFU can 
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cause vasospasm and hemorrhaging when concomitant cavitation is also generated in the tissue 
[71], impotence and incontinence during prostate cancer treatment [72], or creation of an atrial-
esophageal fistula during atrial fibrillation treatment [73]. Furthermore, fistula formation and rib 
necrosis with delayed rib fracture [28] are also considered to be serious complications that can 
occur following hepatic and pancreatic cancer treatment [3].  
3.6 Clinical Application of HIFU 
3.6.1 Liver 
Hepatocellular carcinoma (HCC) or malignant hepatoma is the most common type of liver 
cancer in humans and one of the most complicated types of cancer to treat. The common 
treatment method is liver transplantation. Surgical resection can change the nature of HCC in the 
early stage of the disease [74, 75], but survival rates for this method of treatment are only 25-
30% at 5 years [36]. The transcatheter arterial chemoembolization technique (TACE) that is 
widely used to achieve the cytoreduction of vital tumor tissue is not capable of complete necrosis 
of HCC but only embolization of the hepatic artery [76, 77]. HCC is a multifocal tumor and this 
specific biological behavior leads to poor surgical outcomes and a high risk of postoperative 
recurrence. Replacing surgery with a therapeutic system capable of selectively destroying 
multiple tumor nodules distributed throughout the liver would be a better option. In a study 
performed by Wu et al., the combination of TACE and external focused ultrasound treatment 
(performed 2-4 weeks after TACE) of advanced-stage HCC in patients showed an absence of or 
reduction in blood supply in the target area and longer survival time compared with TACE 
treatment only [78]. In another study in China, 68 patients with advanced primary liver cancer 
were treated by external HIFU; in 30 cases in which surgical excision followed HIFU, the tumors 
were completely ablated [79]. A total of 474 patients with primary and metastatic liver cancer 
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were treated with the same device in China [80]. In another study, 100 patients with liver cancer 
were treated with external HIFU and the clinical effect evaluated [81]. About 87% of patients 
showed symptomatic improvement after treatment, and CT and MRI scans after the procedure 
showed coagulation necrosis and blood supply decrease or complete disappearance of the tumor 
in the target area [81].  
Clinical trials of 68 patients at Royal Marsden Hospital in London showed that HIFU treatment 
for liver cancer is performed on fully conscious patients who are treated on an outpatient basis 
and without local anesthesia or sedation [82]. The procedure was well tolerated by all patients. 
All of the above studies featured ultrasound guided focused ultrasound therapy. However, the 
safety of focused ultrasound therapy can be greatly improved using MRgFUS [60]. In a case 
study of MRgFUS treatment of a patient with HCC (15 mm in diameter) [60], MRgFUS was 
concluded to be superior to USgFUS as it was more feasible and efficient. MRgFUS overcomes 
the limitations of ultrasonography and allows monitoring of temperature elevation in the treated 
tissue and detection of lesions deep in the body. Because MR imaging enables the evaluation of 
the treated volume immediately after treatment, the feasibility and safety of focused ultrasound is 
significantly improved [60].   
3.6.2 Prostate 
Transrectal HIFU for treatment of prostate cancer has shown promise in pilot studies. In the past 
decade, HIFU has been applied to both benign prostate hyperplasia and prostate carcinoma in 
medical centers in more than 100 sites in Europe, the USA, and Asia. The two commercially 
available therapy systems are the Ablatherm® (EDAP-Technomed, Lyon, France) and the 
Sonablate®500 (Focus Surgery, Indianapolis, IN, USA). In these devices, the endorectal probes 
containing the transducer and a diagnostic ultrasound imager are inserted into the body via the 
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rectum and placed close to the target (Figure 3-5). The transducer is designed to move both back 
and forth along the probe axis as well as rotationally 180° around the probe axis (Figure 3-4). 
This design allows for the production of consecutive lesions in a manner such that the focal 
lesions overlap laterally and longitudinally and generate the complete targeted prostate volume. 
Early experiences with HIFU for treatment of benign prostate hyperplasia in patients showed 
encouraging results [83, 84]. These studies showed the possibility of making irreversible lesions 
in the prostate tissue without any damage to the rectal wall. Even though these studies concluded 
that HIFU treatment is a safe treatment technique with minimal side effects and complications to 
relieve the symptoms of prostatism, the long-term outcome after transrectal HIFU therapy has 
been disappointing [85]. The effectiveness of treatment in these studies was evaluated by 
measuring prostate-specific antigen (PSA) nadir level (PSA is a protein produced in prostate) 
[86-90][88-92][88-92][86-90], biopsy [86, 88, 91], and assessment of quality of life including 
factors such as urinary incontinence and erectile dysfunction [86, 88, 89, 92] after HIFU 
treatment. Results showed a significant drop of mean and PSA nadir level after HIFU treatment 
with a promising survival rate in patients with PSA nadir levels ≤ 0.2 ng/mL [90]. Results 
showed that urinary incontinence was not affected by the treatment [86, 88, 91], except for one 
study that reported a general decrease in the symptom score for 63% of patients [92]; different 
erectile dysfunctions were reported depending on the number of patients and follow-up period 
[88, 91, 93-95]. The 2- to 5-years mid-term follow-up of HIFU treatment has shown  that the 
PSA level stays low and the negative biopsy rate stays about 90% [27, 36, 96, 97]. Repeat biopsy 
in disease-free patients showed a success rate ranging from 60 [26] to 80% [98]. The evaluation 
of biochemical disease-free survival rates 5 years after transrectal HIFU treatment of localized 
prostate cancer showed a decrease of serum PSA values to less than 4 ng/mL [99].   
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Complications of HIFU treatment, such as urinary retention, urinary infection, and urethral 
stenosis [94], were reported by many researchers. The rate of complications of HIFU prostate 
cancer therapy, such as urinary retention, incontinence, urinary infection, impotence, chronic 
pain, rectal fistulas, and incomplete treatment of disease [100] are higher with repeated HIFU 
treatment than for a single treatment [101, 102]. Transurethral resection of the prostate before 
treatment can mitigate urinary retention (ischuria) associated with HIFU treatment [101, 102] 
and decrease the time an indwelling catheter is required from 40 to 7 days [96]. 
Interstitial ultrasound applicators such as catheter-based ultrasound applicators were also tried in 
a clinical pilot study to deliver hyperthermia in connection with high dose rate brachytherapy for 
treating advanced prostate cancer and cervical cancer [103].  
In one study of 98 men for a period of 4 years, 43.8% of patients underwent salvage trans-
urethral resection of the prostate after initial HIFU therapy. Therefore, trans-urethral resection is 
still preferred over the current form of transrectal HIFU, and HIFU is not recommended for 
treatment of benign prostate hyperplasia [104]. Treatment of benign prostate cancer presents 
different problems from prostate cancer because prostate cancer is a multi-focal disease and 
detecting the facies with ultrasound is difficult [36]. HIFU ablation of the whole gland has been 
the most successful method of treatment [83, 84]. Compared to focal treatment, whole-gland 
treatment led to a decrease in tumor incidence from 35% to 17% and, in those patients that still 
had the disease after treatment, a decrease in tumor volume of greater than 90% [98]. In another 
study, five patients with unifocal, biopsy-proven prostate cancer (PCa) evident on MRI were 
treated by MRgFUS and then underwent radical prostatectomy [105]. Subsequent histopathology 
showed wide coagulative necrosis, with no residual tumor in the ablated area. Two patients 
showed two significant bilateral residual tumors outside the treated area that were not evident in 
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pre-treatment MRI. They reported an uneventful procedure with no adverse events or surgical 
difficulties through radical prostatectomy in relation to the previous MRgFUS. Clinical HIFU 
prostate cancer treatment has increased the control rates for the treated tumor from 50% at 8 
months in the early days to 90% in more recent experiments [36, 96, 106]. Overall, HIFU 
treatment of prostate cancer is more suitable for overweight patients, men over 65 years of age, 
or those who are not candidates for surgery [107].   
 
 
Figure 3-4 Schematic of a typical transrectal transducer for prostate cancer treatment, 
with both therapy and imaging transducers incorporated into the head of the transducer 
probe.  Longitudinal and lateral rotation movements of the transducer along with the 
imaging probe enable volume ablation and scanning of prostate cancer. 
HIFU transducer
Imaging probe
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Figure 3-5 Schematic of a transrectal ultrasound transducer (rectal HIFU probe) and the 
treatment technique used for prostate cancer treatment. The HIFU ultrasound probe is 
inserted into the rectum and the sound waves target the cancer-affected areas in the 
prostate gland. 
3.6.3 Breast Cancer 
Patients with breast cancer who desire breast conservation usually undergo lumpectomy 
followed by external radiation therapy. Nonsurgical ablation can be a good approach as part of 
breast-conservation therapy in patients with early-stage breast cancer. This can be cosmetically 
and psychologically more satisfactory than conventional breast conservation treatment therapy. 
HIFU is one of the nonsurgical, non-invasive, and effective techniques to affect local tumor 
necrosis and can be an effective approach for treating patients who are a high surgical risk as it 
involves less anesthesia, shorter recovery time, lower cost, lower infection risk, and no scar 
formation [108]. HIFU can precisely deliver energy to a target point in soft tissue without 
affecting skin integrity. In several clinical studies of breast cancer, tumor ablation treatment with 
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HIFU was employed [108-116], including applications for invasive lobular carcinoma, invasive 
ductal carcinoma, and invasive mucinous adenocarcinoma [110, 114]. In most of these studies, 
the tumors were located a distance of less than 1 cm from the skin, nipple, or rib cage and could 
be visualized and targeted for treatment [109, 110, 114]. The clinical devices used in these 
studies included ultrasound guided HIFU using a model JC system [80, 109, 113] that consisted 
of a 12-cm diameter geometrically focused transducer with a 9-cm focal length operating at a 
frequency of 1.6 MHz [109-111]; MRI-guided HIFU using an ExAblate 2000 unit (InSightec 
Ltd., Hifa, Israel) [108, 110, 112, 114] that provided planning and real-time thermal monitoring 
in a closed-loop procedure [110]; or various kinds of custom-made MRgFUS systems [115, 116] 
that included focused ultrasound transducers operating at frequencies of 1.7 [115] and 1.5 [116] 
MHz. Intravenous sedation, general anaesthesia [109, 111], or no anaesthesia [115] were 
employed in these studies. The size of the ablated breast lesion and margin of breast tissue were 
about 1.5-2.0 cm around the visible tumor in each case [109, 111, 113]. Local mammary edema 
in all patients immediately after HIFU treatment, minimal skin burn [44, 45, 46, 47, 49], very 
few severe (2nd- or 3rd-degree) skin burns [108, 110, 112, 114], and a few minor adverse events 
were reported. Coagulation necrosis rates of 100% [109, 111, 113], 97% [110], and 88.3% [114] 
in the treated breast volume were reported. At 5-year follow-up, a disease-free survival rate of 
95%, recurrence-free survival rate of 89%, and average 90% reduction in tumor size were 
reported [111]. HIFU is capable of inducing destructive and sub-lethal damage to tumors with a 
loss of propagation activity [115]. The main limitation of these HIFU methods for breast cancer 
treatment is the inability to assess the margin status mainly due to the lack of pathological 
specimens.  Imaging-based assessments such as radiology and post-procedure contrast-enhanced 
MRI should replace conventional histopathology [36]. In breast fibroadenomata (FAD), which 
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are benign lesions found in about 10% of women, exceptsurgical removal of the lump or 
vacuum-assisted mammotomy other techniques such as HIFU, cryo-, or laser ablation have also 
been applied for treatment. A comprehensive review by Peek et al. compared these ablative 
techniques for treatment of breast FAD [117]. All of the ablative techniques were minimally 
invasive and looked promising for the treatment of FAD; however, heterogeneity between 
studies was observed. Further randomized trials including a larger number of patients are 
required to determine which ablative technique is most precise [117]. 
3.6.4  Uterine fibroids 
Uterine fibroids (also known as uterine leiomyoma) are benign smooth muscle tumors of the 
uterus (also of the fallopian tubes, broad ligament, or cervix) and are one of the most common 
female pelvic tumors, occurring in about 25% of women [118]. Most women have no symptoms 
while others may have heavy and painful periods, pelvic pain, menorrhagia, dysmenorrhea, 
dyspareunia, increased urinary frequency, and infertility [36]. As most women are interested in 
fertility preservation and reduced recovery time after uterine fibroid treatment, a less invasive 
treatment of uterine fibroids is in high demand. The most recent clinical trials conducted with 
more than 2000 patients employed four different commercially available systems: an ExAblate 
2000 system (Insightec, Haifa, Israel), a Haifu JM therapeutic system (JM2.5C, Chongqing 
Haifu Technology Co., Ltd., China), a HIFUNIT 9000 tumor therapy system (Shanghai Aishen 
Technology, Shanghai, China), and a custom made mobile HIFU unit with a 1.07 MHz 
ultrasound source (Storz Medical AG, Kreuzlingen, Switzerland). The superior soft tissue 
contrast capability of MRI has led to its use for further characterization of fibroids and also for 
symptomatic uterine fibroid treatment with MRI-guided focused ultrasound. MRgFUS was 
approved by the US FDA in 2004 and more than 2000 patients have since been treated in the 
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United States [119-121], the United Kingdom, Germany, and Israel [36]. A study on the safety 
and feasibility of MRgFUS in the treatment of fibroids (Phase I/II of study) started in 1999 in the 
United Kingdom, Germany, and Israel. The results showed that MRgFUS creates hemorrhagic 
necrosis in the area of non-perfusion on the post-treatment MR images and only 10% of patients 
experienced pain within 72 h of treatment [36]. A trial on treatment of larger volumes of fibroids 
in women with symptomatic uterine fibroids (Phase III of study) showed that 79% of treated 
patients had a 10-point decrease in their symptom severity score with a 13.5% mean decrease in 
treated fibroid volume at 6-months post-treatment. Most of the improvement was observed at 3 
months and 12 months after treatment, as 15% of evaluated patients reported a 10-point decrease 
in their symptom severity score and only 28% underwent an alternative treatment [122]. 
Researchers who focused on measuring fibroid volume reduction after HIFU treatment reported 
a 31.4% volume decrease after three months [123], 31% [119], 15% [124], or 33% [125] after six 
months, and 9.3% after 12 months [126]. To maximize safety in these FDA approved studies, 
only 10% of the fibroid volume was treated. Based on FDA guidelines for MRgFUS, the 
commercial trial time of treatment is limited to 180 min and the allowed distance between serosa 
and the fibroids must be at least 15 mm [119].  
In MRgFUS treatment of uterine fibroids, the patient lies in the prone position and is placed 
inside the MRI. An MR pelvic coil surrounds the patient to obtain images during treatment 
(Figure 3-3). HIFU is directed towards the fibroid and during each sonication a small volume of 
the fibroid is ablated. The treatment is performed under intravenous conscious sedation [119, 
123]. Care is taken to avoid sensitive structures adjacent to the fibroid, such as skin, bowel, or 
sacral nerve [119, 123] and, for cases in which the bowel is in the way, a degassed water balloon 
is placed on the abdominal wall to compress the bowel away from the acoustic beam [123]. 
 62 
 
 
Conventional transabdominal ultrasound imaging guided HIFU systems [127, 128] and 
interstitial ultrasound applicators have also been used for fibroid treatment [129]. Initial studies 
on the use of interstitial ultrasound applicators for the treatment of large uterine fibroids were 
performed on surgically excised human fibroids. The results showed the ablation of a region 
about 4 cm in diameter and with volumes bigger than 45 cm
3
 with a single needle insertion in 
less than 15 min [129]. In another study conducted in 2014 on the safety and effectiveness of 
MRgFUS, 32 patients with clinically symptomatic uterine fibroids were treated with MRgFUS 
and pre- and post-treatment symptom severity scores were assessed at the time of enrolment and 
at one-, three-, and six-months follow-up [130]. Symptom severity scores decreased notably at 
the follow-up points with significant positive correlations between non-perfused volume ratios 
and reduction in fibroid volumes at six-months follow-up.   
Gormy et al. assessed the results of MRgFUS on 138 patients with symptomatic uterine fibroids 
for a long-term follow-up period of 2.8 years [131]. They observed an incidence of additional 
treatment undertaken at 36- and 48-month follow-up points of 19 and 23%, respectively. Patients 
with disparate fibroids that show brighter on MRI were more likely to need additional treatment 
compared with patients with homogeneously dark fibroids. Additionally, younger women (43.0 y 
± 5.8) were more likely to need additional treatment compared with older women (46.3 y ± 5.6).  
Although clinical results are best estimated using a disease-specific questionnaire, the real 
reduction of fibroid volume and symptom relief cannot be evaluated until some period of time 
after treatment. Even though the apparent diffuse coefficient values were notably low within the 
treated area immediately after treatment (e.g., show cell necrosis and membrane integrity loss), 
the long-term changes in this value and the reason behind these changes remain to be determined 
[131].  Overall, HIFU ablation for treatment of symptomatic uterine fibroids appears effective 
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and safe. Comparison of the long-term rates of additional interventions and related costs after 
MRgFUS of symptomatic uterine fibroids with other uterine-sparing procedures, such as uterine 
artery embolization or myomectomy, shows that MRgFUS is a comparable technique [131] with 
no significant cost difference [132, 133]. Although many women with symptomatic uterine 
fibroids undergo hysterectomy, MRgFUS is the only non-invasive treatment option. The 
procedure has been shown to be safe and effective, especially for patients unresponsive to 
medical treatment [134].  
3.6.5 Kidney tumor 
Total or partial nephrectomy is still the main method of treatment for kidney tumors [135]; 
however, because the size of kidney tumors is small in most cases, a non-invasive ablation of the 
tumor is potentially attractive in addition to available nephron sparing surgical techniques. Few 
clinical studies have examined ablation of small kidney tumors [22, 136, 137] or metastatic 
kidney cancer [138] with HIFU. Treatment of kidney tumors using an extracorporeal HIFU 
device (JC-Model devices C-Model devices [136, 138]), a prototype focused transducer system 
(Storz Medical, Tägerwilen, Switzerland [137]), and a laparoscopic HIFU system (Sonatherm1 
device (Misonix Inc, Farmingdale, NY, USA) [53] have been reported. In one study, an 
extracorporeal HIFU device was used non-invasively at a frequency of 1 MHz and was guided 
by an ultrasound imaging transducer [136]; however, another study invasively applied 
laparoscopic HIFU to bring the laparoscopic probe into direct contact with the tumor at a 4 MHz 
operating frequency [22]. General or epidural anesthesia was performed for patients during these 
studies. Histological evidence of irreversible and homogeneous thermal damage within the 
treated area was shown after excision [22, 139]. MRI assessment of a series of 30 patients with 
kidney tumors treated with extracorporeal HIFU showed necrosis in two tumors in the lower 
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kidney pole shortly after HIFU treatment and shrinkage six months after treatment [136, 137]. 
The ablation of kidney tumors was shown in 67% of treatment cases, assessed radiologically by 
magnetic resonance imaging 12 days after treatment [136]. Wu et al. [138] reported that 90% of 
their 13 patients had their pain resolved immediately following HIFU [138]. Kohrman et al. 
[137] reported unsuccessful HIFU treatment in the upper pole of the kidney due to energy 
absorption by interposed ribs in the way of the beam [137]. Further investigations continue with 
respect to the efficiency of HIFU treatment on patients with advanced stage kidney malignancy 
for both cure and palliation [140].   
3.6.6 Esophageal tumor 
Esophageal cancer is the eighth most common cancer [141]. Esophageal cancer presents as small 
localized squamous-cell cancers in the intraluminal part of esophageal tissue. This disease is 
diagnosed by endoscopic biopsy and is often diagnosed late. The treatment of esophageal cancer 
depends on the stage of cancer and location, together with the person's general condition [142]. 
The common current treatment methods include surgery and chemotherapy with or without 
radiation therapy along with surgery [142]. Results of these treatments are related to the extent of 
disease and medical conditions, but overall these methods of treatment tend to have poor 
outcomes [141, 143]. The 5-year survival rates for this disease are about 13 to 18% [144]. 
Because HIFU is capable of generating rapid, complete, and well-defined coagulation necrosis, it 
has been considered for esophageal tumor treatment. The first clinical results of treatment of 
esophageal tumors by HIFU were reported in 2008 [145]. Thermal ablation of esophageal tumors 
was performed on four patients with a water-cooled interstitial ultrasound transducer operating at 
a frequency of 10 MHz. A single lesion at 10 mm depth from the surface of the transducer was 
induced at 14 W/cm
2
 for 10 s. The interstitial probe capable of mechanical rotation around its 
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axis enables treatment of sectorial or cylindrical volumes and is particularly suitable for 
esophageal tumors. The transducer in this device was such that it could deliver a parallelepiped-
shaped high-intensity beam to the target. A schematic of the therapeutic transducer is shown in 
Figure 3-6. The treatment is monitored using an ultrasound imaging probe located in the head of 
the applicator. The head of the transducer is round to allow for transesophageal application 
without risk of injury (Figure 3-6). The applicator is connected to a flexible metallic shaft as long 
as 80 cm with an outer diameter of 10 mm. The rotation of the applicator is controlled remotely 
through this shaft. The applicator is inserted into the esophagus through the mouth and is placed 
inside the esophageal tumor. Ablation of the tumor is performed under ultrasound guidance 
(Figure 3-7). Complete tumor necrosis was achieved in one patient, while objective tumor 
response was evident in all patients. Significant dysphagia improvement within 15 days was seen 
in all patients, with three of them able to eat a solid diet after treatment. This clinical study 
indicated the efficacy of intraluminal HIFU therapy for local esophageal tumors.  
 
Figure 3-6 Schematic of the front and side view of the head of the interstitial transducer 
used for the treatment of esophageal tumors. The ultrasound imaging probe along with the 
HIFU transducer are located at the head of the interstitial transducer to image and treat 
the region of interest. 
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Figure 3-7 Schematic of the application of the interstitial HIFU probe in esophageal cancer 
treatment. The applicator is inserted into the esophagus through the mouth and the 
transducer placed inside the cancerous cells that line the inside of the esophagus. 
Esophageal cancer ablation along with ultrasound scanning of the targeted area are 
performed simultaneously by this HIFU system. (Courtesy of Mayo Foundation for 
Medical Education and Research) 
3.6.7 Pancreas tumor 
In 2008, Pancreatic cancer was the fourth commonest leading cause of cancer-related death 
across the world [146]. And in 2016, pancreatic cancer moved from fourth to third leading cause 
of cancer-related death in the U.S. [147]. This disease typically spreads rapidly and is rarely 
detected in its early stages; signs and symptoms may not appear until the cancer is in its 
advanced stages. The 5-year survival rate for patients diagnosed with pancreatic cancer is less 
than 5% [148]. Surgery is possible for only 20% of pancreatic cancers and a non-invasive 
therapy technique such as HIFU could be a solution. Studies on the treatment of pancreatic 
tumors in patients not eligible for surgery included approaches that involved only using HIFU 
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[28, 149, 150], chemotherapy using gemcitabine jointly with HIFU [149, 151], and HIFU 
therapy after failure of chemotherapy and/or radiotherapy treatment [149]. A study of 251 cases 
of advanced pancreatic cancer with focused ultrasound surgery in China suggested that HIFU 
can decrease the size of pancreatic tumors with no signs of pancreatitis [152]. The pain related to 
unresectable pancreatic cancer was resolved in 80% of patients within 24-48 h after a single 
session of HIFU treatment and did not return during the follow-up period; the average survival 
rate was 12.5 (223 patients survived 8 to 36 months and 6 patients survived more than 3 years). 
No sign of hemorrhage, large blood vessel rupture or gastrointestinal perforation, dilatation of 
the pancreatic duct in follow-up images, post-interventional pancreatitis, peritonitis, or jaundice 
was observed in any of the patients [152]. In their study with 35 patients, Jung et al. showed 
vertebral necrosis in all patients, subcutaneous fat necrosis in 26% of patients, different pain 
grades in 71% of patients, and transient pancreatitis in 15% of patients [28]. They observed 
major complications for 8.5% of patients including tumor-duodenal fistulas with severe 
abdominal pain, duodenal stent, and a third-degree burn of the anterior abdominal wall 
[28]. Zhao et al. in their study of 30 patients reported no evidence of post-interventional 
pancreatitis or peritonitis during the follow-up period after HIFU treatment [151]. In another 
study by Xiong et al. [149], 89 patients were treated with HIFU; subcutaneous sclerosis due to 
thermal injury to the subcutaneous fat of the anterior abdominal wall was reported in 6.7% of 
cases, pancreatic pseudocysts were reported in 1.1% of cases, and no treated patient reported 
severe complications [149].  
Other human studies have reported the pain relief associated with pancreatic adenocarcinoma 
and observed focally ablated malignant tissue [153]. No skin burns were reported by He et al. 
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[152] or Zhao et al. [151]; however, second-degree skin burns were reported by Jung et al. [28] 
in all 35 patients and third-degree skin burn in 3% of patients.  
Extracorporeal HIFU treatment of pancreatic cancer has been performed using three different 
devices: an extracorporeal ultrasound-guided Model-JC system (HAIFU, Chongqing, China) [28, 
153], HIFUNIT-9000 tumor therapy equipment (Shanghai A&S Sci-Tech Co., Ltd, Shanghai, 
China) [66], and a FEP-BY system (Yuande Biomedical Engineering Limited Corporation, 
Beijing, China) [149]. The patients were in either a prone or supine position and, depending on 
the therapeutic device, the transducer was placed either above or below the patient. Patients can 
be treated without anesthesia [67] or undergo general anesthesia [69] or regional anesthesia [66].  
In these studies, real-time ultrasound images were used to target the tumor during HIFU therapy 
that ablated it slice by slice until the whole mass was covered [28], [151], [149], [150]. In order 
to determine and evaluate the tumor response and ablation after HIFU treatment, both contrast 
enhanced computed tomography (CT) [154] and MRI [28], [150] have been used to determine 
tumor vascularity before and after HIFU therapy. Color Doppler ultrasound [150] was used in 
these studies.  
Overall, pancreatic cancer treatment with HIFU only achieves an average tumor reduction rate of 
50% [150], with concurrent gemcitabine and HIFU treatment showing an overall and partial 
response rate of 43.6% [151] and 14.6% [149], respectively.   
3.6.8 Bone cancer 
A bone tumor is an abnormal and uncontrollable growth of tissue in bone that can be either 
benign (non-cancerous) or malignant (cancerous). The average 5-year survival rate for patients 
diagnosed with bone and joint cancer in the United States is 67% [155]. Surgery is usually 
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performed for primary bone tumors and radiation therapy is used for bone metastases. Because 
of the great difference in acoustic blockage between bone and the surrounding soft tissue, HIFU 
was not initially considered as a potential treatment technique for bone cancer; however, an 
experiment performed by Smith et al. [156] on the thermal effect of focused ultrasound on bone 
tissue showed necrosis of osteocytes in normal rabbits. A pathological study of human malignant 
bone tumors treated with HIFU showed the destruction of endothelial cells of microvessels and 
thrombosis, and the potential of HIFU for preventing haematogenous dissemination of the tumor 
cells [157]. A theoretical study on the optimal external parameters of HIFU for bone tumor 
treatment [158] showed that the treatable diameter of bone tumors increases with increasing 
absorption ratio of bone marrow to tumor, acoustic window of surface skin, and bone diameter; 
the treatable diameter decreases with decreasing muscle thickness and is affected by the specific 
absorption rate ratio of bone tumor site to the surface skin, bone marrow, and bone. They also 
indicated that the specific absorption rate at the bone tumor site should be three times higher than 
that in the surface skin, tumor/marrow, and marrow/bone interfaces to avoid damage to normal 
tissue [158]. Since 2002, patients with bone tumors have been successfully treated with HIFU in 
China [159].  
HIFU studies have been conducted for solace of pain from bone metastases [160-162] and also to 
treat primary bone malignancies [163-165]. HIFU devices that are commercially used for these 
purposes include the MRI-guided therapy system ExAblate 2000 (multielement phased-array 
transducer with a frequency of 1.0–1.5 MHz) [160], [161], [162] and ultrasound imaging guided 
therapy unit Model JC (13.5 cm focal length and 0.8 MHz transducers) [163], [164], [165]. 
Patients undergo either suitable anesthesia [163], [164] [165] or conscious sedation 
[160],[161] [162].  
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The application of HIFU alone in 30 patients with malignant solid tumors who refused surgery or 
were refractory to chemotherapy showed no intensification of all treated regions, with an even, 
thin intensification rim around the treated region [166]. A survival rate of 87% (26 patients) was 
reported after a follow-up period of 10 to 38 months (mean 23.1 months). Complete regression 
of the tumor volume was observed in 10 patients. Shrinkage of the tumor volume of ≥ 50% was 
observed in 13 patients. Examination of large core needle biopsies on eight of 13 patients 
showed necrosis and/or fibrosis, although three patients had local recurrence. No local recurrence 
in most of their treated patients suggested the effectiveness of HIFU alone to manage malignant 
bone tumors. However, nerves might not be clearly monitored during ultrasound guided HIFU, 
as two patients in Chen et al. [166] suffered peripheral nerve injuries and one patient developed a 
skin injury. Bone scan (99mTc-MDP) showed the disappearance of radioactive uptake and 
production of a radioactive cold region that suggested complete inactivation of the tumor foci.  
Further studies were also done using extracorporeal HIFU with or without chemotherapy on 44 
patients with primary malignant bone tumors, with a mean follow-up period of 17.6 months 
[166]. This study had a survival rate of 84.1% and a complication rate of 18.2%. In 34 patients 
with stage II b disease, 30 survived disease-free, two died due to tumor metastasis to brain and 
lung, and three developed local recurrence. Among 10 patients with stage III b disease, five 
survived with tumors, out of which one experienced a local recurrence, and five died due to lung 
metastasis.  
In various other studies, patients were treated using HIFU for ablation therapy of various primary 
bone malignancies, including osteosarcoma, periosteal osteosarcoma, ewing sarcoma, 
chondrosarcoma, giant cell bone cancer, periosteal sarcoma and fibrous histiocytoma, and 
localized painful bone metastases [163], [164], [165]. 
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In a study performed by Li et al. [164] on use of HIFU to treat primary and metastatic bone 
tumors in 25 patients, MRI or positron emission tomography (PET)-computed tomography (CT) 
radiological evaluated patients before and after HIFU treatment. Their study on patients with 
primary bone tumors showed complete tumor ablation in six (46.2%), partial response in five 
(38.4%), moderate response in one (7.8%), and disease progression in one patient. Comparable 
results were observed for metastatic bone tumors: five with (41.7%) complete response, four 
with (33.3%) partial response, one with (8.3%) moderate response, one with (8.3%) stable 
disease, and one patient with disease progression. They reported 1-, 2-, 3-, and 5-year survival 
rates for metastatic tumors of 83.3, 16.7, 0, and 0%, respectively. For patients with primary bone 
tumors, they reported 1-, 2-, 3-, and 5-year survival rates of 100.0, 84.6, 69.2, and 38.5%, 
respectively, which are considerably better than for patients with metastatic bone tumor.  
Another three studies with more focus on palliation of pain of metastasic bone diseases using 
HIFU showed a pain reduction of 92% [161], 69.5% [160], and 82% [162] after three months of 
HIFU treatment compared to pain scores before treatment. HIFU for palliation of pain of 
metastasic bone diseases can be applied with no delay in post-operative chemotherapy as no 
surgical trauma or repair are involved with HIFU treatment [160]. 
Mild local pain and edema in all patients, first- and second-degree burns [163-165], and third-
degree burns that required further surgical interventions, peripheral nerve damage, bone fracture, 
ligamentous laxity, epiphysiolyses, and secondary infections [163] were reported as 
complications of treatment cases in several different studies. 
The results of preliminary studies indicated that HIFU was effective and well tolerated, and it 
was possible to preserve the limb during HIFU treatment of bone tumors as no surgical trauma or 
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rupture of vessels greater than 2 mm in diameter were reported. In fact, the main vessels could be 
retained, which is beneficial for revascularization and repair of inactivated tumor bones [36].   
Local bone denervation by MRgFUS can be a promising tool for palliation of pain due to bone 
metastases. Osteoarthritis causes severe knee pain and troubles at elderly ages. In 2013, 
MRgFUS was used to study the management of osteoarthritic knee pain on eight patients with 
medial knee pain [67]. MRgFUS was applied to the bone surface just below the rim osteophyte 
of the medial tibia plateau with follow-up after one month. Immediate pain relief was observed 
in six patients (75%) after treatment, and a long-lasting effect at 6-months follow-up in four 
patients with no adverse side effects or complications. A notable rise of the pressure pain 
threshold in the treated area represents the successful denervation effect on the nociceptive nerve 
terminals. MRgFUS is an effective, non-invasive, safe, and promising clinical pain management 
technique for knee osteoarthritis. When the acoustic energy is focused on the intact surface of 
cortical bone, it causes a sudden temperature rise that mediates critical thermal damage to the 
adjacent periosteum, the most innervated component of mature bone tissue. This approach is 
very effective in pain management [167]. In addition, local tumor control, allowing 
remineralization of trabecular bone or lesion size reduction, is other potential application of this 
technique [167]. The effectiveness of MRgFUS for treatment of osteoid osteoma, a painful bone 
tumor, has been demonstrated extensively in a review study by Temple et al. [168]. Creation of a 
clinical MRgFUS treatment program for the treatment of bone tumors such as osteoid osteoma 
would not only be a cutting-edge medical treatment but would also help support investigations 
into the treatment of other bone lesions, such as osteoblastoma, aneurysmal bone cyst, and 
eosinophilic granuloma [168].    
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Overall, HIFU alone or combined with chemotherapy can be a safe and very effective way of 
treating primary malignant bone tumors. The limb-salvaging ability of HIFU (preserving good 
function in the limbs) can make HIFU a new clinical modality for treatment of bone tumors. 
Also, MRgFUS can be an alternative non-invasive method for palliation of pain in skeletal 
metastases. MRgFUS offers several key advantages over other non-invasive treatment 
modalities. This technology offers three-dimensional treatment planning along with real-time 
temperature mapping in the target area, and so can be a promising technique for successful 
palliation of bone metastasis pain and tumor control due to the bony structure remodeling 
induced by thermo-related coagulative necrosis [167]. Given the positive results of initial pilot 
studies on MRgFUS, a phase III trial is needed with the results compared to radiofrequency/laser 
ablation [168].  
3.6.9 Brain Disorders 
The ability of HIFU to focus acoustic energy through the intact skull onto a target as small as a 
couple of millimetres would be a considerable milestone in the field of neurosurgery for treating 
brain-based disorders. Recently, MRgFUS has been used in several studies as an effective and 
non-invasive thermal ablation technique to disrupt the blood-brain barrier and make intracranial 
thermal ablation lesions in the brain to overcome certain brain disorders. In MRgFUS, ultrasound 
can be successfully transmitted through the intact skull and overcome the energy dispersion, 
reflection, absorption, and distortion due to the bony skull, and allow the user to monitor tissue 
disruption, ablation, or vascular permeability by real-time MR imaging and MR thermometry. 
This technique can verify the efficiency of HIFU through patient and imaging feedback [169].  
The device usually used for HIFU application to the brain is a spherical, phased array, 
multielement transducer helmet that allows the ultrasound energy to be focused at a target area 
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[170]. The helmet is coupled to software that compensates for the wave front distortions induced 
by passage of ultrasound through the bony skull. An MRgFUS helmet contains more than 1000 
individual transducer elements [169]. MRI is performed during treatment for high resolution 
visualization of the brain target as well as real-time tissue temperature variation mapping [171-
173]. Patients undergo local head anesthesia for the procedure. Figure 3-8 shows a model 
ExAblate Neuro (InSightec, Haifa, Israel) MRgFUS transducer helmet. 
 
Figure 3-8 An ExAblate Neuro (InSightec, Haifa, Israel) MRgFUS transducer helmet on an 
MRI table. Cooled degassed water is carried through the attached hose to the helmet to 
provide the medium through which the ultrasound travels. This water is also used to fill the 
space between the patient’s head and the transducers to keep the skull bone temperature 
within a safe range [169]. 
 
Currently, MRgFUS can be used to focally ablate neural tissue or to temporarily disrupt vessel 
permeability (blood-brain barrier). Current studies on MRgFUS for brain treatments are at 
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different levels of investigation and status [169]. So far, MRgFUS has been used to treat 
movement disorders (essential tremor; ET) [174, 175], Parkinson’s disease (PD), Alzheimer’s 
disease (AD) [176, 177], brain tumors, depression/anxiety, pain syndromes [178-180], epilepsy, 
thrombolysis/intracerebral hemorrhage [181-184], and cerebrospinal fluid (CSF) diversion [185].  
3.6.10 Essential Tremor 
Essential tremor (ET) is a movement disorder that mostly affects the upper extremities and the 
dominant arm in particular. The tremor is commonly postural, is heightened by movement, and 
can lead to significant disability and functional impairment over time [169]. ET is often 
refractory to medical treatment. Up to 25-30% of patients resist common medical treatments, and 
neurosurgical options may be more appropriate. The target for surgical approaches to treat ET is 
the ventral intermediate (VIM) nucleus of the thalamus [186]. In common surgical techniques, 
disruption of the VIM is achieved either by ablating the nucleus through radio frequency (RF) 
thalamotomy at 75-80 °C or by deep stimulation of the brain. Both of these techniques are 
invasive and require insertion of probes inside the brain, which incurs surgical risks such as 
infection and hemorrhage [169]. The first MRgFUS treatment experience was reported in four 
patients with chronic, medically refractory ET [174]. All patients showed immediate and 
sustained improvement in tremor. At the 1- and 3-month follow-up points, patients had tremor 
reductions of 89.4 and 81.3%, respectively. Functional impairment secondary to tremor 
decreased by an average of 40%. One patient experienced post-operative paraesthesia at three 
months and another developed deep vein thrombosis; no serious adverse events were reported for 
the other patients. MRI monitoring of thalamic lesions at time intervals of 1 week and 1 and 3 
months showed a gradual evolution of lesions. MRgFUS thalamotomy was attempted by another 
research group at the University of Virginia on 15 patients with ET [175]. Thermal ablation of 
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the thalamic target was reported in all patients, and four patients (27%) showed adverse effects 
of the procedure including transient sensory, cerebellar, motor, and speech abnormalities with 
persistent paresthesias [175]. At 1-year follow-up, patients had a 75% mean decrease in their 
dominant arm tremor score and 85% decrease in functional disability. In 2015, Chang et al. 
studied unilateral MRgFUS thalamotomy on 11 patients with medication-resistant ET and 
evaluated tremor and neuroimaging at baseline and for a 6-month follow-up period; notably, only 
8 patients received the complete MRgFUS treatment and sufficient temperature increase [187]. 
They assessed tremor severity and functionality at 1 week and 1, 3, and 6 months follow-up 
points. Immediate and sustained improvement in tremors was observed in all patients through the 
6-month follow-up period. One patient experienced mild and delayed post-operative balance 
issues, but others showed no significant post-surgical complications.  
The results of these studies suggest that MRgFUS is a safe, effective, and less invasive surgical 
modality for the management of disabling, medication-resistant essential tremor; however, long-
term follow-up and larger trials are required to validate the safety, efficacy, and durability of this 
new approach. Issues such as optimal patient selection and management during treatment must 
also be resolved before clinical application of MRgFUS. 
3.6.11 Chronic and non-malignant pain 
Chronic and non-malignant pain is considered one of the most challenging conditions to treat. 
The first treatment approach is usually pharmacological medication; however, for patients who 
remain symptomatic despite all medications, surgical procedures with ablative or destructive 
procedures that target either the sensory or affective component of the condition can be used to 
treat both central- and peripheral-type pain syndromes [188]. Central procedures in which the 
brain and spinal cord are targeted include thalamotomy, cingulotomy, and dorsal root entry zone-
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otomy, and peripheral procedures in which specific nerves or nerve bundles are targeted include 
ganglionectomy and rhizotomy [188]. The first examination of MRgFUS on chronic, 
medication-resistant neuropathic pain was a study in 2009 on nine patients [179]. Central lateral 
thalamotomy was conducted on these patients and the ablation target was the posterior part of the 
thalamic central lateral nucleus. None of patients showed any side effects or neurological 
deficits. All patients experienced some level of pain relief during the procedure and in the range 
of 30 to 100% 48 hours after treatment. The size of the lesion at the target site was determined by 
MRI to be 3-5 mm in diameter 48 hours after the procedure. This proof-of-concept study of 
MRgFUS was extended in another study in 2012 on 11 patients with chronic pain [189]. Thermal 
ablation lesions in the posterior part of the central lateral thalamic nucleus that were 3-4 mm in 
diameter were produced and peak temperatures of 51 and 64 °C were applied. Patients receiving 
the MRgFUS treatment were followed for 1 year, with 49% experiencing pain relief at 3 months 
and 57% at 12 months. Immediate pain relief was reported by six patients following their 
procedure; however, a small hemorrhage in the area of the motor thalamus was reported in one 
patient. Also, bleeding complications in the target area with ischemia in the motor thalamus was 
reported in one case; this was interpreted as a safety issue due to potential cavitation or the 
maintenance of sonication temperatures below 60°C. MRgFUS avoids mechanical brain tissue 
shifts and eliminates the risk of infection; in addition, the application of MRI for real-time 
scanning and thermometry monitoring of the target are major factors for optimizing precision, 
safety, and efficacy during treatment with this technique [189].  
3.6.12 Trigeminal Neuralgia 
Trigeminal neuralgia (TN) is a chronic sharp, stabbing electric pain that affects the trigeminal 
nerve, one of the most distributed nerves in the head, and is a form of neuropathic pain. Surgical 
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treatments for those patients for whom medication is insufficient or not tolerated focus on the 
trigeminal nerve and include intentionally damaging the nerve and its divisions in an 
unrestrictive way or relieving vascular compression of the nerve at its root entry zone [190]. One 
of the surgical techniques is gamma knife radiosurgery, in which a gamma radiation dose of 80 
Gy is administered to the mid-cisternal portion of the nerve [169]. Even though most patients 
experience pain relief and are pain-free with or without medication, gamma knife radiosurgery 
includes the variation in susceptibility to radiation between patients, as well as the creation of 
radiation-related complications, such as secondary malignancy [169]. MRgFUS has been of 
interest for treatment of TN; however, there are concerns associated with the production of 
thermal injury next to the trigeminal nerve because of the adjacent petrous bone [169]. This 
limits applications based on the target location, making the technique only optimal for targets in 
the center of the brain. The feasibility of MRgFUS for making a trigeminal root entry zone lesion 
was studied on four unpreserved cadavers in a study in 2013 [178]. The application of MRgFUS 
along the length of the trigeminal nerve starting at the root entry zone for 10-30 s (at 25-1500 W) 
increased the temperature by a mean of 10 °C. The petrous bone got as hot as the nerve yet the 
study concluded that the treatment could be feasible. Some in vivo studies are necessary to 
confirm the safety and efficiency of MRgFUS for TN treatment.   
3.6.13 Brain tumor 
The most common malignant tumor of the central nervous system is glioblastoma. Treatment of 
glioblastoma typically involves radiological tissue diagnosis followed by surgical resection and 
chemo/radiation therapy. In the last 50 years, few advances have been made in the treatment of 
in malignant brain tumors. Brain tumor management has numerous challenges, including the 
infiltrative nature of the tumor, which is shown as diffusely spread throughout the brain at the 
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time of diagnosis, as well as the inability of chemotherapy regiments to effectively cross the 
blood-brain barrier [169]. MRgFUS as a potential non-invasive method of treatment has been 
studied in clinical and preclinical trials to address these two typical challenges. Transcranial 
MRgFUS surgery of brain tumors was studied in three glioblastoma patients in 2010 [191]. The 
feasibility of MRgFUS through the intact skull and the radiologic effect of thermal ablation in 
the target tumor with contrast-enhanced MRI were evaluated in this study. One patient 
underwent the procedure at the highest acoustic power level of 800 W; the other two underwent 
the procedure at 650 W due to a conservative software setting, and only one reported sonication-
related pain. There was difficulty mapping the temperature variation in the tumor in one patient, 
where signal loss in the MRI was presumably due to blood remaining. The authors of this study, 
the first study on patients, could not access sufficient power to clearly achieve thermal 
coagulation and ablation. But, based on extrapolation of their results, they suggest that ablation is 
possible without overheating the skull. They observed focal heating within the target tumor in all 
three patients to an overall maximum of 51°C (individual maxima of 42, 51, and 48 °C) for 20 s 
sonication, which is not clearly above the threshold for thermal damage in the brain [192]. 
However, based on their measurements, they suggest achieving a peak focal temperature of 55 
°C, which is sufficient to produce thermal necrosis, would require a power level of 
approximately 1200 W for a 20 s period. Cavitation effects are more likely to be generated in 
tissue and vessels at a lower frequency and higher intensity. Hemorrhage of small capillary blood 
vessels has been reported in the brain during high-intensity sonication [193-195]. However, 
Hynynen et al. [71] reported that an ultrasound intensity above 4400 Wcm
-2
 for 1 s generates 
transient cavitation in tissue and can cause serious effects on blood vessels as small as 1.0-1.3 
mm in diameter and cause bleeding. Overall, based on findings of McDannold et al. [191], 
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ablation of brain tumors appears to be feasible with MRgFUS; however, additional trials 
investigating MRgFUS ablation for metastatic brain tumors should be conducted to verify these 
findings. A review by Cohen-Inbar et al. extensively discusses the effect of focused ultrasound 
on immunomodulatory therapy as a promising treatment approach for patients with glioblastoma 
multiforme, who exhibit a deficient anti-tumor immune response [196]. Immunotherapy by 
focused ultrasound mostly relies on mechanical acoustic cavitation and immunomodulation that 
play key roles in increasing the host anti-tumor immune response. Considering all focused 
ultrasound-induced pro-inflammatory cytokine secretion and stress responses, changes in the 
intra-tumoral immune cell population, augmentation of dendritic cell activity, and increased 
cytotoxic cell potency, it was suggested that focused ultrasound combined with immunotherapy 
can offer a synergistic treatment to overcome glioblastoma multiforme-induced immune evasion 
[196]. 
3.7 Potential future clinical applications of focused ultrasound  
3.7.1 Vessel occlusion by HIFU  
Blood vessel occlusion aided by HIFU or MRgFUS can be a potential technique in the treatment 
of arteriovenous malformation (a congenital disorder of blood vessels in different parts of the 
body, such as the brain, brainstem, or spinal cord) to control abdominal, peritoneal, and pelvic 
hemorrhage. HIFU or MRgFUS can also be used to block blood supply and interrupt the main 
blood flow to a tumor and may lead to tumor shrinkage. Recently, studies to interrupt blood flow 
have been conducted in animals [197]. A complete stoppage of blood flow, and no damage to 
surrounding soft tissues were observed in color Doppler imaging and MRI, and lack of perfusion 
in the renal cortex was also observed in color Doppler ultrasound image[197-199]. Histological 
results show an infarcted tissue volume corresponding to a wedge shape. The animal studies 
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suggest that HIFU or MRgFUS can be used as a vessel occlusion modality; however, additional 
studies should be done before clinical application to obtain more data about the relationship 
between the HIFU intensity required for flow occlusion, blood vessel diameter, and flow 
velocity, and to investigate possible long-term adverse effects [36]. 
3.7.2 Disruption of blood brain barrier  
The inability of chemotherapy regiments to cross the blood-brain barrier is a challenge that might 
be addressed by MRgFUS. The blood-brain barrier is a filtering mechanism that blocks the 
passage of certain substances by tightly bound capillary endothelial cells. The capillaries that 
carry blood to the brain and spinal cord tissue are lined by a continuous layer of epithelial cells 
that ban the transport of large and harmful molecules between cells [200]. This rigid biochemical 
barrier prevents the use of neurotherapeutic treatments for tumors and diseases associated with 
neurodegeneration of the nervous system (such as Alzheimer’s and Parkinson’s diseases) that 
involve the brain. MRgFUS can be a potential technique to disrupt the blood-brain barrier and 
facilitate the passage of large drugs such as chemotherapy agents and monoclonal antibodies to 
the brain. Preclinical studies show that the disruption is temporary, occurs without any lesions or 
irreversible damage [201], and allows drugs to safely pass the blood-brain barrier. The 
mechanical effect of ultrasound is most often mediated by cavitation bubbles generated in tissue 
by the pressure wave. The production of cavitation bubbles requires very high exposures that are 
often accompanied by blood vessel rupture or occlusion[71], and therefore should be controlled 
for complete tissue disintegration [202] or vaporization [203, 204]. However, these microbubbles 
are very effective energy concentrators and can mediate ultrasound bioeffects at power levels 
less than 0.1% of that needed for thermal coagulation. The generation and interaction of 
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cavitation bubbles in the brain can briefly open the blood-brain barrier with no permanent effect 
on brain tissue [205].  
The introduction of preinjected microbubbles into the capillary along with MRgFUS can also 
ease the procedure [200]. Premade microbubbles are routinely injected in the bloodstream 
because the existence of these microbubbles is helpful to increase ultrasound signals from the 
blood for diagnostic purposes. The oscillation and growth of microbubbles close to endothelial 
cell membranes leads to opening of the blood-brain barrier within seconds of the start of the 
sonication procedure [200, 206, 207]. The generated opening is generally healed within 6 hours 
post-treatment and, in cases with more serious tissue effects, within 24 hours [208]. However, 
these results were from in vivo animal study. Several other animal studies [209-211] have shown 
the proof of concept that MRgFUS can safely disrupt the blood-brain barrier and achieve 
significant brain tissue concentrations of complex and large biologic agents.  
Another disease with the potential to be treated by MRgFUS is Alzheimer’s disease. Alzheimer’s 
disease is one of the most common neurodegenerative disorders, and the very low rate of success 
in medication therapy is associated with the difficulty of passage of amyloid-beta (Aβ) peptide 
through the blood-brain barrier. Some animal studies have shown that only 0.1% of 
intravenously administered anti-Aβ antibodies reach the brain [212, 213]. However, other animal 
studies have shown that the disruption of the blood-brain barrier by MRgFUS is an effective 
approach toward introduction of antibodies and decreasing plaque burden [213, 214]. 
To the best of our knowledge, there are no published reports on human patients. However, a 
group of neurosurgeons at the University of Toronto are conducting human trials for brain tumor 
therapy using MRgFUS [169].  
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3.7.3 Histotripsy 
Histotripsy is an experimental extracorporeal ultrasound technology that relies more on the 
mechanical effect of ultrasound by utilizing cavitational mechanisms of energetic microbubbles 
to generate non-thermal tissue destruction (fragmentation and subdivision of tissue that results in 
cellular destruction). In histotripsy, a number of short, high-intensity ultrasound pulses at a 1 
kHz pulse repetition rate and 18 MPa rarefactional pressure for 20 μs duration are sent to the 
target [215]. Delivery of such intense, high pressure, and short bursts to the tissue leads to 
cavitation bubble formation in the target zone. Subsequent cavitation processes such as 
oscillation, growth, and collapse of microbubbles will occur close to the cells. The cavitation 
process leads to mechanical fractionation of targeted tissues to reduce architectural and cellular 
structures to a fine slurry of acellular debris [216] and a liquefied core with very sharply 
demarcated boundaries [36]. Histotripsy is very similar to HIFU, with the primary difference 
being that the transducer in histotripsy has a center frequency around 750 kHz; HIFU applies less 
intense 3–5 second pulses of acoustic energy to heat tissues and produce thermal coagulation 
[217]. At a fluid-tissue interface, the cavitation process of histotripsy causes localized tissue 
removal with sharp boundaries. Histotripsy was used for cardiac tissue removal in the treatment 
of congenital heart disease (in an in vitro animal study with pigs) [218]. Compared to non-
invasive thermal therapy, histotripsy has some advantages as a potential clinical tool where 
precise tissue ablation and removal are needed (e.g., tumor treatment). The cavitation 
microbubbles produced at the focal point act as a contrast in ultrasound imaging and provide 
real-time feedback during the procedure. The lesion can be produced in a very controlled and 
precise manner and is shown as a darker spot in post-operation imaging. Some animal studies are 
currently underway on applications to the kidney, breast cancer, prostate cancer, several cardiac 
conditions, and breast fibroadenoma [217, 219, 220].   
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3.7.4 Parkinson’s disease 
Parkinson disease is a heterogeneous motor disorder characterized by progressive degeneration 
of motor neurons. Preclinical studies have shown that disruption of key motor nuclei can lead to 
significant improvement in motor symptoms [221]. There is a high potential for use of MRgFUS 
for treatment of Alzheimer’s disease and Parkinson’s disease because this technique can be used 
to perform deep stereotactic thermal ablations. The risk of this technique is low due to the 
absence of penetration of the skin, bone, and brain as well as on-line monitoring of the 
thermocoagulation process. MRgFUS can be used as an ablative surgery tool in neurosurgery for 
treatment-resistant Parkinson’s disease. The target for ablation in patients with disabling 
dyskinesias can be the globus pallidus with pallidotomy, and for patients with tremor-dominant 
disease the target can be ventral intermediate thalamus or VIM thalamotomy [169]. Recently, the 
interest and possibility of performing subthalamic thermocoagulations by MRgFUS with reduced 
risk and optimized accuracy has increased. In 2014, the first clinical study on the use of 
MRgFUS for treatment of Parkinson’s disease was reported by Magara et al. [222]. Thirteen 
patients with chronic (mean average duration of disease for 9.7 years) and therapy-resistant 
Parkinson’s disease were treated with an MRgFUS pallidothalamic tractotomy. The treatment 
procedure was performed in a 3 Tesla (T) MR imaging system (GE Discovery 750, GE 
Healthcare, Milwaukee, WI, USA) using the ExAblate Neuro device (InSightec, Haifa, Israel). 
As shown in Figure 3-9, the patient’s head was covered with a flexible silicon membrane that 
was sealed to outer face of the ultrasound transducer helmet. Degassed and chilled water at a 
temperature between 15 and 18 °C was circulated in the volume between the head and the 
transducer to cool down the surface temperature and avoid damage. The target area of treatment, 
the pallidothalamic tract, was treated by an iterative process guided by MR imaging and MR 
thermometry. The temperature was increased stepwise by increasing the acoustic power to a 
 85 
 
 
maximum of 1200 W and energy to a maximum of 20400 J for 13 s to reach a final temperature 
between 52 and 59 °C (average 56.2°C) at the target (considering the temperature of 54°C 
required for 100% necrosis). The procedure was performed with the patient fully awake. A group 
of four patients (group 1) received a single application at the peak energy, and a group of nine 
patients (group 2) received repetitive applications (4-5 times) of the peak energy on the target. 
Group 1 experienced clear-cut recurrence at 3 months, with thermocoagulation of a volume of 83 
mm
3
 and no sign of thermal lesion in their MR images. In group 2, the repetitive applications 
produced larger thermocoagulation volumes of 172 mm
3
 that remained visible in MR images for 
3 months. Primary relief as a reduction in score on the unified Parkinson disease rating scale was 
measured as 7.6% in group 1 and 60.9% in group 2. Patients’ estimated global symptom relief at 
3-months follow-up was 22.5% in group 1 and 56.7% in group 2. The clinical results showed no 
procedure- or device-related neurological side effects. The targeting accuracy for all patients was 
measured as 0.5 mm anteroposterior, 0.5 mm mediolateral, and 0.6 mm dorsoventral. This study 
indicates that that application of MRgFUS pallidothalamic tractotomy is feasible, safe, and 
accurate. 
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Figure 3-9 Intra-operative patient setup for MRgFUS procedure on the brain. The patient 
lies on the MR bed and the head is placed inside the phased-array ultrasound transducer 
helmet. [222] 
3.7.5 Psychiatric disease 
Ablation treatment approaches for treatment of refractory psychiatric diseases mainly target and 
disrupt the limbic pathways connecting the frontal lobe with subcortical structures [169]. In up to 
a third of patients with mood and anxiety disorders, pharmacologic and psychotherapeutic 
approaches are not completely satisfactory. These patients are candidates for neuromodulation 
techniques, including electroconvulsive therapy, transcranial magnetic stimulation, deep brain 
stimulation, and ablative or lesional procedures [223]. The main targets in cingulotomy (for 
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treatment of depression and obsessive-compulsive disorder) and capsulotomy (for treatment of 
refractory depression) are the anterior cingulate gyrus and anterior limb of the internal capsule, 
respectively [224, 225]. Two different studies on 44 patients with obsessive-compulsive disorder 
(with 32 months follow-up) and eight patients with refractory depression (with 2-3 years follow-
up) showed complete or partial remission in half of the patients [224, 226]. These results suggest 
that MRgFUS can be a potential alternative to psychiatric treatment because of its non-invasive 
nature and ability to give real-time MR guidance.   
3.7.6 Stroke and Thrombolysis 
Deficient blood supply to a part of brain due to obstruction of the inflow of blood and 
hemorrhagic stroke leads to mortality and morbidity. Thrombolytics and surgery, in the case of 
intracerebral hemorrhage, are currently available treatment approaches, with surgery showing 
long-term improved outcomes [227]. For patients with intracerebral hemorrhage, MRgFUS has 
been proposed with the rationale being that it can liquefy blood to facilitate MR-guided 
aspiration and also help decrease the clot burden and mass effect and thus avoid a craniotomy 
[169]. Basically, the mechanical effect of ultrasound and, more specifically, the inertial 
cavitation effect under high pressure amplitude causes MRgFUS-mediated clot lysis. The power 
of ultrasound in this procedure is high so that inertial cavitation is sufficient with no need for 
injection of microbubbles [169]. Preclinical studies have shown liquefaction of intracerebral 
hemorrhage within seconds in a swine model and of more than 90% of the clot in a human 
cadaveric head, resulting in almost complete aspiration of blood [178]. In a recent study, Bonow 
et al. hypothesized that transcranial HIFU may have the ability to induce therapeutic cerebral 
vasodilation and, as a result, can one day be used for treatment of patients with subarachnoid 
hemorrhage [228]. Their review suggests the potential of transcranial MRgUS for treatment of 
 88 
 
 
subarachnoid hemorrhage and other cerebral ischemic disorders. In the future, MRgUS systems 
may find their way to clinical trials and into regular clinical practice for treatment of cerebral 
vasospasm and other cerebrovascular diseases [228].   
3.7.7 Abscesses 
Basically, abscesses generated by bacterial infection consist of a localized lesion with an 
accumulation of pus, surrounded by a capsule built by fibroblasts [229]. Methicillin-resistant 
Staphylococcus aureus (MRSA) is a bacterium responsible for several infections in humans 
[230]. Abscess related to MRSA infections are difficult to treat as they are resistant to many of 
the antibiotics used to treat ordinary staph infections. Abscesses in inaccessible areas such as the 
groin and axillary region or in locations such as the liver, kidney, brain, breast, and bone 
(osteomyelitis) would  benefit from non-invasive therapeutic techniques such as HIFU [231]. 
The heat generated by HIFU can increase the temperature at the precise location of the abscess 
and be used for disinfection or reduction of bacterial numbers. The use of heat for treatment and 
prevention of infection is applied via non-contact radiant heat pads for topical treatment of 
pressure sores [232] and reduction of intraoperative surgical site infection [233]. MRgFUS can 
be a very precise and controlled potential tool with the ability to reach deep tissues in body with 
real-time temperature monitoring. In 2014, an animal study (on mice) was performed to 
investigate the therapeutic effect of focused ultrasound on abscesses induced by MRSA [231]. 
The abscess was generated in the left flank of mice and the procedure performed at an ultrasound 
frequency of 3 MHz. Two different temperatures of 52.3 ± 5.1 and 63.8 ± 7.5 °C were generated 
by HIFU for two different treatment groups. The effectiveness of the MRgFUS treatment was 
determined by evaluating the number of bacteria in the treated abscess at 1 and 4 days after 
treatment. Reduction in the external size of abscess was seen 1 day after treatment, and a 
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significant reduction in bacterial load was observed 4 days after high temperature (63.8 ± 7.5 °C) 
treatment. No change in local neutrophil recruitment in the abscess, no systematic inflammatory 
response, and no open wounds were caused by the treatment. This study suggested MRgFUS is a 
viable option for the treatment of localized MRSA-related infections, and the results were 
promising. However, more extensive and realistic studies on human patients are required to draw 
definitive conclusions. To the best of our knowledge, no human studies have yet to be conducted 
in this regard.  
3.8 Combined mechanisms for therapeutic application of ultrasound 
Other therapeutic techniques involve multiple mechanisms of ultrasound. In intravascular 
catheters, a MHz-frequency transducer is placed near the tip for increasing dissolution of thrombi 
[234]. When the catheter is placed into a deep vein thrombus, the ultrasound is targeted radially 
into the thrombus or an infusion of thrombolytic drug such as tissue plasminogen activator is 
delivered into the thrombus [3]. Ultrasound-assisted drug delivery significantly decreases 
treatment time by increasing the permeability of cell walls and the infusion of drugs into the 
cells.  
Another application of ultrasound is skin permeabilization, which may replace the multiple use 
of needles for drug delivery through the skin for medicines such as heparin and insulin [235]. 
Drug diffusion through the stratum corneum is difficult for molecules with a molecular weight 
greater than 500 Da [236]. Using low-frequency ultrasound (<100 kHz), the permeability of the 
stratum corneum (which is considered a protein diffusion barrier) increases [237] and the drug 
can pass and reach the inner layers and finally the capillary vessels where it is absorbed [238]. 
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The use of low-intensity pulsed ultrasound (about 1.5 MHz) for accelerating the healing of bone 
fractures for cases such as non-union and non-healing fractures is another therapeutic action of 
ultrasound [3]. The biophysical mechanism behind this therapeutic action is not yet clear. 
3.9 Prospective new research areas for application of therapeutic ultrasound  
Several other streams of research are investigating therapeutic applications of ultrasound. These 
new methods mostly rely on low frequency and power ultrasound aided by microbubbles or very 
high power ultrasound for the production of vigorous cavitation [3]. The application of low-
frequency ultrasound for direct sonothrombolysis for treatment of thrombotic disease such as 
stroke is a new strategy [239]. However, this method showed increased brain hemorrhage in a 
clinical trial [240]. Another potential use of ultrasound is to produce cortical and hippocampal 
stimulation in mice [241]. Non-thermal mechanisms have been hypothesized to be responsible 
for the neuronal effects in this method [3]. 
Ultrasound-aided drug delivery is another area of study. This technique is based on microbubbles 
and is under study for direct and targeted therapies that release drugs at a specific location within 
the body (such as cancerous area) without affecting the rest of the body. It can also be used to 
force drug flow from a vessel out into surrounding tissue and to increase intracellular delivery 
[3]. The advantage of ultrasound-microbubble techniques over other techniques such as 
nanoparticle or liposome delivery systems is the ability for external control [3]. DNA transfer in 
gene therapy applications has also been under extensive study [242].  
Histotripsy, equivalent to lithotripsy pulses but at higher frequency and very high amplitude 
pulses, uses only the cavitation mechanism for tissue ablation [243] to homogenize targeted 
tissue, such as tumors, with little heating [244].   
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3.10 Conclusions 
Both thermal and non-thermal (cavitation) effects play a very important role in all therapeutic 
applications of ultrasound. The side effects of these two mechanisms of action can be hazardous 
biologically and are therefore avoided in diagnostic applications of ultrasound but can be 
beneficial in therapeutic applications of ultrasound. The ability to focus ultrasound in an area a 
couple of millimeters in size enhances both the thermal and non-thermal effects of ultrasound 
and results in ablation and necrosis of cells at the applied focal point. This makes ultrasound a 
non-invasive therapeutic ablation technique for deep-seated targets within the body. HIFU 
therapy provides a less invasive approach to cancer therapy that minimizes discomfort to the 
patient and length of hospital stay. Initial studies have demonstrated HIFU to be safe and 
clinically effective and to have high potential clinical acceptance. However, HIFU is still in its 
infancy and further studies are necessary (especially in the field of oncology) regarding the long-
term medical benefits, technical considerations, and treatment delivery before it transitions to 
widespread use. The range of HIFU applications may expand in the future with improved 
imaging; however, MRgFUS is one of the most successful imaging guide approaches in most 
therapies and seems to be an area of continuing interest. In fact, HIFU is an important milestone 
in the development of neurotherapeutics. The ability to focus ultrasound energy onto a brain 
target through the skull with a focal point of only a few millimetres has made HIFU, and 
especially MRgFUS, a fundamental achievement in the world of neurotherapeutics. Studies show 
that MRgFUS is a safe and non-invasive modality that has the potential to be an alternative to 
invasive open neurosurgical approaches. However, there is a need for more studies with long-
term follow-up in this area before definitive conclusions are made. Overall, clinical results of 
therapeutic HIFU applications are encouraging and the method is competing with other 
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established ablation techniques such as RF-, laser-, or cryo-ablation [245], but more studies are 
needed to demonstrate the superiority of HIFU over other available surgery/radiotherapy 
techniques.  
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4.1 Abstract 
Ultrasound is widely used for medical diagnosis and increasingly for therapeutic purposes. 
Understanding the bioeffects of sonography is important for clinicians and scientists working in 
the field, as permanent damage to biological tissues can occur at high levels of exposure. This 
chapter reviews the underlying principles of thermal mechanisms and the physical interactions of 
ultrasound with biological tissues. In this chapter adverse health effects derived from cellular 
studies, animal studies, and clinical reports are reviewed to provide insight into the in vitro and 
in vivo bioeffects of ultrasound. 
4.2   Introduction 
Therapeutic applications of ultrasound in medicine have been accepted and advantageous for 
many years [1]. Ultrasound is widely used as a therapeutic tool in physiotherapy, in lithotripsy 
for kidney stone destruction, in the form of high intensity focused ultrasound (HIFU) for tissue 
ablation in tumor treatment, and as a surgical tool. It has also been applied as a tool for drug 
delivery [2], gene delivery [3], and thrombolysis [4]. Current research suggests promising new 
applications and advancement of biomedical ultrasound in medicine. Further progresses in 
therapeutic applications of ultrasound require more understanding of the mechanisms of 
interaction with tissues to safely advance this technique. 
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4.3 Ultrasound mechanisms 
Thermal and non-thermal physical and biological effects of ultrasound in tissues are the basis of 
various therapeutic applications. Thermal effects of ultrasound that arise from the absorption of 
ultrasonic energy and creation of heat depend on ultrasound exposure parameters, tissue 
properties, and beam configuration [5]. Acoustic radiation force, radiation torque, acoustic 
streaming, shock waves, and cavitation are considered non-thermal effects of ultrasound. 
Radiation force that results from a transfer of momentum from the ultrasound field to the object 
[6] is the cause of contrast agent displacement to the wall of blood vessels in laboratory animals 
[7]. Radiation force is itself an underlying mechanism for radiation torque and acoustic 
streaming effects. Acoustic streaming is when acoustic field propagation in a fluid causes a rise 
in fluid flow. Acoustic streaming has been used as a diagnostic method to noninvasively identify 
cysts [8].  
Cavitation is perhaps the most widely studied non-thermal mechanism of ultrasound and is often 
the basis of a wide range of new therapeutic applications [9]. Ultrasound cavitation is described 
as the formation and oscillation of a gas bubble. Such bubbles can form from a pre-existing 
stabilized gas body or nuclei. Gas nuclei can be stabilized in crevices of impurities in the liquid 
and, as the pressure in the liquid drops, the gas in the crevice expands and forms a microbubble 
[5]. A variety of biological effects, both in vivo and in vitro, can be attributed to acoustic 
cavitation. The non-thermal effects of ultrasound, including cavitation, may play a more 
important role in treatment of soft tissue lesions than thermal effects [10], but this strongly 
depends on the type of cavitation. Non-inertial cavitation is when a bubble is exposed to an 
acoustic field and goes through repetitive oscillations around its equilibrium radius over many 
acoustic cycles. The oscillation of the bubble can result in heat generation, microstreaming of 
 112 
 
 
nearby fluid, and localized shear stresses [5]. Inertial cavitation, known as microbubble 
formation and collapse, is induced by ultrasound waves travelling through tissue fluids during 
ultrasound therapy. When the acoustic field is at higher amplitudes, the radius of a bubble may 
grow to a maximum radius and then collapse. This kind of bubble is called an inertial (transient) 
cavitation bubble. Inertial cavitation bubbles can expand and collapse violently during a single 
ultrasound exposure on the order of one microsecond [11]. Extremely high pressure and 
temperature, high speed microstreaming [12, 13] and high speed jet liquids [14, 15] are induced 
as a result of cavitation processes. The high pressure and temperature generated are localized at 
the minimum radius of the inertial bubble collapse and are temporally limited to the duration of 
collapse [5]. The motion of the bubble wall during inertial collapse produces a spherically 
diverging shock wave in the liquid surrounding the collapsing bubble. Inertial cavitation close to 
a solid surface (such as metal, tissue, cell wall, and stone) generates a high speed jet liquid that 
drives into the solid surface and results in pitting of the surface [16]. This mechanical outcome of 
cavitation is used for fragmentation of kidney stones during lithotripsy.  
One parameter that can directly change the bubble response from non-inertial to inertial 
cavitation is the acoustic pressure amplitude. The acoustic pressure at which this transition 
occurs is called the threshold for inertial cavitation [5]. Another parameter used to determine the 
likelihood of cavitation is the mechanical index (MI). The MI is based on the derated peak 
rarefactional pressure and defined as the maximum value of the negative peak pressure divided 
by the root square of the acoustic center frequency[17]. 
The mechanical effect of cavitation can cause substantial injury to cells when ultrasound-induced 
microbubbles expand and then collapse (microexplosion) close to them. Non-inertial cavitation 
(or stable cavitation in which the microbubble does not violently collapse and instead oscillates 
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for many cycles around its resonance size) is considered more beneficial to injured tissue while 
inertial cavitation (transient) causes tissue damage [18, 19]. Many therapeutic applications of 
ultrasound rely on the ability of ultrasound to focus within tissues at the focal point where the 
beam converges, and use the energy for non-invasive thermal or mechanical effects. A 
quantitative analysis of the amount of heat deposited by ultrasound showed that inertial 
cavitation is key to addressing some of the major challenges of high intensity focused ultrasound 
[20]. In the context of drug delivery, both inertial and non-inertial cavitation bubbles play roles. 
When ultrasound is applied in vivo, cavitation can occur anywhere that appropriate microbubbles 
are present, such as the lung, intestine, or tissue containing ultrasound contrast agents. 
Ultrasound contrast agents are gas-filled microbubbles encapsulated by a protein, lipid, or 
polymer shell, stabilized from dissolution, and injected intravenously [21]. These ultrasound 
contrast agents are used clinically to enhance diagnostic images and have new applications in the 
areas of molecular imaging, drug delivery, and gene therapy [22, 23]. The application of 
ultrasound contrast agents facilitates drug delivery due to the formation of temporary pores in the 
cell membrane by ultrasound. Deng et al. (2004) report that ultrasound raises the transmembrane 
current as a direct result of pore formation that leads to a decline in membrane resistance decline 
[24]. Microbubbles have also been used as a new therapeutic method for direct deposition of 
stem cells to the site of injury after acute myocardial infarction [25]. In this new stem cell 
therapy technique, stem cell-microbubble complexes (StemBells) are assembled by binding dual-
targeted microbubbles to adipose-derived stem cells. These complexes target the myocardial 
infarct area of the heart via microbubbles; specifically, the StemBells were injected into the body 
of a rat acute myocardial infarction-reperfusion model and unloaded via ultrasound. The effect of 
ultrasound on directing StemBells to the vessel wall was shown in an in vitro flow model. The 
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feasibility of improving cardiac function was successfully demonstrated in a rat model [25]. 
Another efficient use of microbubbles and ultrasound is therapeutic gas delivery through 
microbubbles and liposomes. Gaseous molecules of nitric oxide (NO), carbon monoxide (CO), 
xenon (Xe), oxygen (O2), and hydrogen sulfide (H2S) mediate cell signalling pathways, play an 
important role is physiology and biological responses, and have great therapeutic potential. 
However, controlled delivery is a significant challenge for therapeutic techniques using these 
gases. Researchers are using microbubbles and liposomes in novel therapeutic gas delivery [26]. 
Extensive studies performed on microbubble gaseous delivery, such as employed for 
microbubble oxygenation therapy of hypoxic tumors [27]in a rabbit model of hypoxemia [28], in 
rats with acute respiratory distress syndrome [29], and for pancreatic cancer [30]. Tissues that 
naturally contain gas, such as the lung and intestine, as well as vessels containing ultrasound 
contrast agents are more susceptible to ultrasound bioeffects. Mechanical damage (related to 
cavitation) to the microvasculature in the lung and intestine has been observed in several 
mammalian laboratory studies [31, 32].  
Considering that the therapeutic and imaging mechanisms of ultrasound are based on the 
interaction of sound waves with tissue, cavitation could also have hazardous bioeffects on 
tissues. The cavitation that occurs is largely unpredictable and the bioeffects of ultrasound could 
be hazardous to healthy tissues. Further progress in therapeutic applications of ultrasound with 
sufficient safety for patients requires greater understanding of the mechanism by which 
ultrasound interacts with tissues. Therefore, this review concentrates on non-thermal 
laboratory/clinical-based biological effects of ultrasound both in vitro and in vivo.  
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4.4 Mechanical (non-thermal) bioeffects 
Discussion of cavitation behavior usually assumes the pre-existence of bubbles of suitable size or 
bubble nuclei with the potential to grow to a suitable size in the medium propagated by the 
ultrasound beam. Although liquids can be saturated with gas, suitable cavitation nuclei might not 
always be present. In some cases, an ultrasound contrast agent is used and injected into the body 
to improve diagnosis via ultrasound. It is very doubtful if either inertial or non-inertial cavitation 
occurs at diagnostic levels of ultrasound within soft tissues or fluids in the body in the absence of 
contrast agents [33, 34].  
4.4.1 Lung 
Tissues naturally containing gas bodies, such as the lung and intestine, are more sensitive to 
bioeffects from ultrasound exposure because of the presence of gas. Because fetal lungs are gas-
free, they do not exhibit any sign of the lung damage evident in air-filled adult lungs [35]. The 
trauma at the surface of the lung and in the intestine has been interpreted to result from 
cavitation-like processes in the body [32, 35]. To explore the hypothesis of cavitation-based 
bioeffects from diagnostic ultrasound on the lungs of mammals, rat lung was exposed to a 4.0-
MHz (the threshold of lung damage in rat) pulsed Doppler and color Doppler ultrasound; then, 
using a 30-MHz active cavitation detection scheme, the first in vivo evidence of cavitation from 
diagnostic ultrasound pulses was reported [36]. Damage to the microvasculature of the lung was 
characterized by extravasation of red blood cells from capillaries into the alveolar space [37]. 
Although this extravasation of red blood cells was reversible, and apparently occurred during 
exposure without rise in severity in the subsequent 5 minutes, exposure of the lung to pulsed 
ultrasound was deleterious to the lung [37]. The first report of lung damage was in situ and at 
exposure conditions of about 1 MPa peak positive pressure, 2 MHz frequency, 10 µs pulse 
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duration, for 3 min [31] and has since been reported in mice, monkey, pigs, rabbits, and rats [38-
43]. A human study reported a lack of lung damage after intraoperative transesophageal 
echocardiography with ultrasound exposure [44]. Lung hemorrhage may be a result of thermal, 
mechanical, or cavitational effects of ultrasound. Ultrasound-related lung hemorrhage is a 
function of frequency [31, 45], pulse duration [31, 46], pulse repetition frequency [31, 47], and 
duration of exposure [35, 47]. Cavitation-related bioeffects are more dependent on frequency 
[31, 45]. 
Child et al. (1990) observed haemorrhage in mouse lung tissue after ultrasound exposure (at 1.2 
MHz, pulse average intensity 1 mW cm
-2
, 10 µs pulse, peak positive pressure 0.7 MPa, 3 minute 
exposure) [31]. Since then, ultrasound-induced lung haemorrhage has been reported in vivo in 
mice [31, 39, 45, 47, 48], rat [46, 47, 49, 50], rabbits [42, 43], and pigs [42, 43, 51, 52]  
Lung damage shows itself as localised lesions located on the lung surface, but there has been no 
report of damage to adult or neonatal human lungs so far [34]. The reason for this effect of 
ultrasound on the lung surface is not fully understood and is still under investigation. It has been 
interpreted that the presence of gas in the lung and intestine results in mechanical trauma to 
adjacent soft tissues as a result of the cavitation process.  
4.4.2 Intestine 
Acoustic cavitation can be generated in a wide range of intestinal environments, as they contain 
gas bodies located in a fluid-like medium [5]. Cavitation-related damage is more certain in the 
intestine and in microvascular with the presence of microbubbles than in the lung [5]. 
Mammalian studies show the occurrence of intestinal hemorrhage when the thermal effects of 
ultrasound have been minimized [32, 53, 54]. Petechiae hemorrhage in the intestine of laboratory 
animals exposed to a lithotripter field is reported in several studies [53, 55, 56]. The threshold of 
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pressure for intestinal hemorrhage in mice ranges from 1-3 MPa [53, 55]. Further evidence 
showing cavitation as a mechanism for effects of ultrasound on the intestine relies on studies 
utilizing ultrasound contrast agents. The area of murine intestinal hemorrhage significantly 
increased when the vasculature was filled with ultrasound contrast agents and exposed to 
ultrasound [57, 58]. The threshold of intestinal damage in the presence of a contrast agent was 
about 3 MPa at 2.4 MHz with a pulse duration of 10 µs [58]. The effect of ultrasound on 
intestinal damage increases with increasing frequency and decreasing pulse duration [57, 58]. 
The response of microbubbles to negative pressure is greater than to positive pressure. More 
damage was noted in the intestine as well as other tissues of mice exposed to negative vs. 
positive pressure of a lithotripter field in the presence of microbubbles [59]. Lehmann and 
Herrick (1953) observed vascular damage in the wall of the intestine,[60] followed by an 
investigation by Dalecki et al. [61] that noted areas of haemorrhage when several abdominal sites 
of mice were exposed to pulsed ultrasound (10 µs, 100 Hz) at 0.7-3.6 MHz [61]. The 
haemorrhage area occurs at a level of exposure above the threshold of about 1 MPa; lower 
frequency levels are more effective at producing haemorrhage than higher frequency levels. 
Using a piezoelectric lithotripter, Dalecki et al. (1995) determined the threshold of ultrasonically-
produced haemorrhage to be about 1-3 MPa [55]. In addition, they found the importance of gas-
body activation by observing a very extensive haemorrhage in the (gas-containing) intestine of 
adult mice and almost no effect in the (gas-free) intestine of their fetuses (at a pressure amplitude 
of 10 MPa) [32]. Petechiae and haemorrhage in the intestine were also observed by Miller and 
Gies [62]. They found the threshold level for petechiae to be 0.28 MPa (spatial average, temporal 
average intensity (ISATA)=2.6 W cm
-2
) and for haemorrhage to be 0.65 MPa (ISATA=14.2 W cm
-2
) 
for the longest exposure (up to 1000 s) of the sample (hairless mice) to 0.4 MHz continuous 
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ultrasound at 37 °C. Pulsed exposures or higher bath temperature affect the threshold level of 
haemorrhage and particularly petechiae. The threshold level of petechiae increased with pulse 
exposure. In addition, for both continuous and pulsed exposure, using an ultrasound contrast 
agent increased the number of petechiae and haemorrhages [57, 58]. Stanton et al. (2001) 
reported the effect of diagnosis ultrasound on the progression of epithelia cells in the crypts of 
the small intestine through the cell cycle [63]. Histological examination of the distal portion of 
the intestine of adult CD 1 mice whose anterior abdomen had been exposed to ultrasound (at 8 
MHz for 15 minutes; special peak temporal average intensity (ISPTA)=1120 mW/cm
2
; PMAX=420 
mW) showed that the number of cells undergoing mitosis was considerably decreased 4.5 hours 
after exposure and the number of apoptotic cells was significantly increased [63]. Overall, 
investigations on ultrasound-related intestinal damage show that cavitation is the responsible 
mechanism. 
4.5 Urinary tract system   
The application of lithotripsy as a clinical treatment for urinary calculosis, or kidney stones, has 
revolutionized the non-invasive treatment of this disease. During a lithotripsy procedure, high 
amplitude acoustic pulses are generated at the site of the kidney stone using short pulses of high 
acoustic pressure ultrasound. The lithotripter shock wave is a short pulse of about 5 µs duration 
with a near instantaneous jump to a peak positive pressure that typically varies between 30 and 
110 MPa. This fast transition in the wave form is called “shock”. The pressure then falls to zero 
about 1 µs thereafter and is followed by a negative pressure between -5 and -15 MPa.  Most of 
the energy in the shock wave is between 100 kHz and 1 MHz [64]. Most lithotripters generate a 
similar type of shock wave with an intense compressive wave that produces mechanical force 
with a tensile component of about -8 to -15 MPa. This negative pressure drives cavitation 
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bubbles that are critical for stone destruction [64]. Cavitation induced by lithotripters behaves as 
a cluster of bubbles rather than individual bubbles, and the coherent collapse of the cluster may 
give rise to its destructive power [65-67]. Almost all patients who receive at least an average 
dose of shock waves (2,000 shock waves at midrange power or higher) experience some form of 
tissue trauma and some patients can experience severe, even catastrophic adverse effects [68], 
including capillary damage and bleeding around the outside of the kidney [69]. The clinical 
implications of such side effects are still under investigation. The mechanisms that may 
contribute to tissue injury are shear stress and cavitation. In lithotripsy, cavitation is more likely 
to create injury within blood vessels and also cause mechanical damage to organs such as the 
kidney. However, severe full skin burns following extracorporeal shock wave lithotripsy for 
renal calculi [70] or second-degree burn after shock wave lithotripsy [71] are often reported. 
Some patients also face post-operative side effects such as pain, vomiting, and wounds on their 
skin. 
Experiments with lithotripsy show the damage to in vitro cells and in vivo tissue is considerably 
decreased when cavitation is reduced or eliminated [72, 73]. The cavitation cycle time (time for a 
bubble to grow and collapse) is on the order of 300 µs in a free field and about 600 µs on the 
surface of the stone [74]. Based on recent studies, the cavitation bubbles produced by one 
lithotripsy pulse can be manipulated by a second pulse [75, 76]. Lithotripsy is a form of focused 
application of ultrasound.  
High intensity focused ultrasound (HIFU) is another modality of focused ultrasound used to treat 
a range of disorders. In HIFU, the ultrasound beam is focused precisely on a target for a non-
invasive or minimally invasive method of direct acoustic energy delivery into the body. HIFU is 
used for treatment purposes including those related to cancer therapy, surgery, and enhancing the 
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delivery or effect of chemotherapy or immunotherapy. The intention of HIFU is heating a target 
volume of tissue without affecting the tissue in the ultrasound propagation pathway. HIFU can 
increase the temperature of a selected area above 55 °C, which results in coagulative necrosis 
and immediate cell death in a specific volume (the “lesion”) through a focused ultrasound beam. 
Because the ultrasound wavelength at MHz frequencies has a millimetre-scale beam size and the 
ultrasound probe has a concave shape, the ultrasound beam can be focused into small, clinically 
relevant volumes of tissue. The energy absorption raises the temperature at the focus point but 
only to non-cytotoxic temperatures outside the region [77]. HIFU is applied from sources placed 
either outside the body for treatment of liver, kidney, breast, uterus, pancreas, and bone cancer or 
inside the body through the rectum for treatment of prostate cancer [77]. HIFU is gaining rapid 
clinical acceptance for non-invasive tissue heating and ablation for various applications. 
However, there are complications and side effects during HIFU treatment of tumors. For 
example, second-degree skin burns were reported in all patients [78] and third-degree skin burn 
in 3% of patients [79] during HIFU pancreas tumor treatment. Adverse effects such as tumor or 
vessel rupture during HIFU can lead to metastasis via the bloodstream. Serious adverse effects 
such as intrahepatic metastasis [80], lung embolism, deterioration of liver function, renal failure, 
and death can result from HIFU treatment [81]. The rates of adverse events in both malignant 
and benign lesions during HIFU largely depend on the disease type and the HIFU device used s 
[81]. HIFU therapy involves both thermal effects and cavitation that may lead to adverse effects 
and lesions. Skin burn is considered a thermal lesion and arises from the thermal effects of 
HIFU. Adverse effects such as tumor or vessel rupture and bleeding, ectopic embolism, and 
metastasis arise from cavitation during HIFU. The mechanical effect of cavitation can rupture 
vessel walls from the primary tumor site and at the same time detach cancerous cells/emboli and 
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lead to their release into circulation where they may cause metastasis or embolism [82, 83]. For 
example, intrahepatic metastasis [80] and rupture of esophageal varices [84, 85] after HIFU 
treatment have been reported. Cavitation gives rise to sensitivity of tissue to heat and causes 
extension of lesions beyond the HIFU focal point [86] that can lead to severe events if the lesion 
is in the vicinity of vital structures [81]. Peripheral nerve injuries following bone cancer 
treatment (reversible or irreversible) [87], ischiadic or sacral nerve damage, and hematuria 
during uterine fibroid treatment (potentially reversible) [88] are some other adverse effects of 
HIFU treatment. Adverse effects of HIFU frequently happen in tissues adjacent to the target 
focus as well as in the pathway of the HIFU beam. Therefore, selecting a proper delivery 
pathway for the HIFU beam [81], and, more importantly, improving cavitation monitoring 
techniques toward upgrading the accuracy of HIFU devices are necessary for improving the 
safety profile of this technique.        
4.6 Cardiac 
Premature ventricular contractions are another effect that results from exposure to a lithotripter 
ultrasound field [89, 90]; cardiac rhythm can be affected by even a single high-amplitude pulse. 
The threshold required to generate premature cardiac contractions is below the pressure 
amplitudes applied in clinical lithotripsy (positive pressure between 30 and 110 MPa and 
negative pressure between -5 and -15 MPa). To avoid affecting the cardiac rhythm during 
lithotripsy, the clinical delivery of lithotripter pulses is synchronized with an electrocardiogram 
[5]. To cause premature contractions, long ultrasound pulse durations and high-pressure 
amplitudes (e.g., a 5-ms pulse and 2-5 MPa, which is the threshold to cause a premature 
contraction in mice and frog at 1.2 MHz) are required, but these are not exposure characteristics 
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of diagnostic ultrasound [5]. Therefore, premature ventricular contractions should not occur 
during diagnostic ultrasound imaging. 
Investigations using ultrasound contrast agents suggest that cavitation may be responsible for 
ultrasound-related premature cardiac contractions. The threshold for this effect of ultrasound is 
considerably lower in the presence of ultrasound contrast agents and at shorter pulse durations 
(e.g., the threshold for production of a premature contraction in the presence of contrast agents in 
mice exposed to a single 10-µs ultrasound pulse at 1.2 MHz was about 1 MPa [91]) [91-94]. 
Premature ventricular contractions have been reported in humans with ultrasound contrast agents 
in their blood and exposed to diagnostic ultrasound [94]. The threshold conditions for such an 
effect in laboratory animals is a 10-µs pulse of 1-MHz ultrasound and peak pressure amplitudes 
(positive and negative) on the order of 1 MPa [91, 92]. Microvasculature damage in hearts 
exposed to ultrasound in the presence of ultrasound contrast agents has also been reported, but 
without any certain relationship to the generation of arrhythmia [92, 93].  
The other mechanical bioeffect of ultrasound on the heart is cardiac contractility, which can be 
generated by a single pulse of high amplitude ultrasound (peak positive pressure of about 1 MPa) 
[95, 96]. A series of experimental studies suggests that radiation force is responsible for this 
effect [96]. Animal studies (frog) showed the direct aortic pressure effect of ultrasound is related 
to the magnitude of the radiation force extended on the heart [96]. The role of radiation force 
alone on this effect was confirmed by a study in which an acoustic reflector was placed on the 
surface of the heart to preclude the possibility of heating and cavitation and instead maximize the 
radiation force delivered [96]. 
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4.7 Blood vessels and microvasculature 
The rupture or destruction of blood cells in the presence of ultrasound contrast agents at 
diagnostic levels of ultrasound has occurred in in vivo studies with laboratory animals [97]. Fetal 
red blood cells are even more susceptible to lysis from exposure to ultrasound in the presence of 
contrast agents in vitro [98]. However, this is not known to occur in mammals at diagnostic 
levels of ultrasound in the absence of ultrasound contrast agents [5]. In an in vivo study, 
hemolysis occurred when mice were exposed to ultrasound at a frequency of 1.1 MHz (10-µs 
pulse duration) and ~2 MPa negative pressure with ultrasound contrast agents [99]. 
To study the effects of ultrasound and contrast agents on microvasculature, isolated rabbit hearts 
were treated by a cardiac ultrasound system at 1.8 MHz with 1 Hz triggering of imaging frames 
[100]. Capillary damage and red blood cell (erythrocyte) extravasation was observed at an MI of 
1.6 when the treated heart was examined. Chen et al. [101] examined the injurious effects of an 
ultrasound contrast agent (Optison or Definity) in rat heart in vivo, and observed elevation of 
troponin T in blood plasma as evidence of myocardial damage. 
Cavitation is more likely to cause injury within blood vessels than in the surrounding tissue 
because a bubble surrounded by tissue is constrained and cannot go through the violent growth 
and collapse cycle compared to a bubble in a fluid environment such as a blood vessel. Bubbles 
can cause mechanical damage to organs such as the kidney through at least two mechanisms: 
collapse and expansion. The asymmetrical collapse of cavitation bubbles forms high velocity 
microjets of fluid that travel at speeds close to 400 km/h [102] as well as the emission of 
secondary shock waves that are radiated into the bubble and have a comparable amplitude to that 
of the focused shock wave [103]. The liquid microjets are forceful enough to easily puncture the 
fragile wall of a capillary or other blood vessel. Vessel walls may also rupture during the 
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expansion phase of the bubble cavitation cycle [103]. When a bubble undergoes explosive 
growth in the vessel, it pushes the vessel outward and ruptures it. Experiments using capillary 
phantoms in an in vitro system confirm this hypothesis [104, 105].  
The bubble expansion mechanism may also lead to other tissue damage. When blood vessels 
rupture and blood is collected in pools (for example in a hematoma), then the potential for 
cavitation increases because the pooling of blood provides a fluid-filled space in which 
cavitation can occur [103]. Although cavitation is the primary mechanism of tissue injury 
studied, much more investigation is still required [103].  
Damage to the microvasculature in tissues such as the kidney and liver in laboratory animals 
after exposure to lithotripter high-amplitude ultrasound has been reported in several studies [56, 
106-108]. Damage to the microvasculature is considerably increased in the presence of 
ultrasound contrast agents in the vasculature [109-111]. In the presence of ultrasound contrast 
agents and an amplitude of only 2 MPa, reversible microvasculature damage has been observed 
in several soft tissues of mice, including muscle, mesentery, kidney, stomach, bladder, and fat, 
with persistent sensitivity to lithotripter exposure for several hours [109, 110]. In the absence of 
ultrasound contrast agents, minimal damage occurs at amplitudes up to 40 MPa. High amplitude 
pressure lithotripter pulses can cause cavitation in vivo and, in the presence of contrast agents, 
inertial cavitation can cause microvasculature damage. This understanding relies on the fact that 
hemorrhage in tissue (as a sign of response of microbubbles) at negative pressures is much 
greater than at positive pressures, as reported in different studies [5, 59].  
Evidence indicates that pulsed ultrasound can also produce capillary damage in the presence of 
ultrasound contrast agents in the blood. Capillary rupture has been observed in muscle [112, 
113], kidney [114], and cardiac tissues [92] of laboratory animals exposed to diagnostic levels of 
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ultrasound. Considering that no damage has been reported in these tissues from exposure to 
ultrasound in the absence of an ultrasound contrast agent, it can be concluded that normal tissue 
may contain no cavitation nuclei [5].  
The effect of ultrasound on tissues in the presence of ultrasound contrast agents can be decreased 
by increasing the applied frequency as well as decreasing pressure amplitudes and the amount of 
contrast agents in the tissue [5]. In general, the mechanical effect of ultrasound increases in the 
presence of contrast agent microbubbles, which have potential utility in future therapeutic 
applications of ultrasound. For example, the capillary damage effect of ultrasound in the 
presence of ultrasound contrast agents facilitates the process of microbubble drug or gene 
delivery, in which microbubbles are loaded with drug/gene and then unloaded in a specific 
localized area of body [113, 115-118]; it also facilitates arteriogenesis [119, 120] and tumor 
therapy [117, 121-123]. 
In work by Williams et al. [125], therapeutic ultrasound was shown to decrease the 
recalcification time of anticoagulated whole blood in vitro. Therapeutic ultrasound has also been 
demonstrated to be capable of inducing platelet aggregation and releasing the platelet-specific 
protein β-thromboglobulin (β-TG), indicating that the platelet is the probable site of interaction 
and damage [125]. Their study also suggested that ultrasound interacts with blood platelets (the 
exceptionally fragile cells that play an important role in the early stages of clot formation) 
possibly via the occurrence of cavitation processes at MHz frequency levels. Furthermore, their 
in vivo study showed the production of platelet thrombi and true clots within the intact vascular 
system of mice as a result of acoustic microstreaming, similar to that developed around 
oscillating gas bubbles [125].          
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4.8 Prenatal exposure 
At lower levels of ultrasound, such as for diagnostic purposes, ultrasound does not induce 
cavitation in the absence of pre-existing gas bubbles and also does not generally cause heating 
beyond the normal physiological range [34].  Prenatal exposure to a diagnostic level of 
ultrasound produces changes in neuronal migration in the developing brains of mice [124]. 
Significant concerns in the study of side effects of ultrasound in human are related to in utero 
exposure to diagnostic ultrasound. Based on available evidence, there are no effects on perinatal 
mortality and childhood malignancies; however, some observational studies have found an 
increased prevalence of non-right handedness in males with prenatal ultrasound exposure [34]. 
This might reflect confounding effects rather than causation; however, randomly comparing 
individuals who received prenatal ultrasound exposure with those who did not shows weak 
evidence for an ultrasound effect on non-right-handedness [33, 34]. At high levels of exposure, 
ultrasound is capable of causing permanent damage to biological tissue as a result of heating, 
acoustic cavitation, and radiation force [34] that can disturb the development of an embryo or 
fetus, i.e., teratogenic effects.  
4.9 Biological Responses to Acoustic Mechanisms 
The interaction of ultrasound with biological systems has been the subject of a considerable body 
of research. The potential biological changes associated with clinical applications of ultrasound, 
especially in obstetrics and gynaecology, have been studied in a wide variety of in vitro and in 
vivo models and ultrasound exposure conditions. However, sufficient caution must be exercised 
when extrapolating in vitro results to in vivo conditions. For example, the mechanism of 
interaction of sound waves with cells in vitro (in the liquid environment), where cell cultures are 
in suspension in a nutrient liquid medium or attached to a coated surface, may be very different 
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from the in vivo environment that features more solid structures such as tissue and bone [34]. 
The effect of ultrasound in cell suspensions is also different from monolayers of cells attached to 
a surface [34]. In the liquid environment, the most dominant physical mechanisms for biological 
effects of ultrasound are acoustic cavitation and streaming; substantial heating is unlikely 
because of the low acoustic absorption coefficient [34]. When tissue is exposed to ultrasound in 
vivo, high acoustic absorption energy in tissue causing thermal effects becomes more important 
compared to in vitro systems, while the probability of cavitation occurrence in tissue is less than 
in liquid. However, the probability of cavitation occurrence in intact tissue depends on 
temperature, the tissue state, and gas content [33, 34]. Acoustic exposure conditions as well as 
the mode of energy deposition are also very important for studying the biological effects of 
ultrasound. Two acoustic exposure conditions with the same exposure time and energy but 
different modes of energy deposition (one in continuous mode and the other in short pulses at a 
low repetition rate) may result in very different effects in tissue. Cavitation activity and its 
associated characteristic cell damage is more probable with short pulses at a low repetition rate, 
while thermal effects are more likely in continuous mode [34]. Therefore, in diagnostic 
ultrasound that features short exposures and relatively low temporal average intensities, thermal 
effects may not be very important in soft tissue; heating is more likely in tone burst and 
continuous exposure in therapeutic applications. However, high pressure amplitude with even 
short pulse mode exposure, such as used in lithotripsy, may promote acoustic cavitation in liquid 
media [34]. Passive cavitation detection has been used in several studies of ultrasound ablation 
[126-131], lithotripsy-induced cavitation detection [132]. Measurements using passive cavitation 
detection in both human and pig have shown the presence of bubbles in the perirenal fat, the 
collecting system, the parenchyma, and in subcapsular hematomas. The onset of detectable 
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cavitation in the parenchyma of a pig model required approximately 1000 shock waves to be 
delivered by a Dornier HM3 lithotripter [103]. In addition to acoustic exposure conditions, the 
maturity of the individuals being exposed is an important consideration, as biological damage to 
a few cells of the developing embryo is much more significant than to a small volume of adult 
cells. The acoustic properties of the early embryo are very similar to those of water. Therefore, 
bulk heating effects may be unimportant in the early embryo while heating at the bone surface 
may happen in a third trimester fetus in which bone mineralisation has occurred [34].  
4.10 Cellular bioeffects 
To study the interaction of ultrasound with biological systems, experimental studies with cells 
and animals have been performed at a variety of exposure conditions. Studies that describe 
ultrasonically-induced biological changes in cells in vivo and in vitro have been reviewed by 
Feril and Kondo [133], Miller [134], ter Haar [135], the National Council on Radiation 
Protection and Measurements (NCRP) [136], and the American Institute of Ultrasound in 
Medicine [137]. The most important representative examples of potential adverse effects on cells 
are cell lysis, changes in cell division capability, ultrastructural changes, chromosomal and 
cytogenetic effects, and functional changes [34]. The effects of ultrasound on cells fall into two 
categories: gross effects, such as lysis, effects on cell division capability, and damage to cellular 
ultrastructure; and subtle effects, such as chromosomal changes, functional changes, and altered 
growth patterns [34].  
There is extensive and unequivocal evidence that ultrasound exposure of cells in suspension 
leads to cell lysis [34]. Several studies including, for example, Kaufman et al. [138], Morton et 
al. [139], Hallow et al. [140], and Lai et al [141], have shown that cavitation is a major 
mechanism resulting in this sort of complete cellular disruption; however, it is not clear if 
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ultrasound is able to produce lysis in the absence of cavitation effects [34]. Apart from the 
ultrasound exposure conditions, the amount of cell lysis can depend on the concentration of cells 
in suspension [142, 143] as well as cell size [144, 145]. Lysis appears to be an immediate 
consequence of ultrasound exposure effects on cells and this may affect cells in mitosis more 
than other cell cycle stages [146]. Colonogenic assays enable assessment of cell division 
capability following a specific insult. Based on studies performed by Bleaney et al. [147] and 
Morton et al. [139], cells that survive ultrasound exposure and stay intact will continue 
producing progeny in the same way as their untreated counterparts. However, there are 
exceptions for ultrasound exposed cells that remain at elevated temperatures [148, 149].  
The interaction of ultrasound with the cell membrane has been of interest in ultrasound-mediated 
drug delivery and sonoporation [150-152] and extraction of medicinal compounds from 
biological resources [153]. Changes in permeability to ions is one of the usual changes that 
occurs in cells exposed to ultrasound. Research by Chapman [154] demonstrated that acoustic 
exposure at 1.8 MHz and ISATA=1 W cm
-2
 in vitro resulted in sublethal alteration in the 
thymocyte plasma membrane, which leads to a decrease in potassium content. A reversible rise 
in calcium ion uptake in fibroblasts was observed by Mortimer and Dyson [155] at an ultrasound 
frequency of 1 MHz and intensity of ISATA=0.5-1 W cm
-2
. 
Electron microscopy results of cells and tissues following exposure to ultrasound show damage 
to a variety of subcellular organelles, primarily mitochondria, and damage to lysosomes with 
consequent release of lysosomal enzymes in tissue [156-158]. In addition to membrane and 
mitochondrial damage as a result of cavitation, Harvey et al. (1975) observed dilated rough 
endoplasmic reticulum and some irregular lesions [159]. Generally, the cell nucleus seems 
unaffected by ultrasound exposure; the only type of lesion observed is slit-like vacuoles at the 
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nuclear membrane [160]. Watmough et al. (1977) hypothesized that ultrasound may produce 
cavitation microbubbles within cells and that nuclear, mitochondrial, and granular endoplasmic 
reticulum membranes act as nucleation sites; thus, when these organelles are affected, damage 
might show itself as lesions next to the membrane [161].  
Cytogenetic studies on the effect of ultrasound on chromosomes clearly show that high intensity 
ultrasound can cause degradation of DNA in solution. Damage appears to be due to 
hydrodynamic shear stresses, free radical formation, or excessive heating as a result of cavitation 
[162-164]. A large amount of evidence shows that high intensity ultrasound up to a power of 
ISATA=100 W cm
-2
 does not produce chromosomal damage [165, 166]. However, when an 
ultrasound exposure at an intensity of 3 W cm
-2
 and frequency of 810 kHz is followed by (not 
preceded by) X-irradiation to 1 Gy, some synergistic interactions may result in chromosomal 
aberrations [167]. Diagnostic ultrasound even at intensities up to ISATA=3.0 W cm
-2
 (3.15 MHz) 
does not produce sister chromatid exchanges (SCEs) in vitro [168]. Whether ultrasound may 
result in chromosomal damage is not certain; however, the most carefully documented studies 
have returned negative results. It must also be considered that these were in vitro studies, and the 
interaction mechanism in vitro may be different from that in intact tissue in vivo. Overall, 
ultrasound may cause epigenetic changes, such as modification of histone protein structure, that 
can have a long-term influence on gene expression [34]. Ultrasound may also lead to stimulation 
of cellular functions that mostly involve interactions at the cell membrane level [34]. Taylor and 
Newman [169] report that ultrasound exposure at treatment conditions of 1 MHz, ISATA=10 W 
cm
-2 
, pulses of 20 µs-10 ms, for over 2.5 minutes influenced the electrophoretic mobility of 
cells, which reflects a cell surface charge density change as a result of volume changes [170]. 
The results of time-lapse photomicrography of cellular movements in vitro show ultrasonically 
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induced changes that may last for several generations of cells [171]; however, such results are far 
from clear in vivo [34]. To obtain a clearer indication of the biological effects of ultrasound, 
various studies focusing on biological systems such as bone, blood, vasculature, and lung as well 
as effects on the fetus and embryo have been conducted using small animal models.  
4.11 Studies on Biological Effects of Ultrasound 
Low intensity pulsed ultrasound (such as 0.5-50 mW/cm
2
) has a favorable effect on bone fracture 
healing [172]. Several studies have shown that low intensity ultrasound increases the rate of 
tissue repair following injury, especially those associated with bone fracture [173, 174]. The 
reasons why ultrasound can give rise to tissue repair and also the functional significance of 
changes in neuronal migration in the developing brains of mice are not known.  
In physiotherapy, hyperthermia treatment, and pulsed Doppler exposure at its maximum output 
power, one of the main concerns and problems has been pain induction due to heating of the 
highly innervated periosteum. Biologically relevant temperature increases (over 2 °C) at the skull 
bone of laboratory animals have been recorded during ultrasound exposure [34]. Smith et al. 
[175] demonstrated that ultrasound exposure at high intensities (over ISATA= 40 W cm
-2
) in 
thermal ablation therapies can lead to osteocyte damage and thermal necrosis. Evidence shows 
that very low intensity ultrasound (ISATA=12-100 mW cm
-2
) can influence bone regeneration 
[176] and this fact is used for treatment of fractures. These influences are predominantly due to a 
non-thermal mechanism that critically depends on the intensity applied [34]. The temperature 
increase for intensities of ISATA=20-50 mW cm
-2
 was below 1 °C [177]. Duarte et al. [178] also 
report negligible increases in temperature (0.01±0.005 °C) in rabbit fibula osteotomies following 
treatment at ISATA=50 mW cm
-2
 for 15 minutes per day. However, even a small rise in 
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temperature (less than 1 °C) can influence some enzymes, such as matrix metalloproteinase 1 
that has been shown to be very sensitive to temperature [179, 180].  
The biophysical process behind bone regeneration stimulation is still unknown. However, several 
studies suggest that low intensity ultrasound can affect cell membrane permeability [155, 181-
190] and increase hydrostatic pressure [185] or can induce mechanical stimulation of 
micromotion [191] and cause acceleration of fracture healing. Relative to an untreated control, 
high intensity ultrasound (ISATA=0.2-3 W cm
-2
) gives rise to callus formation and accelerates 
fracture healing in rabbit radii [192, 193] and tibia [194] and guinea pig ulnae [195]. High 
intensity ultrasound treatment (ISATA=0.5 W cm
-2
) of limbs resulted in a 36% increase in new 
bone formation and an 80% increase in torsional stiffness compared with controls [177]. 
Studies on the effect of ultrasound on blood have focused on platelets, the most fragile 
component. In vitro experiments show that ultrasound exposure can lead to platelet activation. In 
the presence of stable bubbles (those that do not collapse violently and instead oscillate for 
several cycles around their resonance size), a pressure amplitude of 10 MPa and low average 
ultrasound intensity of ISATA=0.8 W cm
-2
 can cause platelet disruption [196]. Although 
erythrocytes seem to be more resistant than platelets to ultrasound damage, haemolysis has been 
reported when inertial cavitation occurs [197-199]. Williams and Miller (1980) suggest that 
adenosine-5’-triphosphate (ATP) may be released at lower intensities when inertial cavitation 
occurs [200].  
Because of the continual filtration of impurities in whole blood in vivo, the probability of 
cavitation nuclei is reduced and therefore under normal conditions cavitation is unlikely to 
happen [34]. However, Brayman et al. [143] show cavitation may occur at sufficiently high 
pressures. Damage to blood components in vivo has not been clearly demonstrated [99, 201-203]. 
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In experiments by Dalecki et al. [99], a clinically insignificant level of haemolysis (0.46%) was 
detected in mice exposed to ultrasound through the chest wall at a frequency of 2.35 MHz and a 
peak positive pressure amplitude of 10 MPa.  
VanBavel (2007) reviewed the effects of ultrasonically-induced shear stresses on endothelial 
cells and noted that[204], a major stimulus for many endothelia responses is provided by the 
shear stress associated with normal blood flow. For example, normal shear stress found in large 
arteries away from branches is on the order of 2-4 Pa [205] and very rarely exceeds 8 Pa. The 
shear stress that veins experience is around 0.1-0.6 Pa [204]. Microstreaming associated with an 
ultrasonic field induces shear stresses that may be expected to increase biological effects. These 
shear stresses are higher than normal physiological levels and can occur on a membrane, rupture 
it, or alter its permeability [34]. Experiments performed by Dalecki et al. [206] showed that 
ultrasound at acoustic treatment conditions of 1.2 MHz, peak positive pressure of 4 MPa, peak 
rarefactional pressure of 2.5 MPa, 10 µs, pulse repetition frequency of 100 Hz for 3 minute 
exposure may induce haemorrhage near to fetal bone. Haemorrhage has also been observed in 
the lung and intestine of mice when treated at pressures greater than diagnostic levels. However, 
haemorrhage and these kinds of effects in other tissues are more associated with ultrasound 
treatment in the presence of a gas-filled ultrasound contrast agent [34]. Dalecki et al. [206] 
imputed these effects to the relative motion between partially ossified bones and the surrounding 
tissues (that may leads to fragile fetal blood vessel damage); however, Bigelow et al. (2007) 
postulated the involvement of thermal effects[207].  
Application of an ultrasound contrast agent (suspensions of stabilised bubbles) seems to give rise 
to biological effects through gas-body activation [134]. Brayman et al. [208] observed that the 
contrast agent in suspension adjacent to orientation of the monolayer (i.e., simulatingthe sites of 
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ultrasound entry or exit from a blood vessel) gave rise to damage and erosion of cells. They 
modeled the endothelial layer of blood vessels using fibroblast monolayers in vitro and 
ultrasound treatment was performed at 1.0, 2.1, and 3.5 MHz. The lysis or breaking open of 
erythrocytes leads to the release of hemoglobin into the surrounding fluid. The frequency 
dependence of haemolysis with a first-generation ultrasound contrast agent (Albunex) in whole 
blood and a second-generation perfluorocarbon-based ultrasound contrast agent (Optison) was 
studied  by Miller et al. [209] and Miller and Gies [210]. Miller and Gies [211] show that 
Optison caused more haemolysis than Albunex, especially when ultrasound exposure was in 
pulsed mode. The ultrasound contrast agent gas bodies can nucleate inertial cavitation [163] as 
there is good correlation between the amount of haemolysis induced by ultrasound and inertial 
cavitation activity [212-215]. Ultrasonically-induced haemolysis strongly depends on the 
frequency [213, 216, 217], with overall biological effects decreasing with frequency [34].  
Contrast agent injection may enhance the risk of capillary rupture by diagnostic ultrasound [34]. 
Miller and Quddus (2000) anaesthetised hairless mice, injected them with Optison (5 mL kg
-1
), 
and scanned them using a 2.5 MHz transducer (610 ns pulses with 3.6 kHz repetition frequency 
and 61 Hz frame rate); this resulted in an increasing number of petechiae (capillary rupture with 
erythrocyte extravasation) in the intestine and abdominal muscle[112]. The increase in petechiae 
was considerable above 0.64 MPa for muscle and 1 MPa for intestine [34]. The rat heart was 
used as a model system to examine microvascular injury of ultrasound by Li et al. [92, 218]. Rats 
were examined in a water bath using a 1.7 MHz diagnosis ultrasound system and bolus doses of 
three different ultrasound contrast agents (Optison, Imagent, and Definity). They detected 
petechiae on the heart surface and also microvascular leakage by injecting Evans blue dye before 
scanning. The results of their study demonstrated that the contrast agent delivery mode and dose, 
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as well as the ultrasound parameters, have a considerable effect on cardiomyocytes. Vascular 
damage might be physiological and not accompanied by irreversible cellular injury [219]. In fact, 
dynamics of microbubbles both in vitro and in vivo show that the oscillation of microbubbles 
increases vascular permeability and even locally injured vasculature [220, 221]. Depending on 
the amount of temperature rise during ultrasound application, the effects on vasculature can be 
either reversible/repairable or irreversible. In reversible cases, the effects are temporary and no 
permanent vascular occlusion is produced. In irreversible cases, the energy deposition is 
sufficient to produce long-term damage with persistent effects of vascular spasm, obstructed 
blood flow, and increasing endothelial destruction that lead to a loss of vascular relaxation 
responses [222]. Therefore, appropriate strategies need to be designed to minimize irreversible 
damage to capillaries [220]. 
Kobayashi et al. [223, 224] studied the microvascular injury in rat mesentery by applying a 
phased array ultrasound system at a frequency of 1.8 MHz. Endothelial cells were damaged in 
capillaries and venules for all conditions at 0.82 MPa. The influence of contrast-enhanced 
diagnostic ultrasound (Optison and several experimental agents) in kidney of rat at three 
different frequencies of 1.8, 4, and 6 MHz was studied by Wible et al. [114]. Glomerular 
capillary haemorrhage was driven from the glomerular tuft into Bowman’s capsule and proximal 
convoluted tubules. Shigeta et al. [225] demonstrated that platelet aggregation in the liver 
sinusoids of rat occurred after exposure of the liver to diagnostic ultrasound at 8 and 12 MHz 
with an ultrasound contrast agent (Levovist). They also observed endothelial cell damage in 
samples taken five hours after acoustic exposure. Based on experiments by Stroick et al. [226] 
and Hardig et al. [227] in an animal model, the extent of intracerebral haemorrhage is not 
enhanced by ultrasound exposure in the presence of an ultrasound contrast agent. The effect of 
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ultrasound exposure on rat heart was detected using diagnostic imaging with an experimental 
ultrasound contrast agent by Vancraeynest et al, 2006 [228].  Findings of histologically definable 
injury in rat hearts were confirmed by [229, 230] and indicate that elevating the parameters for 
therapeutic efficacy results in severe microscale injury and functional impairment of the heart 
[228].  
New techniques have been developed with respect to the use of ultrasound and specially 
designed contrast agents to aid drug delivery across the blood-brain barrier (BBB) [34]. It was 
first thought that opening the BBB was induced by inertial cavitation, although disruption in the 
absence of indicators of inertial cavitation has been demonstrated [34]. In almost in every study 
featuring a combination of ultrasound and ultrasound contrast agent, some BBB injury has been 
observed [34]. Mesiwala et al. [231] showed that HIFU resulted in selective and non-destructive 
disruption of the BBB in a rat model. It is possible that the BBB is opened at the focal point 
without sharp neuronal damage if microbubbles are introduced into the bloodstream before 
focused ultrasound exposure [232]. Therefore, limiting the effect of ultrasound on the 
vasculature and decreasing the intensity required to produce BBB opening can be achieved by 
introduction of cavitation nuclei into the bloodstream. This also reduces the risk of damage to 
tissue [34]. BBB disruption was also detected by Hynynen et al. [232] and Kinoshita et al. [233] 
after applying contrast-enhanced magnetic resonance imaging (MRI) at the desired location, as 
well as with post-mortem histology by Mesiwala et al. [231] and Kinoshita et al. [233]. Hynynen 
et al. [234] studied the localized effects of ultrasound exposure on rabbit brains using contrast-
enhanced MRI. Their study showed BBB disruption for pressure amplitudes above 0.4 Mpa, at 
10 ms exposure with a frequency level of 690 kHz, a repetition frequency of 1 Hz, and total 
exposure time of 20 s. The results of a histological study four hours after exposure showed about 
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70-80% brain tissue necrosis at pressure amplitude levels above 2.3 MPa. Small areas of 
erythrocyte extravasation were also observed at lower pressure amplitude levels. Another study 
demonstrated that when rabbit brain is exposed to ultrasound at 1.63 MHz, a pulse length of 100 
ms, a pulse repetition frequency of 1 Hz, at 0.7 to 1.0 MPa for 20 s, only a few cells in some of 
the sonicated areas had ischemia or apoptosis, but no ischemic region that would indicate 
compromised blood supply was observed. MRI or histology up to 4 weeks after sonication 
showed no delayed effect [235]. Therefore, it is possible that BBB disruption after ultrasound 
may occur without any basic vascular damage; however, red blood cell extravasation into tissue 
indicates BBB injury has occurred and, as such, the method can be harmful especially for 
therapeutic applications for brain disease [34].  
Hynynen et al. [236] studied the effect of burst mode of ultrasound exposure in the presence of 
an ultrasound contrast agent on brain tissue using contrast-enhanced MRI and histology. Brain 
tissue damage, including vascular wall damage, haemorrhage, and sometimes necrosis, was 
induced at a pressure amplitude of 6.3 MPa (exposure conditions of 1.5 MHz, 10 µs bursts 
repeated at a frequency of 1 kHz for 20 s). At all tested pressure values, occasional smooth 
vascular damage in almost 50% of the sonicated locations was observed without any signs of 
ischemia.  
Fatar et al. [237] applied ultrasound (at 2 MHz, 1052 peak negative pressure, and temporal 
intensity of 37.3 W cm
-2
) and microbubbles (SonoVue) in a middle cerebral artery occlusion 
model in rats and studied the influence on brain infarct volume, apoptosis, IL-6 and TNF-alpha 
levels, and disruption of the BBB. They observed a reduction of the infarct volume in treated 
samples compared with controls. The results showed no additional BBB disruption and also no 
rise in apoptotical cell death outside the infarction area. Another study showed that rabbit brain 
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exposure to low intensity ultrasound (at 1.7 MHz for 30 s) and close to the threshold for tissue 
damage gave rise to apoptotic cells over 48 hours, but the lesions were dominated by necrosis 
[238]. Adding ultrasound contrast agent (Optison) to the treatment process (at 1.5 MHz, 1.4-8.8 
MPa, and for 20 s) resulted in domination of lesions by apoptosis, with the number of apoptotic 
cells approximately six times that of necrotic cells [239]. Another study on the short-term safety 
of BBB opening using focused ultrasound and an ultrasound contrast agent (Baseri 2010) 
reported the feasibility of a safe BBB opening under a specific set of sonication parameters. In 
this study, a short-term (30-min or 5-h survival) histological assessment was performed on 49 
mice with an intravenously injected ultrasound contrast agent. Mice were exposed to ultrasound 
at a frequency of 1.525 MHz, pulse length of 20 ms, pulse repetition of 10 Hz, peak rare 
factional acoustic pressure of 0.15-0.98 MPa, and two 30-s sonication intervals with an 
intermediate 30-s delay. The BBB opening threshold and the safest acoustic pressure were 
reported to be 0.15-0.3 and 0.3-0.46 MPa, respectively (Baseri 2010). Another study indicated 
that repeated opening of the BBB through FUS and ultrasound contrast agents at the basal 
ganglia of non-human primates is safe for up to 20 months with no long-term negative 
physiological or neurological effects (Downs 2015). This study was conducted using ultrasound 
parameters of 500 kHz, 200-400 kPa, administration of 4-5 µm microbubbles, and 2 min 
sonication, resulting in repeated opening of the BBB. These results demonstrate promise for 
clinical and basic scientific applications[240].    
4.12 Fetus and embryo 
Concerns regarding the effect of ultrasound on fetal and embryonic development (teratogenic 
effects) have generated a large number of studies using different animal species and various 
exposure conditions. The probability of adverse effects of ultrasound on fetal and embryonic 
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development has been reviewed by Ziskin and Barnett [241], Miller et al. [242], and Church and 
Miller [243]. Non-thermal interactions of pulsed ultrasound, especially cavitational mechanisms 
in the presence of an ultrasound contrast agent, may have adverse effects on the integrity of 
maternal and developing tissue. However, there is a low possibility of occurrence of these 
interactions in the fetus [244, 245]. In addition, the teratogenic effects of heat as a result of 
probable localized hyperthermia during pregnancy ultrasound scans have been extensively 
reviewed by Miller and Ziskin [246], Miller et al. [242], and Edwards et al. [247]. High maternal 
or fetal temperatures can have adverse effects on many developing tissues, particularly the brain 
and nervous system [242]. 
The teratogenic effect of heat on mammals is well accepted and, among all organs and tissues, 
the developing central nervous systems shows the greatest sensitivity [34]. Miller and Ziskin 
[246], Miller et al. [242], and Edwards et al. [247] conducted animal studies on the possible 
pathogenic mechanisms and thermal effects on the embryo and fetus. Embryo death, growth 
retardation, internal and external abnormalities, developmental deficits, and behavioral changes 
that persist into adulthood are some of consequences of fetal hyperthermia [247]. The occurrence 
of these thermal effects depends on three main parameters: the grade of normal core temperature 
promotion, the duration of the elevation in temperature, and the specific phase of development 
(pre-implantation, organogenesis, or fetal period) in which the heating happened [34]. Edwards 
et al. (2003) demonstrated that the sensitivity of the embryo and fetus to heat changes 
considerably during development and depends on the particular cell cycle, e.g., cell proliferation, 
differentiation, or migration[247]. They also described the teratogenic or biological effects of 
heat at different steps of development. Higher temperatures for a shorter time may raise the risk 
of a certain defect; the best estimate by Miller et al. (2002) is a threshold of 1.5-2.5 °C above 
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normal body temperature for an hour or so in pregnant animals, acknowledging that each type of 
defect and species has its own temperature threshold[242]. In addition to the thermal effect of 
ultrasound, pulsed and continuous-wave ultrasound can affect reproduction and prenatal 
development of the embryo and fetus [248]; [249]. Notable ultrasound effects such as increased 
malformation rates or weight changes have been observed in some studies, while others do not 
report any firm exposure-related effects in either dam or child [250-263]. These studies used 
different endpoints, pregnancy ages, species, and ultrasonic exposure conditions, making direct 
comparisons of results problematic. No considerable treatment-related effects were observed on 
reproductive outcome or maternal weight during gestation, on viability or weight of child, or on 
the morbidity of skeletal or visceral malformations when rats were exposed to 3 MHz continuous 
wave [264, 265] or pulsed ultrasound [254, 255] at up to 30 W cm
-2
 (ISPTA). Statistically 
considerable decreases in body weight of offspring were observed following frequent exposure 
of cynomolgus macaques to ultrasound (at 7.5 MHz and ISATA=0.28-12 mW cm
-2
) [250, 266, 
267]; this effect occurred during the first three months of life and not for the subsequent nine 
months. In a study by Arthuis et al. (2013) in which contrast-enhanced ultrasound imaging and 
Doppler were used to quantitatively monitor uteroplacental perfusion in rat pregnancies, no 
microbubbles were detected in the umbilical vein or fetal components[268]. The absence of 
contrast agents in the fetal compartment would suggest the innocuity of contrast-enhanced 
ultrasound imaging on fetal development [268]. Overall, there may be no real safety concerns 
with respect to common clinical use of sonography; however, caution must be exercised when 
high output regimes such as pulsed Doppler are applied in obstetrics (ter Haar 2010). Ultrasound 
is often used in obstetric including with the Doptone for fetal monitor and hearing the baby’s 
heartbeat. Considering the difficulty in establishing the thresholds for biological effects, it is 
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suggested that as-low-as-reasonably-possible scanner outputs be used to collect the required 
diagnostic information. Unnecessary examinations (non-medical sonography) during pregnancy 
are not advised because of the large number of remaining unknowns (ter Haar 2010). 
4.13 Summary 
Ultrasound interacts with tissue through both thermal and non-thermal mechanisms (mostly 
attributed to cavitation and radiation force) and generates a variety of biological effects at the 
cellular or intact tissue levels (structural or functional changes). Three main factors can result in 
bioeffects due to ultrasound: heating, radiation pressure, and the presence of gas (ter Haar 2010). 
The ultrasound beam’s energy and frequency as well as the properties of the medium through 
which the ultrasound beam passes play important roles in the biological effects. Heating is 
mostly related to absorption of ultrasound energy by tissue. The mechanical effects that arise 
from cavitation are primarily related to bubbles created during the rarefactional cycle of acoustic 
pressure, the presence of gas in the solution that turns to microbubbles via the negative pressure 
of ultrasound, naturally gaseous body tissues, such as lung alveoli or intestine, or introduction of 
stabilized gas-filled microbubbles (ultrasound contrast agent) into the blood stream by 
extravasation.  
Based on evidence from cellular and animal studies, high-power devices used in therapeutic and 
surgical applications, in which the purpose is to deliver high intensity ultrasound to a target 
tissue, can clearly cause potential biological effects in the body. However, these biological 
effects have brought about unique opportunities for non-invasive ultrasound therapy; concerns 
apart from safety are mainly with respect to accurate targeting of ultrasound in the desired target 
volume without damaging other tissues.  
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At lower levels of exposure, such as diagnostic ultrasound, there is no established evidence of 
any specific harmful effect; however, too few research data are available to draw firm 
conclusions, especially with respect to the long-term use of ultrasound. The subtle effects of 
diagnostic ultrasound, such as neuronal migration or changes in membrane permeability, are not 
completely understood.  
While the application of ultrasound in fetal imaging has evolved beyond medical practice to 
commercial souvenir scans, detailed 3D facial imaging, or recording of the baby’s movement in 
the womb via 4D sonography, which require prolonged and more intense ultrasound exposure, 
there are unconfirmed indications from the biological and epidemiological literature of possible 
neurological influences on in utero ultrasound exposure. Therefore, diagnostic ultrasound should 
be used wisely, especially with respect to newer equipment that can have higher acoustic output 
levels than earlier models. Furthermore, for continued safety, there is a great need to further 
study the long-term hazards of exposure, especially in utero exposure, to diagnostic ultrasound.  
In addition, a better understanding of the direct physical effect of ultrasound (acoustic cavitation) 
is required to determine the cause of any biological effects in human (e.g., trauma to lung or 
intestine, capability to improve healing of bone and soft tissue, platelet damage as a result of 
cavitation) as well as improve the quality of ultrasound applications in many clinical practices 
(e.g., drug delivery, tumor ablation, etc.). Based on a literature review by ter Haar (2010) [269] 
presented from a diagnosis safety viewpoint, most bioeffects from clinically relevant practices 
arise from short, high-amplitude ultrasonic pulses at high repetition rates. However, most studies 
until recently have focused on continuous-wave (long-tone-burst) exposures. Furthermore, most 
in vitro studies have investigated the effect of ultrasound on either suspended culture cells or 
monolayers, yet the way ultrasound interacts with cells in an aqueous environment is different 
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from intact tissues (ter Haar 2010). Because thermal effects can be better observed through 
energy absorption of tissue, cultured cells may not properly reflect thermal effects and instead 
may more show more cavitation effects. When an in vivo study is performed, the body’s 
physiological response can also be studied. Also, the size of the animal (and consequently the 
attenuation of the beam in its body) in most in vivo studies is much smaller than a human. In 
small animal studies, it is usual for most of the body to be exposed to the ultrasound beam (ter 
Haar 2010). Therefore, having the more appropriate model size and measuring the attenuation 
due to the intervening tissue can ensure the findings are relevant with respect to effects in 
humans. Although ultrasound bioeffects shown in animal models occur under conditions similar 
to those used in humans, we cannot confidently relate these results to humans. The absence of 
human studies on the bioeffects of diagnostic ultrasound does not necessarily mean there are no 
effects but, rather, a lack of techniques to detect them. Cavitation thresholds are usually 
determined experimentally through acoustic emission, broad band noise, and subharmonic 
signals from bubbles. Because of the attenuation of signals in tissue, detection of signals arising 
from deep in tissue is more difficult than for those from the surface. This makes the detection of 
cavitation in tissue very difficult. Detection and visualization of cavitation responses in the body 
at different operating conditions would be very helpful in threshold determination as well as 
characterization and analysis of cavitation in the human body.  
A complete understanding of the interaction of ultrasound with ultrasound contrast agents is 
required to develop the full potential of ultrasound contrast agents in biomedical ultrasound 
applications such as drug/gene delivery, tumor therapy, and arteriogenesis. More information 
regarding the location of microbubbles in the body as well locating the area where microbubbles 
are in contact with tissue and cells subjected to ultrasound exposure is necessary.  
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Further advances in the use of ultrasound in medicine require better knowledge of the cellular 
and molecular events interfering with physical mechanisms of ultrasound combined with their 
related biological effects. In addition, more effort is required to visualize, detect, and monitor 
ultrasound-induced cavitation bubbles combined with ultrasound contrast agents deep in body to 
have more control over the biological effects of ultrasound.   
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Chapter 5 Medical applications and detection techniques of ultrasound 
cavitation and microbubble contrast agents 
This chapter has been submitted as “Zahra Izadifar, Paul Babyn, Dean Chapman, 2016, Medical 
applications and detection techniques of ultrasound cavitation and microbubble contrast agents, 
Measurement Science and Technology (Under Review)” According to the Copyright Agreement, 
"the authors retain the right to include the journal article, in full or in part, in a thesis or 
dissertation".
 
5.1 Abstract 
The presence of microbubbles in the human body can be induced either through cavitation or 
exogenous introduction of bubbles. One of the effects of ultrasound is cavitation, or microbubble 
formation and collapse. Cavitation produces high pressures and temperatures, and microbubble 
expansion and then collapse close to cells can lead to cellular damage or hemorrhage in 
biological tissues. Cavitation is, in most cases, an undesired event in clinical diagnostic imaging. 
Considering that cavitation microbubble formation is largely unpredictable, ultrasound imaging 
may present a rare or yet unknown risk, particularly to fetuses and embryos. Although most 
therapeutic ultrasound modalities work based on physical and thermal effects of cavitation, the 
safety of treatment strongly depends on accurate knowledge of the location of the cavitation 
inception point. Cavitation detection is an important factor with respect to improving the safety 
of ultrasound imaging and therapy. It is essential to recognize the existence and location of 
cavitation inception points. In addition, the use of encapsulated microbubbles as contrast agents 
for diagnostic imaging, as vehicles for local drug or gene delivery, and as tools for microbubble 
and ultrasound therapy in thrombolysis has increased the demand for an accurate deep tissue 
microbubble detection technique. Over the past decades, different techniques have been 
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investigated for detecting microbubbles. In this chapter the state-of-the-art of medical 
microbubble detection along with therapeutic, monitoring, and diagnostic applications are 
reviewed. A novel imaging technique for detection of cavitation bubbles deep in tissue is also 
addressed.   
5.2 Introduction 
Cavitation is defined as the formation of bubbles (cavities) when the propagation of an acoustic 
wave through a liquid induces a strong enough negative pressure [1]. The term cavitation 
process is used to describe the process in which vapor- or gas-filled cavities undergo growth and 
implosion in a liquid host medium on exposure to acoustic radiation. The fundamental physics of 
the cavitation process in human tissues during clinical ultrasound applications still requires 
further study. Frenkle [2]and Skripov [3] largely deal with the fundamental physics of nucleation 
in very pure liquid and clean environments. 
Multiple physical effects are associated with the growth and violent collapse of cavitation 
bubbles, including direct physical phenomena such as luminescence, free radical formation, very 
high pressure shock wave emissions, shear stress, and high-speed microjet production. In 
ultrasound diagnostic imaging, cavitation can be an undesired and unwanted phenomenon. 
Although some therapeutic modalities work based on cavitation, it can also be considered an 
undesired bioeffect (e.g., giving rise to hemorrhaging) in other therapeutic modalities (e.g., 
lithotripsy).    
There has been interest in the use of higher frequencies and higher acoustic power for improved 
imaging resolution [4]. In addition, more recent interest in three-dimensional fetal images as 
souvenirs in obstetric ultrasonography raises concern with respect to potential bioeffects. As a 
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mechanical bioeffect, cavitation can cause local tissue injury in the immediate vicinity of the 
cavitation activity, including cell death and hemorrhage of blood vessels [5]. 
Because cavitation plays a significant role in therapeutic modalities such as extracorporeal shock 
wave lithotripsy (ESWL), intracorporal lithotripsy, and the ultrasonic cavitation devices used in 
surgery to dissect or fragment tissues, the safe application of these modalities largely depends on 
precisely locating the cavitation microbubbles generated by these devices.  
Microbubbles can also be introduced into human tissues by injection and are used as 
microbubble contrast agents for ultrasound diagnostic imaging or as vehicles for drug or gene 
delivery. Considering that the entrance of medical microbubbles (e.g., ultrasound contrast 
agents) into the human body is followed by ultrasound radiation, the growth and violent collapse 
of microbubbles can have the same or similar effect as cavitation on cells, blood vessels, or 
tissues. Therefore, cavitation bubbles and ultrasound contrast agents should both be further 
studied in the body to provide safety assurance and minimize the side effects of clinical 
ultrasound modalities. However, to accurately assess and control cavitation, it is first essential to 
determine the existence of microbubbles and locate any cavitation inception points. 
This review briefly describes the fundamentals and clinical applications of cavitation phenomena 
and ultrasound microbubble contrast agents. The biological effects of cavitation/microbubbles 
and concerns regarding their adverse effects on tissue and organs in the human body are 
discussed. This is followed by a review of the various modalities that have been used for 
detection of microbubbles/cavitation bubbles, and their relative advantages and disadvantages.   
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5.3 Understanding cavitation phenomenon 
When an ultrasound wave is applied to a liquid, the molecular structure of the medium goes 
through alternating expansion and compression cycles. As expansion (rarefaction) and 
compression cycles travel through a medium, rarefaction pulls molecules apart and compression 
pushes them together. If the ultrasound wave is strong enough, the expansion cycle can 
overcome intermolecular binding forces and lead to a sudden pressure drop and creation of 
bubbles of gaseous substances in the liquid. These bubbles grow in size with the ensuing 
expansion cycles of ultrasound until they reach an unstable size and then violently collapse 
(Figure 5-1). This physical phenomenon is called acoustic cavitation.  
 
Figure 5-1 Schematic image of acoustic cavitation process 
Cavitation bubbles are typically initiated at a micron size in the fluid [6] but, depending on the 
frequency, power, and environment, their size will vary. For example, in a lithotripter shock 
wave the bubble can grow from a 1 µm radius to a ~1 mm radius over a period of 150 µs; it then 
takes a further 150 µs for the bubble to collapse [1]. The size of cavitation bubbles primarily 
depends on the ultrasonic frequency. At a given ultrasonic power, higher frequencies produce 
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smaller cavitation bubbles and lower frequencies generate bigger cavitation bubbles [7]. This is 
partially due to the fact that the increased wavelength at lower frequencies allows more time and 
space for the bubbles to grow to larger sizes before they implode. The energy released in the 
zone as the bubbles implode directly relates to the bubble size. Larger bubbles require more 
energy to grow and, in turn, a larger amount of energy will be released when they implode [7]. 
Decreasing the frequency enhances the likelihood of cavitation activation [5]. Based on the 
conservation of energy, at a constant frequency a higher ultrasonic power will lead to a larger 
number of cavitation bubbles [7]. 
Two types of cavitation bubbles form based on the behavior of microbubbles within a medium. 
When a bubble forms in a liquid medium, it grows until it reaches a critical size known as its 
resonance size, which depends on the frequency of the applied sound field. If the microbubble 
reaches its resonance size and then becomes unstable and collapses violently within a single 
cycle or over a small number of acoustic cycles, it is called inertial cavitation (or transient 
cavitation). If, however, the microbubble does not violently collapse and instead oscillates for 
many cycles at, or around, its resonance size, it is called non-inertial cavitation (or stable 
cavitation) [8]. In non-inertial cavitation, the ultrasound pressure acts as a driving force that 
changes the bubble size and shape; the bubble behaves as an oscillator with a stiffness provided 
by the gas within the bubble and inertia provided by the liquid surrounding the bubble that 
moves with the bubble wall. Generally, higher acoustic pressures lead to inertial cavitation and 
lower acoustic pressures result in non-inertial cavitation [9]. Non-inertial cavitation can be as 
important as inertial cavitation as it includes the initiation of surface oscillations and 
microstreaming. These bubbles are usually long-lived and their integrated effect can be 
substantial [10].  
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The whole inertial cavitation process—in which vapour bubbles form, grow to many times their 
original size, and undergo rapid implosive collapse—happens within about 400 µs. Normally, 
cavitation occurs at pre-existing weak points in the fluid, such as gas-filled crevices in suspended 
material or transient bubbles remaining from previous cavitation events [11]. In successful 
cavitation processes, the cavities can grow and collapse violently with the release of enormous 
amounts of energy in the form of an acoustic shock wave, temperature, pressure, and visible light 
[12]. The estimated rapid adiabatic compression of gases and vapours within the bubbles or 
cavities produces hot spots with extremely high temperatures and pressures that approach 5000 
°C and 1000 atm, respectively, during bubble collapse.  
Many theories have been proposed to explain the chemical effects stemming from cavitation 
bubble collapse. Cook in 1917 theoretically calculated and found the pressure developed when 
cavitation bubble collapse is arrested by impact against a rigid concentric obstacle is 10300 atm 
or 68 tons per sq. inch [13]. A hot spot theory was proposed by Noltingk and Neppiras in 1950 
[14].  Flint and Suslick in 1991 [15] proposed an electrical discharge theory that states that an 
electrical charge forms on the surface of the bubble when the cavitation bubble starts to collapse 
into tiny microbubbles. This was also proposed by Margulis in 1990 [16]. 
Because the size of the bubbles is very small relative to the total liquid volume, the heat 
produced by bubble collapse is rapidly dissipated with generally no appreciable change in overall 
environmental conditions [11]. The cooling following the implosion of a cavitation bubble is 
estimated to be in the region of 10 billion °C/s [11]. The bubble collapse can cause emission of 
light and also gas temperatures that can reach over 1000 °C [11]. The inertial cavitation process 
can potentially create free radicals or give rise to emission of light, which is known as 
‘sonoluminescence’. 
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When the acoustic cavitation bubble collapse is close to or on a solid surface, the dynamics of 
collapse change dramatically. In the absence of any close physical boundary, the bubble retains it 
spherical shape during collapse because its surroundings are uniform. However, close to a 
physical boundary, it can only collapse asymmetrically because the solid surface provides 
resistance to liquid flow. This asymmetric collapse produces high-speed liquid jets driving into 
the surface of the solid at speeds close to 400 km/h (111 m/s) [11]. The impact of the jets on the 
surface is very strong and can result in serious damage to impact zones and cause surface pitting 
(erosion). After its collapse, the bubble might fragment or may repeat its growth/collapse cycle. 
The probability of inertial cavitation occurrence for a particular bubble nucleus depends on the 
acoustic pressure amplitude, the acoustic frequency, and the bubble radius. The influence of the 
physical characteristics of fluid viscosity and surface tension on the dynamics of cavitation 
bubbles was studied by Plesset, who derived the Rayleigh-Plesset equation in 1949 [17]. In any 
cloud of bubbles in the medium within the same ultrasound field, both inertial and non-inertial 
cavitation may occur simultaneously. However, when the bubbles are small the surface tension 
prevents initial growth and therefore the bubbles do not grow. When the cavitation nuclei are 
large, they can grow initially but do not collapse to generate sufficiently high temperatures. 
Therefore, for a specific frequency and nucleus radius a threshold pressure is required to initiate 
inertial cavitation. Apfel and Holland studied the theoretical threshold acoustic pressure for 
inertial cavitation in blood and water [18]. If the bubbles are close to an elastic medium, their 
motion along the surface (shear motion) can lead to an increase in the heating of the medium 
(shear loss). In a study by Holt and Roy [19], a considerable temperature rise was generated in 
agar-based tissue with the application of an ultrasonic pressure above the threshold level for 
cavitation. Also, when the bubble is pulsing, the inhomogeneous periodic field around the bubble 
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can produce a small steady flow of fluid known as microstreaming [20]. Extremely high shear 
stresses near the bubble surface will be produced because of the variation of this flow with 
distance from the bubble. Cell membrane destruction and temporary alterations in permeability 
have been associated with this high shear stress.  
An excellent review on the subject of acoustic cavitation has been written by Neppiras [10], in 
which the physics of cavitation are extensively reviewed. The mathematical derivations of the 
basic theories of cavitation and dynamics of bubbles along with some experimental data for those 
theories can be found in the books by Young [1], Brennen [10], and Leighton [11]. The 
fundamental behavior of bubbles in an acoustic field is reviewed by Lauterborn [12]. 
5.4 Effect of cavitation/microbubbles on tissue and body fluid 
The presence of microbubbles in the body can result from either exogenous introduction of 
microbubbles into the body or endogenous generation of microbubbles in the body as a result of 
ultrasound propagation. The properties of endogenous microbubbles generated within the area of 
an ultrasound beam will depend on the ultrasound wave’s properties. Cavitation microbubbles or 
endogenous bubbles can be intentionally produced in the body for clinical applications such as 
lithotripsy, as explained later in this review.  
Ultrasound microbubble contrast agents (medical microbubbles) are exogenous microbubbles 
generated outside of the body and then injected into the vasculature for different medical 
applications. Considering that these microbubble contrast agents can easily expand, move, and 
fragment by ultrasound, additional safety considerations are needed during insonation to avoid 
thermal and mechanical biological effects [21]. The presence of either endogenous or exogenous 
microbubbles can have multiple thermal and biological effects. 
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At high ultrasound pressure (mechanical index (MI)>1.0), microbubbles are forced to expand 
and then are compressed, which results in their destruction. Destruction of these microbubbles 
close to a living cell leads to permeability of cell membranes [22]. The destruction of 
microbubbles with ultrasound has caused rupture of microvessels with extravasation of red blood 
cells [23]. As a mechanical bioeffect, cavitation activation can cause local tissue injury in the 
immediate vicinity of the cavitation activity, including cell death and hemorrhage of blood 
vessels [5]. For example, cavitation-mediated tissue damage in shockwave lithotripsy has been 
reported [24]. Large surface hemorrhaging over both the targeted and contralateral kidneys along 
with hemorrhaging of the spleen, intestine, and peritoneum have been observed in small animal 
or in vitro studies [24]. Tissue histology has revealed vascular rupture in the kidney, necrosis of 
the walls of the intralobular arteries and veins, and diffuse damage to the targeted kidney tissue 
that may be due to cavitation [24].  
The exact mechanism by which microbubbles enhance the permeability of cells is still 
unresolved [22]. When an ultrasound wave is applied to tissues, it creates cavitation bubbles in 
the fluid that, along with the cavitation process, result in an incremental increase in cell 
permeability. In fact, the cavitation process on its own increases cell permeability [25]. However, 
the presence of additional microbubbles along with the high acoustic pressure due to ultrasound 
exposure have additional effects on cell permeability [26]. Cavitation in body tissues or blood 
sets fluid in motion and makes small shock waves that give rise to microstreaming along the 
endothelial cells [22]. High-energy microstreams or microjets produced by cavitation bubbles 
during the cavitation process cause shear stress on the membrane of an endothelial cell [27], 
which increases the cell permeability. This increase is probably due to transient holes in the 
plasma and nuclear membrane [22]. Other proposed mechanisms for cell permeability increase 
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include the generation of reactive oxygen species in endothelial cells during the cavitation 
process [28], an increase in intracellular radical production (which is associated with cell killing 
in vitro and endothelial cell layers), a rise in temperature (which can influence the fluidity of 
phospholipid bilayer membranes), and endocytosis or phagocytosis (which may activate 
membrane transport mechanisms) [22]. When a bubble collapses following highly energetic 
ultrasound, all of these phenomena can result in a local increase in cell permeability. Considering 
this fact, drugs and genes can be attached to microbubbles that are then used as a vehicle to 
transport them to specific body areas for delivery to local cells. Unger et al. describe how drugs 
or genes can be attached to microbubbles [29]. Briefly, drugs can be attached to microbubbles by 
incorporation within the bubble or within the bubble membrane, attachment to the membrane, 
attachment to a ligand, or incorporation in a multilayer microbubble [22]. Drug and gene 
delivery with microbubbles is a promising technique; however, adverse effects such as a rise in 
blood temperature or hemolysis and possible side effects on tissue and organs in humans have 
been a cause of concern in several studies [22, 30-32]. Bioeffects are mainly influenced by 
factors such as the choice of ultrasound frequency and its amplitude, both of which need further 
investigation. 
5.5 Ultrasound microbubble contrast agents application 
5.5.1 Diagnosis and monitoring  
Many of the ongoing improvements in sonographic diagnosis have been related to the entry of 
ultrasound microbubble contrast agents (medical microbubbles). Small exogenous gas bubbles 
are used to increase ultrasound contrast. The first reported use of microbubbles as a contrast 
agent was in echocardiography by Gramiak and Shah in 1968 [33]. Ultrasound microbubble 
contrast agents permit reliable, reproducible left ventricular opacification and are currently in 
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widespread clinical use. Evidence has shown that contrast echocardiography is clinically 
effective, reduces downstream costs, and precludes patients from further potentially hazardous 
investigations [34]. These medical microbubbles are used to increase the reflectivity of perfused 
tissue in cardiology and radiology applications [21].  
Microbubbles used in echocardiography as contrast agents are small gas-filled microspheres with 
specific acoustic properties. First generation microbubbles are room air microspheres [35] that 
disappear a few seconds after intravenous administration [36, 37]. Second generation  
microbubble contrast agents are filled with a heavy molecular weight gas such as sulphur 
hexafluoride and stabilized with a thin shell such as sonicated albumin and (phosphor)lipids to 
improve survival and stability of microbubbles under high pressure [35]. Second generation 
microbubbles have a much smaller diameter (about 2.5 µm) than first generation microbubbles to 
ease their passage through the pulmonary capillary bed [22]. Diagnostic imaging with contrast 
agents is improved when an acoustic pressure higher that 0.05 is used (mechanical index, 
MI>0.05). An MI higher than 0.05 causes emission of non-linear harmonic signals at multiples 
of the transmitted frequency [29]. This improves the signal to noise ratio and creates an acoustic 
impedance mismatch between body tissues and fluids containing microbubbles, which makes 
these microbubbles beneficial in diagnostic ultrasound imaging [38]. 
When ultrasound is applied, small exogenous gas bubbles oscillate and can be deflected to a 
vessel wall and then fragmented into nanometer-sized particles. Microbubble fragmentation 
facilitates imaging of multiple targets when single-session molecular imaging is difficult with 
affinity-based strategies [21]. Clinical ultrasound systems take advantage of the unique nonlinear 
properties of these small gas nuclei for diagnosis and monitoring.  
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The application of encapsulated microbubbles as a contrast agent has remarkably improved 
diagnostic capabilities. The addition of microbubble contrast agents increases the sensitivity of 
ultrasound to capillary-sized vessels and very low flow rates [21]. Because these microbubble 
contrast agents are highly compressible and their presence results in strong scattering of 
ultrasound, their expansion and compression generates nonlinear signals [39, 40] and also 
appears bright on an ultrasound image [39]. Power Doppler imaging combined with ultrasound 
contrast agents significantly improves detection of blood flow in small vessels [21]. Tumor 
diagnosis and monitoring the response of cancers to new anti-angiogenesis treatment can be 
facilitated by means of combined power Doppler and ultrasound contrast agents. In a study by 
Yang WT et al. [41], a strong correlation between histologic microvascular density of human 
breast masses with 2- and 3-D power Doppler sonography was shown. In another study in mice, 
the ratio of increased pixels to total pixels in the tumor was used to follow antiangiogenic 
treatment of xenografted tumors [42]. The signal-pixel rate in the treated sample was 
considerably decreased compared to the controls and correlated with histologic microvascular 
density [42]. Contrast-enhanced phase inversion imaging can subjectively diagnose 
neovascularity [43] that can significantly ease detection of tumors. Contrast-enhanced phase 
inversion harmonic imaging of xenografted tumors correlates with a semi-quantitative scale of 
immunohistochemical staining as a predictor of tumor angiogenesis [44]. 
5.5.2 Ultrasound drug delivery 
Cell membranes often prohibit large molecules (e.g., drugs and genes) from entering cells. The 
mechanical force of focused ultrasound through endogenous microbubbles of stable (or non-
inertial) cavitation can improve cell membrane permeability and give rise to absorption of drugs 
or genes. This effect, known as sonoporation, creates pores in cell membranes via stable 
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cavitation and allows a greater volume of compounds to enter the cell [45]. In addition, the 
acoustic streaming induced by stable cavitation gives rise to the flow of fluid in the local 
environment of the cell. This helps open pores in the cell membrane and also directs the 
molecules of the drug toward the cells [46, 47] .  
On the other hand, several properties of exogenous medical microbubbles make them promising 
tools for delivery of drugs and genes to living cells [36, 29, 48-52, 27, 53]. Ultrasound contrast 
agents combined with focused ultrasound is uniquely suitable for localized drug delivery. Many 
diseases such as cancer, inflammatory diseases, or thrombo-embolic processes may require high 
concentrations of certain drugs. However, high drug concentrations can have toxic side effects 
on the rest of body. In addition, systematic drug delivery requires plasma concentrations to be 
within the therapeutic range, but this is limited by the occurrence of potential side effects. In 
more specific drug delivery, microbubbles can be coated with a drug by attaching it to a ligand 
on the outside of the drug-laden microbubbles (Figure 5-2a). Focused ultrasound is then applied 
locally at the targeted area, resulting in selective delivery of the drug in the body [54]. 
Alternatively, drugs may be incorporated into the microbubbles and released in the region of 
interest by rupturing the microbubbles with localized focused ultrasound (Figure 5-2b) [55, 56]. 
Another approach is to systematically and simultaneously inject the drug and an ultrasound 
contrast agent and then apply focused ultrasound to the target region (Figure 5-2c). The 
oscillation and destruction of the bubbles in small vessels alters the vessel walls and results in 
extravasation of the drug [57, 58]. As shown in Figure 5-2d, the permeability of cells during drug 
delivery can be increased (1) through non-inertial cavitation when the bubble behaves as an 
oscillator and microstreaming around the bubble increases the permeability (Fig. 5-2d-1), (2) 
through collapse of the gas bubble and emission of a shock wave (Fig. 5-2d-2), or (3) through 
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asymmetric bubble collapse close to the cell wall producing a liquid jet that pierces and ruptures 
the cell (Fig. 5-2d-3). 
 
Figure 5-2. Illustration of variety of ways drug delivery can be enhanced by utilizing 
microbubbles. (a) Microbubbles with drug-laden external membranes are freely circulated 
in the vessel and bind in the target region, then are ruptured by ultrasound and the drug 
payload liberated in the target area; (b) Microbubbles carrying drugs inside of them are 
circulated in the vessel and destroyed by ultrasound and the transported substances thus 
released into the surrounding targeted tissue; (c) Free circulation of drug particles (yellow 
circles) along with ultrasound microbubbles (grey circles) in vessels, and the effect of 
ultrasound on growth and burst of microbubbles results in extravasation of drug; and (d) 
Schematic of various modes by which microbubbles increase the cell permeability: 1: non 
inertial cavitation when a bubble behaves as an oscillator and microstreaming around 
bubble increases the permeability; 2: collapse of a gas bubble and emission of a shock 
wave; and 3: asymmetric bubble collapse close to a cell wall producing a high speed liquid 
jet that pierces and ruptures the cell. 
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Drug delivery via drug-loaded microbubbles that are ruptured with localized ultrasound 
can result in local drug release in higher concentrations than can be achieved with systemic 
administration. In addition, the drug will be pushed directly into the cell given the higher cell 
permeability in this technique [22]. 
5.5.3 Gene therapy with microbubbles 
Gene therapy may play a significant role in the treatment of several (cardiovascular) diseases in 
the near future. In gene therapy, first the gene needs to be delivered to the tissue and taken up by 
the cells. Then, it should be incorporated into the genome in the nucleus of the cell without being 
digested. The direct intravascular injection of genes is not possible as the DNA consists of large 
molecules and results in the removal of the gene from the blood. In addition, the gene is too long 
to enter the cell passively [22]. Several studies have shown that ultrasound in combination with 
microbubbles can be a safe method of gene delivery to cells [25, 59, 60, 48, 61].  
5.5.4 Smart microbubbles in diagnostic applications  
Considering that microbubbles in current use are comparatively stable and circulate throughout 
the body, it is possible that the contents of the microbubbles may be deposited in undesired 
tissues. To avoid this problem, microbubbles can be combined with ligands and receptors that are 
incorporated in the bubble shell, creating “smart microbubbles” that target specific tissues [22]. 
These smart microbubbles can also be useful for active attachment of microbubbles to target 
tissues and provide further potential for diagnosis or localized drug delivery to targeted lesions 
for therapy.  
Smart microbubbles have been described in several studies where they have targeted different 
types of tissues and processes, including endothelial cells (for diagnosis of preclinical 
atherosclerosis) [62], non-invasive identification of acute cardiac transplant rejection in mice 
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[63], inflamed tissue and angiogenesis [64] (for ultrasound imaging of inflamed tissue [65, 66] 
such as post-ischemic myocardial inflammation [67]), and vascular clots or thrombi 
(visualization of vascular clots associated with cardiac vascular disease such as stroke and 
myocardial infarction, which can be used for identification and cure of vascular clots in humans) 
[68]. Ultrasound is known to improve clot lysis in blood vessels, and ultrasound in combination 
with targeted microbubbles loaded with thrombolytic agents can further drive this effect by 
cavitation [22].  
Due to the action of microbubbles, ultrasound also became of interest as a potential therapeutic 
tool in thrombolysis. In several serious cardiovascular diseases such as myocardial infarction and 
non-hemorrhagic stroke, rapid thrombolysis by fibrinolytic therapy improves morbidity and 
mortality, but recanalization of the occluded vessel is not easily achieved. Systematic 
administration of thrombolytic agents can be complicated, especially due to bleeding [69]. The 
application of ultrasound at low frequencies (from 26 kHz to 10.03 MHz) and high power in the 
presence of absence of fibrinolytic therapy has been shown to increase clot lysis in both in vitro 
and in vivo studies [70-77].  
The effect of the cavitation process on the surface of the vascular clot plays an important role in 
micro fragmentation, which can make the clot more susceptible to fibrinolytic agents [78]. The 
presence of microbubbles lowers the energy needed for cavitation. Destruction of microbubbles 
by high power ultrasound creates powerful microjets that accelerate the effect of ultrasound in 
thrombus dissolution compared to ultrasound alone [22]. Although the influence of different 
types of microbubbles and different ultrasound operating conditions (170 kHz and 0.5 W/cm 
[79], 10 MHz and 0.5-1.0 W/cm [80], 20 kHz and 1.5 W/cm [81], 20 kHz and 40 W/cm [82], 10 
MHz and 1.02 W/cm [83]) have all shown significant improvement on thrombolysis, there is still 
 178 
 
 
uncertainty about whether the same effects can be reached in humans. These assessments have 
been reviewed in [22]. Endothelial cell injury of microvessels, which can be a potential clinical 
danger, has been reported by Kobayashi et al. [84]. Diagnostic ultrasound imaging commonly 
works at frequencies between 2 and 15 MHz [85]. Most cavitation processes occur at lower 
frequencies and higher powers, and thrombolysis by ultrasound would require such operating 
conditions. Considering the bioeffects of ultrasound at low frequency and high power, the safety 
of all of these techniques requires further study; microbubble detection techniques, especially for 
future applications in humans, are also needed. At the cellular level, the interaction of 
fluorescent-labeled microbubbles and myocardial or endothelial cells under high ultrasound 
pressure can be precisely studied using live-cell imaging techniques (such as multi-dimensional 
digital imaging microscopy) [22]. But to control the exact area that microbubbles deposit the 
gene or drug in the body or are interacting with live cells deep in tissue, an imaging technique 
capable of detecting microbubbles deep in tissue (such as the human body) without disturbing 
the microbubbles is required.  
5.6 Detection and imaging of cavitation and microbubbles 
Over the past decades, different techniques have been investigated for detecting and mapping 
microbubbles. These techniques mainly include optical, acoustic, and scattering methods. Optical 
methods include high-speed photography, sonoluminescence, and sonochemiluminescence, and 
acoustic methods include active cavitation detection (ACD) and passive cavitation detection 
(PCD), and the Doppler method. Scattering methods include laser and synchrotron based X-ray 
methods. Each of these techniques has specific strengths and weaknesses for detection and 
mapping microbubbles. These signatures can be used to detect the microbubbles through 
physical and chemical techniques. Most published studies of visualization and detection of 
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microbubbles come from in vitro experiments. There have been few attempts to detect 
microbubbles in animals [86, 87]. One challenge for in-vivo detection of the cavitation 
microbubbles is attributed to the high attenuation and inhomogeneous nature of tissues which 
affect the sound wave propagation and consequently the behavior of the ultrasound-induced 
microbubbles in-situ. A couple of techniques can also measure either exogenous microbubble or 
endogenous cavitation bubbles. In the following section, the different modalities that have been 
used to study microbubbles are briefly reviewed. 
5.7 Optical methods 
5.7.1 Detection of physical and chemical responses 
The presence of cavitation can be indirectly assessed through a variety of physical and chemical 
methods [88]. These methods rely on detection and measurement of free radicals 
(sonochemiluminescence), and sonoluminescence, created from cavitation bubbles [89]. The 
results of these measurements must be considered based on a basic interpretation of the 
cavitation process, which can be complicated. The high temperatures and pressures that result 
from cavitation can lead to light emission (sonoluminescence) and increased chemical reaction 
rates (sonochemistry). Some techniques of assessment of the presence of cavitation depend on 
the creation and detection of free radicals, sonoluminescence, and acoustic emission from 
cavitation [90]. Sono- and chemiluminescence detection and electron spin resonance (ESR) 
measurements are two techniques applied to detect the presence of free radicals [91, 92]. 
Production of light and by-products from chemical reactions as a result of cavitation has been 
used to quantify cavitation activity [93, 94]. Other techniques to measure cavitation have been 
developed based on the influence of cavitation on a metal foil; cavitation can lead to pitting on 
metal foils, so these techniques have used the number and depth of pits to assess the violence of 
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cavitation [95-97]. The mechanical force exerted on a steel ball by both the incident shock wave 
and the cavitation phenomenon have been measured using an electromagnetic probe device [98]. 
However, these methods of quantifying cavitation are secondary measurements of the cavitation 
field, and interpreting the results can be complicated [1]. Sono- and chemiluminescence and ESR 
measurement techniques are useful for detecting cavitation bubbles in vitro but their use is 
limited in in vivo biological systems. Detecting luminescence is possible either in an optically 
transparent medium or by introducing an optical probe into the system. ESR is destructive to the 
sample and real-time measurement is not possible. In addition, cavitation is not directly detected 
in these techniques, but rather its presence is inferred from the nature of the onset of free radical 
production [99]. 
5.7.2 High speed photography 
In an in vitro setting, cavitation bubble behavior can be observed by means of a high-speed 
camera [100-103]. High-speed photography has revealed the dynamics of the cavitation process. 
In principle, the dynamics of a bubble from genesis to extinction may be tracked by this 
technique; however, this is not feasible in practice. In order to image the bubble during the 
growth phase, imaging is required at length scales on the order of a millimeter and time scales on 
the order of tens of microseconds in a transparent media. At the nadir of the collapse, the bubble 
radius is less than one micrometer and the time scale of the collapse is about a nanosecond. After 
collapse, the remaining bubble is on the order of 10 micrometers and exists for hundreds of 
milliseconds before it dissolves. Therefore, it is virtually impossible to capture all bubbles 
dynamically considering the range of temporal and spatial scales. Another limitation of imaging 
photography is the limited depth of field, which cannot give an adequate record of bubble 
dynamics in the substantial volume of the cavitation field [1]. Bubble dynamics in water were 
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displayed in sequential photographs for the first time by Tomita and Shima [104]. Figure 5-3 
shows the series of photographs of the cavitation process very close to a solid surface (top 
frame). The time interval between each of these numbered images is 2 µs and the frame width is 
1.4 mm. 
 
Figure 5-3  A series of 18 photographs demonstrate the dynamics of the cavitation process 
very close to a solid surface. Reproduced from Tomita and Shima [104] with permission. 
One of the techniques that can be used to study the dynamic interaction between microbubbles 
and cell membranes is high-speed photography along with fluorescence microscopy. Using this 
technique, Ibsen et al. [105] released optical images of the interaction of a unique drug delivery 
vehicle (fluorescently labeled microbubbles loaded with drug) with ultrasound. Subsequently, 
Ibsen et al. designed an analysis system combined with a fluorescent microscope, high-speed 
camera, and definable pulse sequence of focused ultrasound and observed the real-time 
interaction between focused ultrasound, echogenic drug delivery vehicles, and live cell 
membranes [106]. Figure 5-4a shows sequential images of the interaction of focused ultrasound 
with a microbubble inside the echogenic drug delivery vehicle. The ruptured outer membrane of 
the microbubble leaves a debris field of fluorescent particles. The membrane fragmentation 
generates a jet of debris in frame 3 that is followed by the diffusion of a lipid debris cloud in 
frame 4 [106]. A fluorescent image series of the interaction of the echogenic drug delivery 
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vehicle with an artificial cell membrane under focused ultrasound pulsation is shown in Figure 5-
4b. 
 
Figure 5-4 (a) Sequence of fluorescent images illustrating the interaction of focused 
ultrasound with the microbubble inside the echogenic drug delivery vehicle and (b) 
sequence of fluorescent images of the interaction of an echogenic drug delivery vehicle and 
an artificial cell membrane under ultrasound pulse sequence. Reproduced from Ibsen et al. 
[106] with permission. 
Another imaging technique is ultra-high-speed imaging using a Brandaris camera. Using this 
technique, both the interaction of a cavitation bubble with the surface and the sub-microsecond 
timescale dynamics of the cavitation bubbles are visualized. In a study performed by Zijlstra et 
al. [107], high-speed imaging of microbubbles driven by a 1-MHz megasonic cleaning device in 
contact with a rigid wall was achieved. In their experimental setup, one side of a transparent 
glass microscope slide was coated with a layer of gold nanoparticles, and then removal of the 
gold nanoparticles with continuous sound illumination under an angle to the slide was observed. 
Depending on the driving pressure, the time required to visualize a bubble dynamic in their study 
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was ~1 µs. Using a specialized high-speed imaging system called “Brandaris”, the dynamics of 
an individual bubble at less than microsecond resolution were also visualized. 
In another study by Chen [108], ultra-high-speed optical imaging of ultrasound-activated 
microbubbles in mesenteric microvessels was performed. The rat mesentery was chosen as it has 
optical transparency and can be used for imaging of insonated pre-injected microbubbles in 
microvessels to study the dynamics of microbubbles and their effect on the vessel walls in vivo. 
The mesentery was exteriorized through abdominal midline incision, sandwiched at the edge by 
two D-shape plates, and placed in a synchronized optical-acoustic system set up for ultra-high-
speed imaging. An ultra-high-speed camera (Imacon 200; DRS Hadland, Cupertino, CA, USA) 
with a minimum exposure time of 5 ns was coupled to one side port of an inverted microscope 
(TE2000-U; Nikon Inc., Melville, NY, USA) used for imaging of the bubbles. High-intensity 
focused ultrasound (HIFU) with a center frequency of 1 MHz was used for sonication. The tissue 
was placed in water and the microbubbles were injected into vessels. When bubbles were in the 
field of view of the microscope, the ultrasound pulse was sent to the tissue sample and the 
dynamics of bubble along with its interaction with the vessel walls were studied. 
5.7.3 Optical detection technique 
In order to improve the efficiency of cavitation and microbubble application in clinical use, 
optically observing the microbubbles, the cavitation process, and the interaction of microbubbles 
with membranes has been attempted. Different imaging systems, such as electron microscopy, 
flow cytometry [109], atomic force microscopy [110, 111], and home-made instruments based 
on white light illumination [112] have been investigated for studying the interaction of pre-made 
microbubbles with ultrasound and membranes of artificial cells in vitro. 
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Direct detection of cavitation is possible by imaging bubbles in the medium. However, the very 
high speed of the cavitation phenomenon as well as the small size of the microbubbles make it 
difficult to see individual bubbles without a high-speed camera, and bubbles are usually observed 
as a cavitation cloud. In addition, cavitation detection deep in tissue at different operating 
conditions can be a difficult task.  
 If cavitation bubbles are produced at low acoustic frequencies, the bubble size is big enough for 
human visual perception unaided by a magnifying or light-collecting optical device. However, at 
higher frequencies the size of the cavitation bubble decreases and is on the order of a couple of 
microns. The lifetime of each individual bubble (bubble dynamics) is dictated by the period of 
the driving pressure [107]. The lifetime of cavitation bubbles is very short and visualizing 
cavitation bubble dynamics at less than microsecond resolution requires a specialized high-speed 
imaging system.  
Another optical imaging technique is based on the microbubble oscillation. During an 
ultrasound/acoustic pulse, either exogenous or endogenous cavitation-induced microbubbles go 
through an expansion and contraction cycle as a result of the pressure rarefaction and 
compression of the applied acoustic beam. Capturing the expansion and breakup of the process 
requires a shutter speed on the order of tens to hundreds of nanoseconds. This can be done with a 
high-speed camera capable of nanosecond shutter speeds (Figure 5-5a) [21]. In the absence of a 
nearby solid boundary, the bubble’s symmetric spherical oscillation is observed using a radius-
time “streak” imaging technique. In addition, the effect of ultrasound on the microbubble can be 
characterized by measuring the radial oscillations using a radius-time curve image of a single 
line through the center of the microbubble (Figure 5-5b) [113, 39].  
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Figure 5-5  (a) Sequence of two-dimensional images of a microbubble oscillation affected by 
a 2.25-MHz center frequency pulse ultrasound over 10 nanoseconds. (b) Radius-time image 
of a microbubble oscillation and a distance-time image of a single line through the center of 
the microbubble oscillation for characterization of the effect of ultrasound on the 
microbubble. Reproduced from Ferrara et al. [21] with permission. 
 
5.7.4 Acoustic detection of bubbles (active and passive imaging) 
An increasing number of ultrasound therapies are trying to harness the potential benefits of 
cavitation, both with or without intravascular ultrasound contrast agents. In order to precisely 
guide therapy at the focus and avoid undesirable cavitation events elsewhere within the beam 
path, cavitation events must be detected and mapped. Magnetic resonance imaging (MRI) can be 
used for anatomical targeting but is not capable of directly monitoring the effect of cavitation. In 
addition, cavitation does not necessarily only have a thermal effect and may happen on a very 
short timescale and therefore magnetic resonance thermometry is not sufficient [114]. Efforts are 
being made to detect cavitation events by ultrasound. Acoustic detection methods rely on 
acoustic emission created from cavitation bubbles. When a microbubble is affected by an 
acoustic field, two acoustic emissions are generated by the bubble: one when the bubble is hit by 
the acoustic wave and one when the bubble collapses. This unique signature is called “double-
bang” and is used for acoustic detection of microbubbles. This method is powerful because it can 
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be used in vivo (living subject). In this method, the sound waves are sent toward the cavitation 
field and then the sound reflections from the bubbles are picked up. Acoustic detection is usually 
performed either as active cavitation detection (ACD) or passive cavitation detection (PCD) 
[115-117]. In ACD, one transducer sends the ultrasound wave toward the cavitation field and 
another transducer picks up sound reflections from cavitation bubbles, while PCD involves one 
or more receiving transducers for the double-bang induced acoustic emissions from cavitation 
bubbles [1]. In dual PCD, it is possible to use two receiving transducers and coincidentally detect 
a small and discrete cavitation field volume where the transducers intersect [118]. Both ACD and 
PCD are described in more detail elsewhere [116, 117]. In many thermal therapy applications of 
ultrasound where cavitation is unwanted, such a system may be used to record the broadband 
emissions related to inertial cavitation in order to terminate them before inadvertent tissue injury. 
Such a clinical ultrasound system is now commercially available (ExAblate®, Insightec, Haifa, 
Israel). Similar systems may be also used to monitor the broadband and harmonic emissions 
from the desired cavitation or intravascular ultrasound contrast agents. Real-time adjustments to 
the transmitted acoustic power can be performed with post-processing of signals to obtain a 
specific treatment effect [114]. In initial work by Hockman et al., cavitation-enhanced thermal 
lesioning was tested in agar gel and the process controlled using a single passive cavitation 
detector [119]. Passive cavitation mapping relies upon the scattering of the irradiation field by 
the bubble clouds, and its use to guide therapy is still in its early stages. More passive cavitation 
mapping systems with slightly higher coverage have been evaluated in vitro using multi elements 
arrays [120, 121], but for clinical use the detected area of cavitation events should be correlated 
with histological lesions in vivo. Currently, passive cavitation imaging is the only clinically 
relevant method capable of specifically monitoring cavitation events as well as providing 
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information about the mode and strength of the oscillations in real time [121, 122]. In this 
method, which mostly relies on the formation of diverging pressure waves from oscillating 
bubbles at frequencies different than focused ultrasound device, the final two- or three-
dimensional image of the cavitation bubbles (source of emission) can be estimated through back-
propagation. The application of this imaging method within a tissue phantom and an in vitro flow 
phantom was described in studies by Gyongy and Coussios [121] and Haworth et al. [122], 
respectively.  
The size of the initial cavitation bubble and the sonic amplitude of the equipment that produced 
the cavitation bubbles affect the timing and amplitude of cavitation bubble emissions. Therefore, 
although acoustic detection is not able to provide information on the number and size of bubbles 
(this method does not image the bubbles), this method provides valuable data that can be helpful 
in characterizing the acoustic intensity of ultrasound therapeutic equipment (such as a lithotripter 
or HIFU device) in the body as well as analyzing the environment and dynamics of the cavitation 
field [102, 118, 94]. 
In 1996, Christy et al. reported the first direct evidence of in vivo cavitation from diagnostic 
ultrasound pulses [86]. They employed an ACD to detect short-lived cavitation in rat lung 
exposed to the output of a clinical diagnostic scanner (5 MHz) to identify the cause of damage. 
They reported observing the 30-MHz interrogating signal scattered by the short-lived bubble as a 
direct indication of cavitation. They reported that the bubble complex existed for a period of 1 
µs, the same as the 5-MHz Doppler pulse duration. 
There is a high demand for detection of cavitation occurrence in kidney tissue, as it is a critical 
step toward determining the mechanisms of tissue injury in shock wave lithotripsy. Both B-mode 
ultrasound [123, 124] and focused, single-element, passive receivers [125, 102] have been 
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studied to establish direct evidence of cavitation within the kidney. However, it not possible 
when using one transducer to differentiate between the occurrence of cavitation within kidney 
parenchyma and that in the fluid spaces of the collecting system [118]. Bailey et al. developed a 
cavitation detection system in which dual passive receivers and B-mode ultrasound were 
coaligned with the focal point of a Dornier HM3 lithotripter to interrogate cavitation occurrence 
within the renal parenchyma as well as in the collecting system during lithotripsy [87]. Their 
study provided direct evidence of cavitation occurrence in the renal parenchyma. Monitoring of 
thermal lesioning with B-mode ultrasound requires interleaving with the treatment beam. It 
typically displays a hyperechoic area secondary to bubble formation, but these bubbles may be 
induced through boiling of the tissues and are often undesirable because scattering from the 
larger bubbles can extend the area of coagulation into the prefocal zone [126].  
Ultrasound-guided localized detection of cavitation during lithotripsy has been also studied in 
vivo by a dual passive cavitation detection (DPCD) system in pig kidney [127]. The cavitation 
appeared as a hyperecho on the B-mode image of the kidney. Following imaging, dissection of 
the kidney revealed a V-shaped lesion created by the transducer.  
Measurement techniques currently used to measure key acoustic output and exposure parameters 
such as cavitation that might be relevant to biological acoustic effects are performed in water. 
The acoustic properties of the water medium are very different from those of tissue [128]. 
Therefore, estimation of in situ ultrasound exposure at a site of interest within the patient is very 
difficult [90]. 
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5.8 Scattering methods 
5.8.1 Laser scattering technique 
Another method of measuring cavitation is laser scattering of single bubbles, in which the 
dynamics of a single bubble of spherical shape can be very precisely measured [93]. In this 
technique, a laser beam illuminates the bubble, and a photodetector collects the scattered light 
from the bubble. For a single spherical-shaped bubble, the amplitude of the scattered light 
changes predictably with the radius of the bubble. In this method, most of the temporal and 
spatial scales related to the dynamics of a cavitation bubble can be captured. However, there are 
several restrictions related to this method: the volume of the sample is very small; the method 
requires unrestricted visual access at high magnification; and the theory behind this method that 
is applied to determine the actual bubble size is based on assumption of a single spherical-shaped 
bubble [1]. Therefore, this method is not able to give qualitative information about either bubble 
clouds or non-spherical bubbles produced in clinical applications of ultrasound, such as 
lithotripsy and HIFU [1]. 
5.8.2 Synchrotron X-ray imaging technique 
Another recent attempt to study and directly visualize microbubbles or ultrasound-induced 
cavitation bubbles uses synchrotron X-ray imaging. Among the different synchrotron X-ray 
imaging techniques, X-ray phase contrast imaging (PCI) and analyzer based imaging (ABI) have 
shown potential for detection of microbubbles. In ABI, which is a phase-sensitive imaging 
technique, a very bright and highly collimated X-ray beam is sent toward the cavitation field 
where small structures such as microbubbles will refract and scatter the X-rays through small 
angles. Using ABI, these small angles can create contrast based on the very narrow reflectivity 
curve of the analyzer crystal. The refracted and scattered X-ray beams are collected at the 
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detector behind the sample. This technique is also capable of in vivo detection of microbubbles 
deep in tissue. The advantage of using an X-ray technique such as ABI is that the microbubble 
properties can be visualized in vivo without any effect of the X-rays on the bubbles or vice versa. 
In 2010, Arfelli et al. studied the feasibility of visualizing the microbubbles as contrast agents 
using ABI  [129]. Microbubble contrast agents commonly used to improve ultrasound imaging 
are gas-filled microbubbles with shells composed of albumin, galactose, lipids, or polymers 
[130]. They contain either air or perfluorocarbon gas, and are stable for several minutes. These 
microbubbles are administered intravascularly and are sized to pass intact through the smallest 
vascular components. The ideal diameter of microbubble contrast agents is between 2 and 8 µm, 
which is smaller than red blood cells. These microbubbles are invisible in conventional X-ray 
absorption techniques. [129]. Arfelli and colleagues evaluated the possibility of visualizing two 
different microbubble contrast agents commonly used in clinical ultrasound examination 
(Levovist® and OptisonTM) in sizes ranges between 1 and 8 µm using ABI [129]. In their 
experiments, different custom-made phantoms based on microbubble contrast agents were 
prepared to study the potential of scattering-based contrast agents using ABI. They reported that 
ABI demonstrated high visibility of the details with stronger contrast than normal X-ray 
absorption techniques. On the other hand, because microbubbles contrast agents can act as an X-
ray lens, with individual microbubbles refracting and a population of them scattering the X-rays, 
PCI was considered a potential synchrotron based X-ray imaging technique for detection of 
microbubbles by Millard et al. [131]. They developed and validated a model that enables 
quantification of microbubble concentration for both phase-retrieved images achieved by 
processing multiple frames and also by “single-shot” images. Their validation was based on ABI 
with straightforward extension to other phase-based modalities. Millard et al. also studied the 
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potential of X-ray phase contrast imaging as a functional modality through the use of 
microbubble contrast agents [131]. In their experiment, imaging the targeted microbubbles 
injected into the circulatory system was performed by collecting a sequence of X-ray dark field 
images for varying concentrations of microbubbles flowing through a tube. They reduced the 
microbubble concentration and acquired images continuously to study the possibility of using 
PCI as a modality for dynamic functional imaging of microbubbles, enabling quantification of 
microbubble concentration in a given volume. Their work demonstrated the ability of PCI to 
quantitatively monitor the concentration of a microbubble suspension and provided the basis for 
a dynamic imaging technique. All of these studies focused on visualization and monitoring 
exogenous microbubbles contrast agents that usually contain either air or perfluorocarbon gas 
with premade shells and have prolonged longevity because of their low solubility (they are stable 
up to several minutes). Recently, another study attempted to use an ABI modality to visualize 
microbubbles/ultrasound-induced cavitation bubbles (endogenous microbubbles) at the 
biomedical imaging and therapy (BMIT) beamline at the Canadian Light Source (CLS). Direct 
visualization of ultrasound-induced cavitation bubbles was achieved at 20 kHz and 130 W [132] 
and at a therapeutic clinical system level of 0.88 MHz and 14 W [133]. Figure 5-6a shows the 
spatial structural pattern of ultrasound-induced cavitation bubbles from a therapeutic clinical 
system using the ABI technique. The cavitation bubbles appear in a periodic pattern and the 
distance between two consecutive parallel lines of the pattern (Figure 5-6b) was measured as 
0.99 mm. This work demonstrated that ABI has significant utility with respect to detecting and 
visualizing microbubbles/cavitation bubbles.  
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Figure 5-6  (a) ABI of the whole ultrasound beam of a therapeutic ultrasound system at 
0.8835 MHz and 14 W and (b) the sequence and location of cavitation bubbles, with 
approximately the same interval between sequences. From Izadifar et al. [133] 
Although this technique is not capable of giving information about the dynamics, size, or 
behavior of a single bubble, it provides valuable data about the qualitative dynamics of the 
microbubbles in the cavitation field (the location of microbubble formation or their existence). In 
the next phase of study by the authors, ABI will be investigated in tissue toward achieving the 
goal of applying this imaging modality for characterizing and analyzing the environment and 
dynamics of the cavitation field in vivo. A comparison of different imaging methods for 
visualizing microbubbles in terms of practical advantages and disadvantages is given in Table 5-
1. 
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Table 5-1 Advantages and disadvantages of different imaging modalities for visualizing 
microbubbles. (-) indicates the inability or limitation of the technique and (+) indicates the 
capability of each listed assessment capability in detection modalities. 
Imaging 
modalities 
In 
vivo 
In 
vitro 
Dynamic 
detection 
Passive 
detection
* 
Sample 
volume 
independent 
Sample area 
independent 
Qualitative 
assessment 
High-speed 
photography 
− + + + − − − 
Laser 
scattering 
− + + + − _ − 
Chemical 
and physical 
methods 
− + − + + + − 
Acoustic 
detection 
+ + − − + + + 
Synchrotron 
X-ray 
detection 
technique 
+ + − + + + + 
 Passive detection refers to an imaging technique that can detect microbubbles without 
disturbing the cavitation process and/ or microbubbles 
5.9 Summary and recommendations for future research 
Advances in diagnostic ultrasound imaging have expanded its use to obstetrics and fetal, embryo, 
or follicle development imaging. In recent decades, large numbers of fetuses have been scanned 
on a routine basis. Furthermore, the ability of ultrasound to penetrate deep into soft tissue at low 
frequencies (0.7-3.3 MHz) has prompted its use for non-invasive therapies such as hyperthermia 
and extracorporeal shock wave lithotripsy. Although the therapeutic and imaging mechanisms of 
ultrasound are based on the interaction of sound waves with tissue, cavitation can also occur 
during ultrasound imaging and therapy and result in hazardous bioeffects on tissues. It is 
essential to conduct fundamental cavitation studies to identify the threshold parameters of bubble 
formation and collapse that give rise to bioeffects. These findings may improve standards of 
ultrasound safety for a range of therapeutic and diagnostic applications, such as fetal and embryo 
imaging. High levels of ultrasound exposure have well-recognized acute harmful effects 
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(measures and guidelines exist for medical uses to avoid these). At lower levels of exposure, 
especially diagnostic ultrasound levels, there is no established evidence of specific hazards; 
however, few data are available to confirm this, especially over the long term. This concern has 
been also stated in the report of the advisory group on non-ionizing radiation [90]. In addition, 
microbubbles and cavitation are playing increasingly important roles in clinical applications of 
both diagnostic and therapeutic ultrasound. Microbubbles have been used as contrast agents in 
clinics for decades. They have also been developed as vehicles loaded with therapeutic agents for 
drug delivery and gene therapy. These vehicles are traced to the target site using diagnostic 
ultrasound [134]. The use of microbubbles in the future for drug/gene delivery is promising. 
Also, controlled cavitation is being studied as a means to enhance the speed and efficacy of 
treatment in HIFU surgery and lithotripsy.  
Monitoring the cavitation/microbubbles in different tissues in vivo for different treatment 
conditions will give more insight into the conditions under which ultrasound can be used safely. 
Furthermore, for high power devices used in therapeutic and surgical applications in which the 
purpose is to deliver high-intensity ultrasound to a target tissue, the concerns apart from safety 
are mainly with respect to accurate targeting of the desired target volume to avoid damaging 
other tissues. Detecting the existence and location of microbubbles/cavitation bubbles in tissue 
will provide more insight for more precise application of therapeutic ultrasounds such as HIFU, 
lithotripsy, and drug/gene delivery. Various imaging techniques have been evaluated for 
detection of microbubbles/cavitation bubbles. Each imaging technique has advantages and 
disadvantages for studying microbubble behavior. However, their application in vivo and 
particularly deep in tissue for locating microbubbles in the human body is an aspect of interest 
for future clinical study. Among the different microbubble detection techniques, acoustic and X-
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ray detection techniques have advantages for use in vivo and particularly in the human body. 
Also, X-ray imaging techniques can detect microbubbles without disturbing them, which is not 
the case with acoustic detection methods such as ACD and PCD.  
The ABI technique has shown promise for direct visualization of cavitation bubbles deep in 
tissue through the use of a very bright and collimated X-ray beam from a synchrotron. This 
imaging technique is under study by the authors at the BMIT beamline at the CLS [132]. ABI 
has a significant and demonstrated ability to image structures that feature interfaces between 
materials of different density, such as that between air and water in a bubble. The advantage of 
using an X-ray technique is the ability to visualize the cavitation bubbles/microbubbles in an 
optically opaque material, such as tissue, without any physical interaction with the bubbles.  
There is no doubt that continuous discoveries and developments in microbubble detection 
modalities will lead to safer and more efficient therapeutic and diagnostic equipment and also 
more precise microbubble applications in medicine.   
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Chapter 6 Visualization of ultrasound induced cavitation bubbles using 
synchrotron X-ray Analyzer Based Imaging technique 
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Izadifar, Dean Chapman, 2014, Visualization of ultrasound induced cavitation bubbles using the 
synchrotron X-ray Analyzer Based Imaging technique, Phys Med Biol., 59(23):7541-55. doi: 
10.1088/0031-9155/59/23/7541” According to the Copyright Agreement, “the authors retain the 
right to include the journal article, in full or in part, in a thesis or dissertation”. 
 
6.1 Abstract 
The observation of cavitation bubbles deep within tissue is very difficult. The development of a 
method able to probe cavitation with little concern for the location in tissues would improve the 
efficiency and application of ultrasound in the clinic. A synchrotron X-ray imaging technique 
capable of detecting cavitation bubbles induced in water by a sonochemistry system has been 
reported, with possible extension to study therapeutic ultrasound in tissues. In this study, two 
different X-ray imaging techniques (Analyzer Based Imaging (ABI) and phase contrast imaging 
(PCI)) were examined to detect ultrasound induced cavitation bubbles. Cavitation was not 
observed by PCI, however was detectable with ABI. Acoustic cavitation was imaged at six 
different acoustic power levels and six different locations through the acoustic beam in water at a 
fixed power level. The results are promising indicating its utility for cavitation studies in tissues, 
but time consuming which may be improved by optimization of the imaging method.  
6.2 Introduction 
Cavitation, known as microbubble formation and collapse, is an effect induced by ultrasound 
waves travelling through fluids. There are a wide variety of physical phenomena associated with 
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the onset of cavitation in a liquid such as luminescence, shock wave emissions, free-radicals 
formation, and high liquid jet speed production as a result of cavitation. Substantial injury to 
cells and a solid surface can occur when ultrasound induced microbubbles expand and then 
collapse close to cells or a solid surface. Cavitation can have hazardous bioeffects on the tissue 
under ultrasound therapy or imaging. Briefly, when the sound waves pass through a liquid 
medium at high ultrasound power, the traveling compression and rarefaction cycles create and 
collapse bubbles. Extreme temperature and pressure can be generated within the bubbles at the 
point of bubble collapse. When the collapse takes place near a solid boundary, high-speed jets of 
liquid are produced and driven into the surface at speeds close to 400 km/h [1], which can 
seriously damage the impact zone and create a newly exposed surfaces. Moreover, the high 
temperatures and pressures generated within the bubbles can generate highly reactive radical 
species that can chemically attack the surface.  
The influence of cavitation on tissues has made ultrasound a potential non-invasive therapy tool 
for tissue fractionation and treating of benign disease and cancer [2]. Energetic microbubbles 
fragment tissue resulting in cellular destruction. An experimental study performed by Daniels et 
al. (1995) revealed damage to red blood cells during irradiation with 0.75 MHz continuous-wave 
ultrasound.  It was found that pulsed ultrasound within the diagnostic imaging range had the 
ability to induce lung damage in mice [3]. Additional experiments on animals showed that 
ultrasound is capable of creating lesions on the lungs of pigs, mice, rabbits, rats, monkeys and 
dogs [4-12]. These bioeffects are mainly concerned in ultrasonography. In ultrasound therapy 
(i.e. high intensity focused ultrasound), gas generation caused by cavitation abruptly changes the 
pattern of heat transfer induced by ultrasound which results in the extension of the lesion from 
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the targeted area to surrounding healthy tissues [13]. These bioeffects are some examples of 
concern in ultrasonography and therapeutic applications of ultrasound. 
The risk of ultrasound, theoretically, would depend on different factors such as: levels of 
acoustic intensity and frequency, duration of ultrasound exposure, and frequency of ultrasound 
sessions.  Consequently, it is essential to conduct fundamental cavitation studies to identify the 
threshold ultrasound parameters causing bubble formation and collapse at different levels of 
frequencies and intensities. These findings may improve standards of ultrasound safety for a 
range of therapeutic and diagnostic applications, such as imaging susceptible fetuses and 
embryos.  One step toward improving outcomes and safety with this equipment is to have a 
better understanding of cavitation bubbles, and eventually to determine the safe levels of 
ultrasound operation below which they are unlikely to form. Thus the goal of this study is to 
move toward visualization of cavitation bubbles.  
So far there have been a number of techniques to measure cavitation. One of these techniques is 
high speed photography [14-17]. This technique is applicable for in vitro systems and it is 
virtually impossible to capture all the bubbles considering the range of temporal and spatial 
scales. Another limitation of this technique is the limited depth of field of the camera [18]. 
Another method of measuring cavitation is laser scattering of single bubbles. With this method, 
most of the temporal and spatial scales related to the dynamics of a cavitation bubble can be 
captured. However, this method is not able to give qualitative information about bubbles or non-
spherical bubbles considering that all forms of bubbles, spherical and non-spherical, are 
produced in clinical application of ultrasound (such as lithotripsy and high intensity focused 
ultrasound). In this technique the volume of the sample is very small and also this method needs 
unrestricted visual access at high magnification. In addition, the theory behind this method is 
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only applied to spherical shape bubbles [18]. Another method of characterizing bubble dynamics 
is acoustic detection.  A positive aspect of this method is that it can be used in vivo, however the 
size of the initial cavitation bubble and the amplitude of the ultrasound that produced the 
cavitation bubbles affect the timing and amplitude of the cavitation bubbles’ emissions.  
 
Figure 6-1 Schematic of the ABI set up at the Canadian Light Source used for imaging 
ultrasound induced cavitation bubbles in water. 
 
Detecting ultrasound cavitation bubbles in vivo and in tissue can be facilitated by Analyzer 
Based X-ray Imaging (ABI) using a synchrotron [19]. The advantage of using an X-ray 
technique is that cavitation bubble properties can be visualized even in an optically opaque 
material, such as tissue. Therefore this method can provide information about cavitation bubbles 
in vivo without having any effect of X-rays on the bubbles or vice versa.  
The operating frequency and acoustic intensity of ultrasound differs based on the clinical 
application of ultrasound. Both acoustic frequency and power of ultrasound are always 
considered as important factors in different applications of ultrasound. To improve the safety 
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level and more efficient usage of ultrasound equipment, a better understanding of the effect of 
ultrasound frequency and power on occurrence of cavitation is required. In order to study the 
effect of acoustic frequency on cavitation, a wide variety of frequencies should be investigated. 
In this pilot study cavitation bubbles were created by a sonochemistry device working at 20 kHz 
at different operating powers.  This frequency was chosen as a starting point for validating the 
synchrotron visualization methods described below because at this frequency the cavitation 
bubbles are known to form. Also this type of sonochemistry device was more portable. The 
information obtained will be used for planning the second phase of the study for visualization 
and characterization of cavitation bubbles created by clinical acoustic equipment in tissues.  
Synchrotron facilities produce X-ray radiation with high photon flux, large range of selectable 
energies, high brilliance, and monochromatic beams which makes the synchrotron a good source 
for studying cavitation bubbles. The goal of this study is to use two different synchrotron X-ray 
imaging techniques for the visualization of ultrasound induced cavitation bubbles. 
6.2.1 X-ray ABI 
X-ray ABI is a phase sensitive imaging technique with the ability to detect subtle projected 
density variations in materials such as tissue. As the X-ray travels through the object being 
imaged, it may be refracted, scattered or absorbed.  Small structures such as a bubble will refract 
the X-rays through small angles and with ABI, these small angles can create contrast based on 
the very narrow reflectivity curve of the analyzer crystal.  Thus the ABI technique is particularly 
well suited to visualize interfaces of micro scale features in soft tissues. ABI is particularly 
capable of visualizing bubbles in soft tissues.  In animal models, for example lung tissue which 
has very high ABI contrast, particularly when the analyzer is placed at the peak position.  The 
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alveoli appear as a “bubbly” structure which very effectively refracts the X-rays and thus create 
contrast. 
Detecting ultrasound cavitation bubbles in tissues can be facilitated by ABI. The bubbles will be 
of a transient nature and should provide sufficient contrast to be imaged in a time averaged 
exposure. For example, a single bubble the same size as a detector pixel typically generates 
~20% contrast compared to a region not containing a bubble. Using ABI the density of stationary 
and moving bubbles in the tissue and intravascular can be indirectly inferred by measuring the 
ultra-small angle X-ray scattering distribution in the region of images where bubbles are formed. 
However, at the top or peak location of the analyzer, there is a distinct loss of intensity due to 
scattering from the bubbles.  In addition, the ABI technique can provide real time imaging of 
stationary and moving bubble formation during the focused ultrasound treatment on animals.  
With ABI, the X-ray imaging beam is prepared by Bragg diffraction from a perfect crystal 
monochromator which is typically made with silicon crystals (see Figure 6-1).  A double crystal 
arrangement is used so that the imaging energy can be changed while the exit beam is in the 
same direction as the incident synchrotron beam.  The imaging energy is usually selected 
according to the sample’s composition, thickness and features of interest. The object is placed in 
this beam with an analyzer crystal downstream of the object before the detector.  The analyzer is 
parallel to the double crystal monochromator crystals and is of the same orientation, reflection 
and crystal type.  In this arrangement, as the analyzer is rocked in angle near the Bragg angle for 
the energy and lattice plans chosen, the intensity profile is called a rocking curve.  An example 
of the rocking curve is shown in Figure 6-2 for the imaging conditions used in this experiment.  
Note that the full-width at half maximum is less than two microradians.  Thus the analyzer 
appears to be a very narrow angular slit when located at the peak position and acts like an 
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extreme scatter rejection element.   When the X-ray beam travels through the sample being 
imaged, the X-rays are refracted at the interfaces of features or structures in the sample through 
angles of a few nanoradians to microradians. The analyzer can be adjusted over these angular 
ranges and the character of the image is greatly affected by the angular setting. The analyzer at 
the peak setting is sensitive to scatter and removes it from the image. The ABI experimental 
procedure has been described in more detail in other publications [19-21]. ABI has demonstrated 
a remarkable ability to image structures that have interfaces between materials of different 
density such as that between air and water in a bubble. The cavitation bubble will be of a 
transient nature; however, they are continuously created and may provide sufficient contrast to 
be imaged in a time averaged exposure.  
 
Figure 6-2 Calculated analyzer rocking curve for the reflection and energy used in the ABI 
experiments; Si (4,4,0) reflection @ 40keV.  Note that the rocking angle scale is in 
microradians (1microradian = 57.3 x 10
-6
 degree) 
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Figure 6-3 Schematic of the PCI set up at the Canadian Light Source used for imaging 
ultrasound induced cavitation bubbles in water. 
 
6.2.2 X-ray PCI 
X-ray in-line or propagation-based PCI is another phase based imaging technique which requires 
an X-ray source with some degree of transverse coherence.  This coherence can be achieved by 
either having a small source size and/or the source can be placed far from the object and detector 
(see Figure 6-3).  As with ABI, PCI relies on the same sources of contrast within the object, 
however, the method used is somewhat different and simpler. When the X-ray beam passes 
through the sample, changes occur in the phase of the X-ray beam. In PCI, information about the 
beam’s phase shift caused by the sample is transformed into intensity variations and is recorded 
by the detector [22]. Since the X-ray phase shift can be quite high, PCI is very sensitive to 
density changes in the sample compared to conventional transmission-based X-ray imaging. 
Even tiny structures can produce phase contrast clearer than absorption contrast. In-Line PCI 
[23] is particularly easy to apply, especially at a synchrotron.  The distance between the object 
and detector is used to ‘tune’ the amount of phase contrast from features in the object.  Larger 
separation distances give better phase contrast, however, at the expense of lower resolution.  Due 
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to its simplicity and ability to visualize microstructural details in various biological tissues, in 
this study PCI was examined for detection of cavitation bubbles. 
6.3 Materials and method 
6.3.1 Materials 
 Tap water was used as the sample in which the ultrasound induced cavitation bubbles were 
produced. The tap water was boiled and left to stand for 48 hours in advance of the experiment to 
decrease dissolved gases to avoid stationary bubble formation. 
6.3.2 Ultrasound treatment 
Sonication of tap water was performed by means of an ultrasonic processor (sonochemistry 
device), with timer and pulser (VCX-130-115V, Cole-Parmer, Montreal, QC, Canada) with the 
specification of 115 VAC, 20 kHz, 130 W, connecting a sonotrode with a flat tip diameter of 3 
mm (1⁄8") titanium probe and tip, and 116 mm length (YO-04712-12, Cole-Parmer, Montreal, 
QC, Canada). The sonicator output frequency was 20 kHz. The ultrasound processor was brought 
to CLS and the probe was mounted on the specimen stage at the experimental endstation of 
BMIT 05B1-1 beamline. The pulse mode was adjusted for continuous acoustic irradiation and 
the power output of the processor was adjusted at 100% of the maximum output. We developed 
an electronic switch that was connected to the ultrasonic processor foot switch interface and 
controlled through National Instrument data acquisition and control system. This arrangement 
allowed us to control the ultrasonic processor through LabVIEW software (National Instruments 
Corp., Austin, TX, USA), and collect long image sequences automatically with the sonicator 
turned on and off as needed in the different parts of the experimental sequence. A 250 ml cell 
culture container was used as sample holder for this experiment. The top part of the container 
was cut off using a foam cutter hot knife. Then, the rectangular sample holder, 8 cm wide, 11 cm 
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high, and 1.3 cm deep was placed on the imaging stage in such a way that the largest surface of 
the sample holder faces the imaging beam.  
The sample holder was filled with the pre-boiled tap water to a height of 8 cm. The tip of the 
sonicator probe was placed in the sample top at 3.5 cm below the surface of the water (Figure 6-
4a), which meant that the tip was about 5.5 cm above the bottom of the container. The sample 
holder was placed on the scanning stage. The sonicator probe was mounted on the scanning stage 
using a support stand, and was connected to the ultrasound generator which was placed on the 
table away from the X-ray beam. Care was taken to prevent any possible damage to the probe by 
X-ray beam during sonication; the entire probe was protected from the X-ray imaging beam with 
lead foil, while the tip of the probe was shielded with an additional piece of copper (Figure 6-
4b). A visual monitor camera was adjusted at the sample below the probe in order to monitor the 
sample and the sound jet produced in the sample during the experiment from outside of the hutch 
(Figure 6-4b). The best mounting position and spatial orientation of the ultrasound processor and 
sample holder with respect to the incident beam was identified for obtaining as much information 
as possible. The X-ray beam horizontally covered the entire width of the sample holder for 
imaging. Images were taken at different positions relative to the probe (different selected 
distances below the tip of the probe) for different field of views. Changing the experimental 
system position for different fields of views at each experimental condition was achieved from 
outside the hutch by adjusting the scanning stage. 
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Figure 6-4 Preparation of the sample for ultrasound treatment and X-ray imaging: 
(a)mounting the sonicator probe on the scanning stage and inserting sonotrode inside and 
at the center of sample/water; (b) covering the transducer and sonicator probe with lead 
shielding and copper and adjusting camera at the sample. 
6.3.3 Synchrotron imaging 
Imaging of ultrasound induced cavitation bubbles was performed at the Biomedical Imaging and 
Therapy bend magnet (BMIT-BM 05B1-1) beamline of the Canadian Light Source (CLS), 
Saskatoon, SK, Canada. A highly collimated, monochromatic, X-ray beam with maximum 
horizontal beam size of 250 mm and maximum vertical beam size of 8.0 mm produced by a bend 
magnet (1.354T). Preliminary experiments tested the utility of X-ray beams with photon energies 
of 20 and 40 keV using crystal reflections of (2,2,0) and (4,4,0), respectively. The (4,4,0) crystal 
reflection at 40 keV provided the highest contrast images and was chosen for this study. Since 
the usable vertical size of the beam depends on the photon energy, at 40 keV, the X-ray beam 
with vertical beam size of 4.0 mm and horizontal beam size of 250 mm at the sample location 
was used for imaging experiments. The size of the beam (scanned region) was 4 mm (vertical) × 
240 mm (horizontal) at the detector. Images were taken using a X-ray camera (VHR-90, 
Photonic Science, Mountfield, East Sussex, UK) with gadolinium oxysulphide scintillator layer 
having a density of 7.5 mg/cm
2
 and area of 74.9 mm × 49.9 mm (4008 × 2672 pixels) with an 
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effective pixel size of 18.5 μm.  Pixel binning of 4 × 4 was used (optical pixel size of 74 μm × 74 
μm) and the region of interest of 100 × 77 pixels (7.4 × 5.7 mm) was selected. For the second set 
of experiments in ABI imaging, the exposure time was about 2500 ms. The images were taken 
with an average ring current of 170 mA and ring energy of 2.9 GeV. 
6.3.3.1 ABI setup 
A schematic of the ABI system used for these experiments is shown in Figure 6-1. The distance 
between the sample and the X-ray source is approximately 26m and the distance between the 
double crystal monochromator and sample was approximately 13 m. The monochromator - 
analyzer used in ABI was a silicon (2,2,0) /(4,4,0) configuration. The analyzer was adjusted at 
the top of the rocking curve. The distance between the analyzer crystal and detector was 0.6 m 
and the sample was 0.7 m away from the analyzer as shown in the figure. Single image contrast: 
For the first set of experiments, images at different distances from the tip of the probe were taken 
and the contrast of each image was evaluated. With the tip of the sonicator probe placed 3.5 cm 
below the surface of the water, the selected distances (field of views) were: 1, 2, 3, 4 cm from the 
tip of the probe. One image was taken while the sonicator was off and then the sample was 
sonicated at 100% amplitude (continuous mode) and during the sonication process another image 
was taken (from the sample at each of the distances from the probe).  An earlier, dark image was 
taken with the X-ray beam off to eliminate non-beam detector response. The dark-corrected 
sonicator-on images were divided by the dark-corrected sonicator-off images in ImageJ [24], and 
then the gray value across each image area was evaluated.  
Multiple image contrast: For the second part of the experiment a large number of images in 
sequence mode were collected with the goal to improve the signal to noise ratio and to minimize 
the effects of the small drift of the analyzer crystal. For this part of study, the X-ray beam was 
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prepared by the Si (4,4,0) double crystal monochromator at 40 keV, the images were taken at the 
peak of the rocking curve and the output power of sonicator was set for 90% output power (117 
Watt). The imaging sequence contained 700 on-off cycles. In each cycle 2 images were acquired. 
First the ultrasound was turned on and an image was collected, immediately after that the 
ultrasound was turned off and after a 500 ms delay another image was collected. The time 
necessary to complete one cycle is small and both images were collected practically at same 
point of the analyzer rocking curve. Planar ABI was performed to scan the sample over the 24 
mm range below the tip of the probe of sonicator in the sample by taking 6 frames and 
incrementing the position of the scanning stage by 4 mm between each frame (at six different 
locations of 4, 8, 12, 16, 20, and 24 mm below the tip of the probe). The exposure time for each 
frame was 3.5 sec, chosen based on the intensity of the X-ray beam. On completion, all 700 
images with ultrasound on were summed and all the 700 images with ultrasound off were 
summed. Then the two resulting summed images were divided by each other using ImageJ 
software program. The intensity ratio (on divided by off) was evaluated for each image set. At 40 
KeV the total radiation exposure was approximately 1.7 Gy for the 1400 images. 
Using the same imaging procedure, ABI-based imaging studies of ultrasound induced cavitation 
bubbles at 20 kHz level of frequency were performed for seven different acoustic power levels of 
26, 39, 52, 78, 104, 117, and 130 Watts (20%, 40%, 60%, 80%, and 100% of output power) at a 
scanning position of 2 mm below the tip of the probe. The images were analyzed using the 
ImageJ computer software program.  
In addition, in order to have a view of the cross section of the beam (Figure 6-10), software of 
FileBoss (version 3) and NRecon SkyScan to produce a cross section of the cavitation bubbles 
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through the acoustic beam.  This was possible due to the near rotational symmetry of the probe 
and beam profile.  The sinogram for reconstruction used an image line replicated 2500 times. 
6.3.3.2 Phase contrast set up 
 
A schematic of the PCI system used for these experiments is shown in Figure 6-3. The procedure 
for mounting and setting the sonicator and sample on the scanning stage was the same as 
described in the ABI section (2.2.1). For the first set of images the distance between the sample 
and the X-ray source was 26 m and the distance between the sample and detector was 1.3 m.  For 
the second set of experiments, the distance between the detector and sample was increased to 6 
m which reduced the source to sample distance to 21.3 m. The PCI images were taken at both 
20.05 keV and 40 keV. For taking images, both single image and multiple image contrast 
procedures described above for ABI were tested. 
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Figure 6-5 The comparison of contrast from PCI and ABI. The PCI image shown at the top 
with the ABI just below with the same contrast scale. The plot below shows the contrast 
across the field of view for PCI and ABI. PCI shown at the top with the scale on the right 
and ABI below with the scale at the left. 
6.4 Result and discussion 
6.4.1 Phase contrast 
Ultrasound induced cavitation bubbles were not detectable beyond the image noise level either 
with a single image set or with the 700 summed image set.  A representative multiple image is 
shown at the top of Figure 6-5.  As can be seen there is no visible contrast from the acoustic 
beam.  That same figure shows a direct comparison with the ABI multiple image obtained under 
the same conditions which clearly shows contrast.  The lower section of Figure 6-5 shows a line 
plot across the image field of view showing the change in contrast observed by both methods. 
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6.4.2 ABI Images 
Cavitation bubbles were observed in the water sample during multiple image experiments. The 
processed results obtained from 700 on-off images revealed the region of cavitation bubbles at 
the center of the image in the area below the ultrasound probe. Since the signal from an 
ultrasound-induced bubble in the water was very weak (or in the other words, the signal to noise 
ratio was very low) the features of bubbles in the water were not visible in one single image. By 
taking more images and summing them, the signal to noise ratio was improved. Also by 
increasing the number of images, the number of photons in the final, averaged image is increased 
and more features of bubbles were revealed. Figure 6-6 (a) is a photograph of the ultrasound 
beam and Figure 6-6 (b) shows the scan of the whole ultrasound beam till 24 mm below the tip 
of the probe. The presence of cavitation bubbles was detected as decrease in intensity which 
appears as the dark shadow at the center of the image (Figure 6-6(b)). 
 
Figure 6-6 Ultrasound beam (a) Vertical scan of the whole ultrasound beam till 24 mm 
below the tip of the probe at 20 kHz and 90% acoustic output power (117 W) (b). 
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Figure 6-7  The line intensity profile of images taken of the cavitation bubbles at 20 kHz 
and 90% acoustic output power at different distances from the tip of the probe; 4 mm(a), 8 
mm (b), 12 mm (c), 16 mm (d), 20 mm (e), 24 mm (f). 
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Figure 6-8 ABI-based images of the cavitation bubbles at location of 4 mm below the tip of 
the probe at acoustic powers of 26 W(a), 39 W(b), 52 W(c), 78 W(d), 104 W(e), and 130 
W(f). 
As observed in Figure 6-6, the direction of the acoustic beam is not completely straight 
downward; it tended a little to the left side of the probe direction which may be a result of some 
non-uniformity on the surface of the probe. This was also visually observed (see Figure 6-6 (a)).  
The spatial structure of the ultrasonic field will strongly determine the most probable locations of 
the cavitation bubbles. The shape of the source, its dimension with respect to the wavelength of 
the ultrasound propagated in the sample and whether it is pulsed or continuous are important 
factors in controlling the beam structure in the sample. The source of ultrasound in this study 
was a circularly symmetric source of continuous sound at a single frequency and amplitude. The 
analysis of such an ultrasound beam has been well developed in the literature [25][26]. As the 
speed of sound in water is around 1480 ms
-1
, at 20 kHz, the wavelength in water and soft tissue 
is about 7.5 cm. The line intensity profile of each image at different distances from the tip of the 
probe is shown in Figure 6-7. 
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The line intensity profile of images at different distances from the tip of the probe shows that the 
intensity decreases as a result of the presence of bubbles. This decrease has the largest magnitude 
immediately below the probe (4 mm) and weakens with distance from the probe tip. This shows 
that the density of cavitation bubbles is highest close to the probe and decreases with distance 
away from the probe. In addition, the width of the dip in the graph increases with distance from 
the tip of the probe, illustrating the horizontal area in which cavitation bubbles are present. As 
seen in Figure 6-7, the width of the beam is much smaller in Figure 6-7 (a) than Figure 6-7(f) 
where the image was taken 24 mm away from the probe. From previous image (Figure 6-6) it is 
observed that the acoustic beam can be cone shaped meaning that by increasing the distance 
from the probe the width of distribution of cavitation bubbles is also increased.  This is 
confirmed by the intensity dips in the line plots across the image. 
The images of the bubbles at different levels of acoustic powers (26, 39, 52, 78, 104, 117, 130 
watt) recorded at the same location of sample (4 mm below the tip of the probe) are shown in 
Figure 6-8. It is seen that the density of bubbles decreased by decreasing the acoustic output 
power and the cavitation bubbles were not detectable beyond the noise level at and below 20% 
amplitude (26 W) of acoustic power (see Figure 6-8(a)).  
Figure 6-9 demonstrates the line intensity profile of images taken at 4 mm below the tip of the 
probe at acoustic powers of 26 W, 39 W, 52 W, 78 W, 104 W, and 130 W, showing that the drop 
in intensity due to the presence of bubbles decreases as the acoustic power is decreased. At 26 
watt level of acoustic power (20% amplitude) no intensity change is observed (Figure 6-9 (a)). 
Therefore, 26 Watt could be considered as the threshold output power level of ultrasound 
induced cavitation bubble or the threshold level of capability of ABI for detection of ultrasound 
induced cavitation bubbles at 20 kHz of frequency.  
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Figure 6-9 The line intensity profile of images taken of the cavitation bubbles at a location 
of 2 mm below the tip of the probe at acoustic powers of 26 W(a), 39 W(b), 52 W(c), 78 
W(d), 104 W(e), and 130 W(f). 
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As mentioned in section 2.3, the sonotrode was connected to a circle shape probe with a flat tip 
diameter of 3 mm.  Thus the acoustic beam should be rotationally symmetric beam.  In order to 
simulate a view of the cross section of the beam the software tools FileBoss and NRecon (Bruker 
MicroCT, formerly SkyScan, Kontich, Belgium) were used and all projections of the beam were 
replicated, constructed and presented in slice sections. As an example, slices for projections of 
the beam at locations of 4 mm (just below the beam), 8 mm, 16 mm, and 24 mm are shown in 
Figure 6-10. As observed from Figure 6-10, the diameter of the beam increases at greater 
distances from the tip of the probe.  
 
Figure 6-10 Representative axial full cross-section ABI of simulated ultrasound beam at 
different distances from the tip of the probe; (a) 4 mm (b) 8 mm. 
6.5 Conclusion 
Cavitation bubbles were successfully detected by ABI giving cloud-like contrast.   However, the 
PCI imaging technique was not able to detect the bubble as implemented on the BMIT beamline. 
ABI demonstrated the ability to detect cavitation bubbles in water, although the acquisition time 
was somewhat long. Since the flux at 40 keV on the BMIT beamline is quite low, the imaging 
time was long. However if the flux was much higher, the imaging time could be shorter and 
probably bubbles could be detectable at acoustic powers less than 26 W. Considering a very 
small size and life time of each cavitation bubble, detection of one single bubble was not 
possible (as it would need a very high speed camera), and the presence of cavitation bubbles 
were detected as a time-averaged bubble region. Using ABI the density and location of bubbles 
(b) 
(d) 
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in water was indirectly inferred by measuring the ultra-small angle X-ray scattering distribution 
in the region of images where bubbles (cavitation) were formed. At 26 Watt output power the 
cavitation bubbles were not detectable anymore as the threshold level of output power or ABI 
capability in bubble detection. This set of experiments demonstrates the utility of synchrotron 
ABI for visualizing cavitation bubbles formed in water by ultrasound, providing the first step in 
more detailed characterization of cavitation bubble formation. Future experiments will 
investigate both the visualization of cavitation at higher X-ray beam flux, additional frequencies 
and powers, and the additional challenges of visualizing bubble formation in biological tissues.    
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Chapter 7 Application of Analyzer Based X-ray Imaging technique for 
detection of ultrasound induced cavitation bubbles from a physical 
therapy unit 
“This chapter has been published as “Zahra Izadifar, George Belev, Paul Babyn, Dean Chapman, 
2015, Application of analyzer based X-ray imaging technique for detection of ultrasound 
induced cavitation bubbles from a physical therapy unit, Biomed Eng Online, 19;14:91. doi: 
10.1186/s12938-015-0085-6” According to the Copyright Agreement, “the authors retain the 
right to include the journal article, in full or in part, in a thesis or dissertation”. 
7.1 Abstract 
The observation of ultrasound generated cavitation bubbles deep in tissue is very difficult. The 
development of an imaging method capable of investigating cavitation bubbles in tissue would 
improve the efficiency and application of ultrasound in the clinic. Among the previous imaging 
modalities capable of detecting cavitation bubbles in vivo, the acoustic detection technique has 
the positive aspect of in vivo application. However the size of the initial cavitation bubble and 
the amplitude of the ultrasound that produced the cavitation bubbles, affect the timing and 
amplitude of the cavitation bubbles’ emissions. The spatial distribution of cavitation bubbles, 
driven by 0.8835 MHz therapeutic ultrasound system at output power of 14 Watt, was studied in 
water using a synchrotron x-ray imaging technique, Analyzer Based Imaging (ABI). The 
cavitation bubble distribution was investigated by repeated application of the ultrasound and 
imaging the water tank. The spatial frequency of the cavitation bubble pattern was evaluated by 
Fourier analysis. Acoustic cavitation was imaged at four different locations through the acoustic 
beam in water at a fixed power level. The pattern of cavitation bubbles in water was detected by 
synchrotron x-ray ABI. The spatial distribution of cavitation bubbles driven by the therapeutic 
ultrasound system was observed using ABI x-ray imaging technique. It was observed that the 
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cavitation bubbles appeared in a periodic pattern. The calculated distance between intervals 
revealed that the distance of frequent cavitation lines (intervals) is one-half of the acoustic wave 
length consistent with standing waves. This set of experiments demonstrates the utility of 
synchrotron ABI for visualizing cavitation bubbles formed in water by clinical ultrasound 
systems working at high frequency and output powers as low as a therapeutic system. 
 
 
 
7.2 Introduction 
One of the main interaction mechanisms that occur during the propagation of an ultrasonic wave 
through tissues is the possibility of acoustic cavitation. Cavitation is a complex phenomenon that 
involves creation, oscillation, growth and collapse of bubbles within a liquid medium to local 
pressure variation. A consequence of the cavitation process is the release of an enormous amount 
of energy in the form of an acoustic shock wave, temperature, pressure, and as visible light. 
When the acoustic cavitation bubble collapses close to or on a solid surface, it can collapse 
asymmetrically and produce high-speed jets of liquid being driving into the surface of the solid 
have been observed at speeds close to 400km/h [1]. This can seriously damage the impact zone 
and create a newly exposed surface. This fact makes cavitation one of the important mechanisms 
in shock wave lithotripsy for kidney stone destruction. Cavitation can also injure tissue during 
lithotripsy [2]. Studies [3-5] have provided indirect evidence that tissue injury response during 
shock-wave lithotripsy corresponds to cavitation. A number of studies have been attempted to 
control cavitation to obtain accelerated fragmentation while minimizing cell lysis and tissue 
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injury [2]. Furthermore, cloud cavitation (bubble cloud) which is produced during lithotripsy is 
potentially the most destructive form of cavitation[2]. It has been shown that cloud cavitation is 
more destructive to high-speed turbo-pumps and ship propellers than the individual bubbles 
collapse [2]. The effect of cavitation on tissue has made a potential non-invasive therapy 
application of ultrasound for tissue fractionation and treatment of benign disease and cancer[6, 
7].  It has been estimated that rapid adiabatic compression of gases and vapours within the 
bubbles or cavities produces hot spots with extremely high temperature and pressure approaching 
5000°C and 1000atm during this collapse. As ultrasound propagates through tissue, part of its 
energy is absorbed by tissue which is converted to heat and energetic microbubbles that can 
result in cellular destruction. Damage to red blood cells [8], lung damage in mice by pulsed 
ultrasound in the diagnosis imaging range [9], lung lesions of pig, mice, rabbits, rats, monkey 
and dogs during ultrasound [3, 10-12] [13, 14] [15, 16] [17]bring concern in ultrasonography. 
Furthermore, high intensity focused ultrasound treatment (HIFU) in which the ultrasound is 
focused into a small focal zone can damage tissue. Tissue damage occurs as a result of the very 
high temperature inside the bubbles produced, the collapse that creates a shock wave and jets, 
and also time duration of tissue exposure. The high temperature produced at the focal point 
HIFU leads to instantaneous cell death and coagulative necrosis at the focal point and with the 
margin of six to ten cells between live and dead cells at the edge [18]. Since the onset of 
cavitation and the resulting tissue damage is not predictable, high acoustic intensity is generally 
avoided in clinic, however cavitation is under investigation to be used as a means to enhance 
HIFU ablation. Another application of cavitation is in a relatively new field of medical therapy 
[19, 20] in which cavitation in HIFU is used for drug delivery in selectively permeable regions of 
tissue [21, 22]. Direct evidence of cavitation bubbles within the tissue is crucial for further 
 231 
 
 
development and refinement of such applications. In HIFU, gas generation, caused by cavitation, 
abruptly changes the pattern of heat transfer induced by ultrasound, which results in the 
extension of lesion from targeted area to surrounding healthy tissues [23].  The lack of cavitation 
bubble field probes is one of the reasons that limit the clinical development of cavitation. 
Consequently, it is essential to conduct a fundamental study for cavitation detection and cloud 
cavitation control to improve the safety and application of ultrasound therapy (such as lithotripsy 
and HIFU) and possibly for ultrasonography which is pervasively used for neonatal imaging.  
The variation in bubble characteristics inside the cavitation field is one of the causes that make 
the study of cavitation characteristics so complex [24]. Once the cavitation bubbles are 
generated, they may undergo nonlinear oscillations during many cycles of the acoustic wave, 
called “stable cavitation”, or they may grow and collapse more or less violently,  called “inertial 
cavitation”[24]. The cavitation state induced in liquid is seldom studied in most experiments. It is 
important to develop monitoring methods to correlate the cavitation state induced in a liquid to 
the biological effects observed. Since visualization of cavitation bubble field has been quite 
complex, workers have used some other indirect observations of macroscopic criteria to describe 
the induced cavitation state in a liquid[24]. However, the easiest way to study cavitation is the 
direct observation of the bubble field. In addition, to study the cavitation field in the body, a 
technique that enables detection of cavitation bubbles in tissue is required. 
So far there have been a number of techniques for direct observation of the bubble field such as 
high speed photography [25-27] [28], laser scattering of single bubbles, and acoustic detection of 
bubbles [29]. The high speed photography techniques are only applicable in in-vitro systems and 
it is virtually impossible to capture all the bubbles considering the range of temporal and spatial 
scales. This technique has a very limited depth of field due to the camera [30], and in addition, 
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the sound wave that produces the cavitation induces an acoustic-optic effect [24]. Also, the 
presence of collapsing bubbles can be inferred from second harmonic generation [29].  With 
laser scattering method, most of the temporal and spatial scales related to the dynamics of a 
cavitation bubble can be captured; however this method is not able to give qualitative 
information about bubbles or non-spherical bubbles.  In addition, the theory behind this method 
is only applied to spherical shape bubbles considering that all forms of bubbles, spherical and 
non-spherical, are produced in clinical application of ultrasound [30]. In this technique the 
volume of the sample is very small and unrestricted visual access at high magnification is 
required[30]. The acoustic detection technique has the positive aspect of in vivo application, 
however the size of the initial cavitation bubble and the amplitude of the ultrasound that 
produced the cavitation bubbles, affect the timing and amplitude of the cavitation bubbles’ 
emissions.  
Analyzer-based X-ray imaging (ABI) [31]has the potential to detect and visualize ultrasound 
cavitation bubbles in thick, optically opaque materials such as in vivo tissue relying on the high 
penetration of X-rays and a sensitivity to small angle refraction.  As such, ABI can visualize and 
characterize properties of the cavitation bubbles in vivo without having any influence on the 
bubbles or vice versa. 
The present authors have used ABI for visualizing cavitation bubbles from a high intensity 
sonochemistry system [32].  In that work, the operating conditions are well beyond that used for 
any physical therapy or imaging application (130 W and 20 kHz).  The system relies on 
generating cavitation bubbles for cell disruption.  The present chapter addresses cavitation 
bubble formation in a type of ultrasound system commonly used for physical therapy 
applications (14 W and 0.88 MHz) where one might not expect to observe cavitation bubbles.  
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Again, the use of an X-ray method can allow observation of cavitation in opaque systems 
without interacting with the cavitation process. 
7.2.1 X-ray ABI 
X-ray ABI is a phase sensitive imaging technique that can detect subtle projected density and 
thickness variations in materials such as tissue. As a collimated X-ray beam travels through the 
object being imaged, it may be refracted, scattered or absorbed.  Small structures such as a 
bubble in tissue or water will refract the X-rays through very small angles. With ABI, these small 
angles can create contrast based on the very narrow reflectivity curve of the analyzer crystal 
placed after the object.  Thus the ABI technique is particularly well suited to visualize interfaces 
between features within soft tissues such as bubbles.  This leads to very high contrast for some 
tissues such as lung particularly when the analyzer is placed at the peak position.  The alveoli 
appear as a “bubbly” structure which very effectively refracts the X-rays and thus create contrast.  
The effect of multiple refraction events by several alveolar interfaces creates a scatter 
distribution (ultra-small angle X-ray scattering) of the X-rays which effectively removes X-rays 
from their original collimated trajectory.  This scatter distribution can be very effectively 
interrogated by the analyzer crystal. 
Detecting ultrasound cavitation bubbles in tissues can be simplified by ABI. The bubbles will be 
of a transient nature and should provide enough contrast to be imaged in a time averaged 
exposure. For example, a single air bubble the same size as a detector pixel can generate ~20% 
contrast compared to a region not containing a bubble. Applying ABI the density of stationary 
and moving bubbles in the tissue and intravascular can be indirectly inferred by measuring the 
ultra-small angle X-ray scattering distribution in the zone of images where bubbles are formed. 
However, at the top or peak spot of the analyzer, there is a recognizable loss of intensity due to 
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scattering from the bubbles.  With ABI, the X-ray imaging beam is prepared, or collimated, by 
Bragg diffraction from a perfect crystal monochromator which is typically made with silicon 
crystals (seeFigure 7-1).  A double crystal arrangement is applied so that the imaging energy can 
be varied while the exit beam is in the same direction as the incident synchrotron beam.  The 
imaging energy is usually selected based on the sample’s composition, thickness and features of 
interest. The object is located in the beam with an analyzer crystal downstream of the object 
before the detector.  The analyzer is parallel to the double monochromator crystals and is of the 
same direction, reflection and crystal type.  In this arrangement, as the analyzer is locked in 
angle near the Bragg angle for the energy and lattice plans selected, the intensity profile is called 
a rocking curve.  When the X-ray beam passes through the sample being imaged, the X-rays are 
refracted at the interfaces of features or structures in the sample through angles of a few 
nanoradians to microradians. The analyzer can be adjusted over these angular ranges and the 
character of the image is greatly affected by the angular setting. The analyzer at the peak setting 
is sensitive to X-rays redirected in angle such as scatter and removes it from the image. The ABI 
experimental procedure is explained in more detail in other publications [31] [33, 34]. ABI has 
demonstrated a noticeable ability to image structures that have interfaces between materials of 
various density such as that between air and water in a bubble. The cavitation bubble will be of a 
transient nature; however, they are continuously created and may provide enough contrast to be 
imaged in a time averaged exposure.  
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Figure 7-1 Schematic of the ABI set up performed for imaging therapeutic ultrasound 
induced cavitation bubbles in water at Canadian Light Source. 
7.3 Materials and method 
7.3.1 Materials 
Tap water was used as the sample to produce ultrasound induced cavitation bubbles in it. The tap 
water was pre-boiled and let stand for 48 hours in advance the experiment. 
7.3.2 Ultrasound treatment 
Sonication of water was performed by means of a therapeutic ultrasound device (Burdick 
ultrasound therapy unit model UT-420A), with specifications of 0.8835 MHz, 3.5 W/cm
2
, 14 W, 
connecting a probe with size of 13 cm
2
.  The ultrasound therapy unit was brought to the 
Biomedical Imaging and Therapy (BMIT) bend magnet beamline (BM 05B1-1) of the Canadian 
Light Source (CLS), Saskatoon, SK, Canada. A tissue culture flask (300 cm
2
, 1900 ml) was used 
as sample holder for this experiment. The top part of the flask was cut off by a foam cutter hot 
knife. Then the sample holder was placed on the imaging stage in such a way that the largest 
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surface of the flask faces the imaging beam. The probe was mounted on the specimen stage at the 
experimental endstation of BMIT beamline using a support stand. The sample holder was filled 
with pre-boiled tap water (to a height of 100 mm) and the probe was placed in the water top at 
2.7 cm below the surface of the water with a 60 degree angle (Figure 7-2(a)). The probe was 
connected to the signal generator/amplifier that was placed on the table away from the X-ray 
beam (Figure 7-2(b)). The pulse mode was adjusted for continuous acoustic irradiation and the 
power output of the processor was adjusted at the maximum output. An electronic switch that 
was connected to the ultrasonic processor foot switch interface was developed and controlled 
through National Instrument data acquisition and control system. This arrangement allowed the 
control of the ultrasonic processor through LabVIEW software (National Instruments Corp., 
Austin, TX, USA), and collect long image sequences automatically with the sonicator turned on 
and off as needed in the different parts of the experimental sequence. Two visual monitor 
cameras were adjusted at the sample and at the generator in order to ensure the synchronize 
operation of the probe and generator along with the Lab VIEW software during image sequence 
collection. The best mounting position and spatial orientation of the ultrasound and sample 
holder with respect to the incident beam was identified so that the X-ray beam horizontally 
covered the entire width of the sample holder for imaging. Images were taken at four different 
positions. The experimental system position for various fields of views at each experimental 
condition was changed by adjusting the scanning stage.  
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Figure 7-2 Preparation of the sample for therapeutic ultrasound treatment and X-ray 
imaging: (a) mounting the ultrasound probe on the scanning stage and inserting probe 
inside and at 45 degree angle of sample/water; (b) setting the signal generator/amplifier on 
the table and setting the experimental system. 
7.3.3 Synchrotron imaging 
Imaging of therapeutic ultrasound induced cavitation bubbles was performed at the CLS 
synchrotron source (BMIT-BM 05B1-1). A highly collimated, monochromatic, X-ray beam with 
maximum horizontal beam size of 250 mm and maximum vertical beam size of 8.0 mm 
produced by a bend magnet (1.354T) was used for imaging. The X-ray beam with photon energy 
of 40 keV was prepared by the double crystal monochromator reflection of Si (4,4,0) to provide 
high contrast images. Depending on the chosen photon energy, the X-ray beam with vertical 
beam size of 4.0 mm and horizontal beam size of 250 mm at the sample location and the detector 
was applied for imaging experiments. Images were collected by an X-ray camera (VHR-90, 
Photonic Science, Mountfield, East Sussex, UK) with gadolinium oxysulphide scintillator layer 
having a projected density of 7.5 mg/cm
2
 and area of 74.9 mm × 49.9 mm (4008 × 2672 pixels) 
with an effective pixel size of 18.5 μm. Pixel binning of 4 × 4 was applied (optical pixel size of 
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74 μm × 74 μm) and the region of interest of 100 × 77 pixels (7.4 × 5.7 mm) was selected. Planar 
ABI was performed for imaging of therapeutic ultrasound induced cavitation bubbles in this 
study. A schematic of the ABI system applied is shown in Figure 7-2. The distance between the 
sample and the X-ray source was about 26m and the distance between the double crystal 
monochromator and sample was approximately 13.5 m. The monochromator - analyzer used in 
ABI was a silicon (4,4,0) configuration. The analyzer was adjusted very close to the top of the 
rocking curve. The distance between the analyzer crystal and detector was 0.6 m, and the 
distance between the sample and the analyzer was 0.7 m as demonstrated in the Figure 7-1. 
Multiple image contrast technique was used for collection of images at each distance from the tip 
of the probe. In this technique a large number of images in sequence mode were collected to 
improve the signal to noise ratio and to minimize the effects of the small drift of the analyzer 
crystal. The imaging sequence contained 7000 on-off cycles. In each cycle 2 images were 
captured. First an image was collected when the ultrasound was turned on, immediately after that 
the ultrasound was turned off and after a 500 ms delay another image was collected. The time 
necessary to complete one cycle is small and both images were collected practically at same 
point of the analyzer rocking curve. More details on this method of imaging can be found of the 
previous work of authors [32]. When the ultrasound was on, the output power of sonicator was 
set for 14 Watt. The sample area of 17.75 to 31.75 mm below the lowest point of the tip of the 
probe in the sample was imaged. The sample over 14 mm range was scanned by taking 4 frames 
and incrementing the position of the scanning stage by 3.5 mm between each frame (at four 
different locations of 19.5, 23, 26.5, and 30 mm below the tip of the probe). The exposure time 
for each frame was 2.5 sec, selected based on the intensity of the X-ray beam. In total 7000 
images with ultrasound on and 7000 images with ultrasound off were acquired. Then the two 
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resulting summed image sets were divided by each other. The initial results were calculated and 
analyzed by ImageJ software program. Then, a dedicated program was written in Interactive data 
language (IDL) software program (Exelis Visual Information Solution, Inc., Boulder, Colorado, 
USA) and the final results were analyzed. The intensity ratio (on divided by off) was evaluated 
for each image set. At 40 keV the total radiation exposure was about 17 Gy for the 14000 
images.  
7.4 Result and discussion 
7.4.1 Preliminary experiments 
Preliminary experiments were performed by means of a therapeutic ultrasound system (Intelect 
advanced, Chattanooga group, a division of encore medical, L.P. 2005) with the specification of 
0.8835 MHz, Duty cycle 100%, 1 W/cm
2
, 4 Watt, Duty frequency 100 Hz, treatment time of 60 
min, and probe size of 5 cm
2
. During preliminary experiments it was observed that at two 
specific points of the sample holder, at the wall close to the probe (Figure 7-3(b)), and also at the 
bottom center of sample holder (Figure 7-3(c)), the sample holder was melting. This means that 
the transducer field was consistently energetically non-uniform with some spatial ‘hot-spots’ 
occurring during the application which lead to burning points (Figure 7-3(a)). These non-
uniformities in the acoustic field, simultaneously with the high time-averaged intensities 
produced, can cause patient burns (Advisory group on non-ionising radiation 2010). This issue 
has become the issuing of a recent safety in Scotland [35]. 
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Figure 7-3 The experimental set up of the preliminary experiments and the observation of 
the sample container melting (a) the melted sign of container on the wall (b) and at the 
center bottom of the container (c) 
7.4.2 Main experiments 
Ultrasound induced cavitation bubbles produced by the therapeutic system (physical therapy 
device with unfocused beam) were detected during multiple image ABI experiments. The 
processed results from the 7000 on-off images, showed the region of cavitation bubbles in the 
area below the probe, with 60 degree angle from the water surface along the direction of 
ultrasound probe. The scan of the ultrasound beam in the area between 17.75 to 31.75 mm below 
the surface of the probe is shown in Figure 7-4 (a). The presence of cavitation bubbles was 
detected as loss of intensity that appears as the dark shadow in the area below the ultrasound 
probe, with a 60 degree angle at the center of the image (Figure 7-4(a)). The spatial structure of 
the ultrasonic field can determine the most probable location of the cavitation bubbles.  The 
spatial structure of the beam can be controlled by factors such as the shape and dimension of the 
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source with respect to the wavelength of the ultrasound propagated in the sample, and also the 
pulsed or continuous mode of sound propagation in sample.  In this study the shape of the probe 
was a circularly symmetric source and the ultrasound was propagated in the sample in a 
continuous mode at a single frequency and amplitude. The analysis of such ultrasound beams has 
been well studied in the literature [36, 37]. As the speed of sound in water is around 1480 ms
-1
, at 
frequency of 0.8835 MHz, the wavelength in water and soft tissue is approximately 1.675 mm in 
which the wavelength was calculated as follow: 
λ=c/f           (1) 
where λ is the wavelength in mm, c is the velocity of sound in mm/s, and f is the frequency in 
Hz. Based on a previous study performed by the authors, the current multiple imaging technique 
was established for visualization of ultrasound induced cavitation bubbles [32]. The signal to 
noise ratio from a single ultrasound –induced cavitation bubble is very weak. The features of 
cavitation bubbles in water are not revealed by a single ABI image and the signal to noise ratio is 
improved by taking more images and summing them. The number of photons in the final, 
averaged image is raised by increasing the number of images and as a result more features of 
bubbles are revealed due to the increased signal-to-noise.  
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Figure 7-4 Vertical scan of the whole ultrasound beam of a therapeutic ultrasound system 
below the tip of the probe at 0.8835 MHz and 14 W (a) the sequence form of cavitation 
bubbles’ location with approximately same intervals between sequences 
As shown in Figure 7-4(b), it was observed that the cavitation bubbles appeared in a periodic 
pattern. The most likely reason for this spatial structure can be the production of a standing wave 
in the sample. In case the pattern in Figure 7-4 is the formation of an acoustic standing wave 
field due to trapped cavitation induced bubbles, then the standing wave patterns should be one-
half of the wave length. To investigate this, the distance between the two consecutive parallel 
lines of the pattern in Figure 7-4(b) was measured as 0.99 mm.  The periodicity can also be 
obtained from Fourier analysis (Figure 7-5(b)) and was found to be 1.15 line-pairs (lp) per mm. 
Figure 7-5(b) is a spatial power spectrum of the acoustic field region shown in Figure 7-5a and 
the bright regions indicate spatial periodicities of higher amplitude.  Note the somewhat dual 
circular appearance of the power spectrum which indicates there are multiple directions which 
describe the acoustic pattern.  We have selected the component that corresponds to the pattern 
most prominent in Figure 7-5a and 4b. This is the reciprocal of the periodicity distance and leads 
to a spatial periodicity of 0.870 mm.  Therefore, the distance between the two consecutive 
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parallel lines of the pattern is 0.99 mm from Figure 7-4b and the Fourier analysis giving 0.870 
mm is close to the theoretically calculated value of 0.838 mm meaning that the assumption of 
having acoustic standing wave and also the first harmonic can be correct. However, it should be 
noted that the geometry of the container did not support the formation of the standing wave 
completely; there was no surface perpendicular to the acoustic wave (or surface parallel to the 
probe surface).  The pattern of Figure 7-4 indicates that an acoustic standing wave was formed in 
the container at applied therapeutic ultrasound frequency, and the generated cavitation bubbles 
were trapped at the nodes or anti-nodes of the acoustic standing wave field, and form the 
temporary stationary bubbles.  The fact that the container surfaces were not parallel to the probe 
surface may give rise to a complex standing wave pattern as indicated by the Fourier power 
spectrum (Figure 7-5(b)) where there appear to be several standing waves which in that Figure 
which form a somewhat circular pattern. The stationary bubbles dance/vibrate at their zone and 
act as sound scatterers [38]. These bubbles finally collapse as the ultrasound goes through off 
cycle. Although the vibration of bubbles causes the scattered acoustic energy to modulate the 
exciting carrier signal, the constant generation of these bubbles at same locations and their 
collapse afterward can release energy and possibly cause damage.   
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Figure 7-5 The region selected from Figure 7-4(a) for Fourier analysis (a) The power 
spectrum obtained from Figure 7-4(a). The black line shows the wave vector associated 
with the strongest Fourier component whose magnitude is approximately 1.15 line-
pairs/mm (b). 
The line intensity profile of images at different imaging distances from the tip of the probe is 
shown in Figure 7-6. The line intensity profile of each image obtained from the average of 31 
image lines about the center of each image. The intensity profiles demonstrate that the intensity 
loss as a result of the presence of bubbles. This loss has the highest magnitude at the closest 
distance to the probe (19.5 mm below tip) and weakens with distance from the probe tip. This 
demonstrates that the density of cavitation bubbles is higher close to the probe and declines with 
distance away from the probe. In addition the width of the dip in the graph rises with distance 
from the tip of the probe, showing the horizontal area in which cavitation bubbles are present. As 
shown in Figure 7-6, the width of the beam is much smaller at 19.5 mm (Figure 7-6(a)) than 30 
mm (Figure 7-6(d)) away from the tip of the probe. It is observed from Figure 7-5 that the 
acoustic beam can be cone shaped meaning that the width of distribution of cavitation bubbles 
increases by increasing the distance from the probe. The width of the intensity dips in the line 
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plots across the image in Figure 7-6 confirms the rise in width of cavitation bubbles’ distribution 
in the sample with distance from the probe. 
 
Figure 7-6 The intensity profile of images taken of the cavitation bubbles at different 
distances from the tip of the probe; 19.5 mm(a), 23 mm(b), 26.5 mm(c), 30 mm(d). 
7.5 Conclusion 
The pattern of cavitation bubbles in water driven by a 0.8835 MHz therapeutic ultrasound system 
at 14 watt output power was detected by synchrotron X-ray ABI. Since the flux of X-ray at 40 
keV on the BMIT beamline is quite low, the imaging time was long. Although the acquisition 
time was somewhat long, the pattern of induced cavitation bubbles was revealed. The cavitation 
bubbles’ pattern was observed in repetitive lines. The calculated distance between intervals 
revealed that the distance of frequent cavitation lines (intervals) is one-half of the acoustic wave 
length consistent with standing waves. The presence of bubbles was observed as a time-averaged 
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bubble region. The density and location of bubbles were inferred indirectly by measuring the 
ultra-small angle X-ray scattering distribution in the region of images where bubbles (cavitation) 
were formed. This set of experiments demonstrates the utility of synchrotron ABI for visualizing 
cavitation bubbles formed in water by a clinical ultrasound system working at high frequency 
and output power as low as a therapeutic system. This can be the first step toward more detailed 
characterization of cavitation bubbles formation in other clinical acoustic systems such as HIFU 
and lithotripsy.  
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Chapter 8 Conclusion and future research 
8.1 Conclusion 
The interaction between ultrasound and tissue can potentially affect cells due to ultrasound-
induced thermal and mechanical bioeffects that occurs in the beam pathway. These bioeffects 
should be prevented or minimized during ultrasound diagnosis but can be effectively used for 
therapeutic purposes (e.g. focused ultrasound lithotripsy), if precisely controlled. The ultrasound-
induced thermal and mechanical effects take place simultaneously as a result of ultrasound 
energy deposition in the tissue; as such, it would be very difficult to differentiate between these 
effects. Cavitation is a process which is recognized as a major cause of ultrasound-induced 
mechanical and thermal effects, and can be accentuated by the presence of ultrasound contrast 
agents in the tissue. It is clear from the evidence reviewed in chapter 2.3 of this thesis that 
cavitation can have hazardous bioeffects on the tissue under ultrasound therapy or imaging if not 
controlled. 
One step toward improving the outcomes and safety of ultrasound diagnostic and therapeutic 
applications is to have a better understanding of cavitation bubble formation during the imaging 
or therapeutic procedures. A better insight into the ultrasound-induced cavitation process will 
eventually help with the determination of safe levels of acoustic intensity and frequency, 
duration of ultrasound exposure, and frequency of ultrasound session.  One challenge is to 
visualize the cavitation bubbles in physiologically relevant media for mapping the cavitation 
bubble formation patterns under diagnosis or therapeutic ultrasound conditions without contrast 
agents. This study was a step forward to use synchrotron X-ray for visualization of cavitation 
bubble formation patterns in a physiologically relevant medium (e.g. water, saline) without 
contrast agent under clinical diagnostic/therapeutic ultrasound conditions. 
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First, this study aimed to exploit the interaction between a cavitation bubble and synchrotron-
based X-ray to examine the suitability of synchrotron X-ray for visualizing ultrasound-induced 
cavitation bubbles. In the second part of this study, we examined phase-sensitive imaging 
modalities, DEI, ABI and PCI, for mapping the ultrasound-induced cavitation bubble formation 
patterns in water. A comparison between the aforementioned imaging methods led us to identify 
the most suitable synchrotron imaging technique as a protocol for investigating cavitation bubble 
formation for the rest of our study. Although studies have shown that PCI can be an effective 
imaging method for visualization of soft tissues, PCI was unable to visualize the ultrasound-
induced cavitation bubble formation patterns as implemented in BMIT beamline in our study. In 
contrast, the ABI showed promises for visualization of cavitation bubbles as well as their 
formation patterns in water. Water was used as a representative for very soft tissues such as 
embryo and its surrounding fluid.  Using the ABI approach, the density and location of bubbles 
were inferred indirectly by measuring the ultra-small angle X-ray scattering distribution in the 
region of images where cavitation bubbles were formed. Therefore, utilization of the synchrotron 
X-ray ABI in BMIT at CLS for visualizing ultrasound-induced cavitation bubble formation in 
water provided a foundation for further studies to characterize cavitation bubble formation 
patterns.  
As inspired, we applied the developed ABI to map the ultrasound cavitation bubble formation 
patterns induced by different ultrasound devices with emphasis on clinical ultrasound devices 
operating at various ultrasound frequencies and amplitudes. Also, ABI was used to identify the 
cavitation threshold associated with the ultrasound beam propagation in water. Cavitation bubble 
formation patterns were successfully mapped using ABI at X-ray energy of 40 keV for two 
different ultrasound devices including a clinical ultrasound system. The low X-ray photon flux 
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corresponding to X-ray energy of 40 keV required a longer acquisition time for a higher signal to 
noise ratio, leading to success in mapping the cavitation bubble formation patterns at therapeutic 
output powers. One limitation of this study was the low X-ray photon flux corresponding to X-
ray energy of 40 keV at the BMIT bending magnet beamline. Considering that the ultrasound-
induced cavitation bubbles are very small and their life time is very short, the detection of an 
individual cavitation bubble essentially requires a high X-ray photon flux and very high speed X-
ray camera. To overcome these limitations in our study, we used a local time-averaging approach 
based on which the probability of local cavitation bubble formation within a fixed window 
corresponding to the ultrasound beam propagation in the sample was determined from multiple 
X-ray images as described in chapters 6 and 7. This approach shows promises for detecting 
cavitation bubble formation patterns in water. Besides, the exposure time can be effectively 
lowered if the photon flux can be improved by using wiggler rather than bending magnet or a 
higher storage ring energy synchrotron. If the flux was much higher the imaging time could be 
shortened and bubbles probably would be detected at lower acoustic powers than what was 
measured in this study. As the higher ultrasound frequency and lower ultrasound output power 
were applied, the required imaging acquisition time dramatically increased. As demonstrated in 
chapters 6 and 7 the initial hypothesis of the thesis regarding the capability of synchrotron based 
phase based X-ray imaging techniques for visualization of ultrasound induced cavitation bubbles 
was confirmed correct with ABI but not with PCI. ABI could successfully visualize ultrasound 
induced cavitation bubbles and provide an overall distribution pattern and location of cavitation 
bubbles in water sample.  
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8.2 Recommendation for future work 
Results from this study indicate that ABI shows promise for visualization and detection of 
ultrasound-induced cavitation bubble formation patterns in water. Before ABI technique can be 
applied to biological tissue and animal/human for cavitation bubble formation mapping, further 
studies are needed in vivo. In our studies, water was used as a physiologically relevant medium 
to assess the ability of ABI for mapping cavitation bubble formation patterns, but we do not 
exactly know how these results may relate to cavitation bubble occurrence in biological tissue, 
animal/human. Thus, animal studies will be required to assess the capability of ABI towards 
possible applications in human studies.  
Cavitation thresholds and related safety considerations are usually determined experimentally 
through different detection techniques in water. Although water can be a good representative for 
human soft tissues, it may not reflect the real characteristics of human body. For example, X-ray 
attenuation and refractive index of water may not exactly represent those of most tissues in the 
body. Furthermore, the reflection of ultrasound waves corresponding to interfacial 
microstructural features of soft tissues, which possess different acoustic properties, can generate 
standing waves leading to more likelihood of cavitation bubble formation. The absence of 
organelles and their related interfacial features in water limits our ability to acquire the 
corresponding information attributed to ultrasound cavitation bubble formation. On the other 
hand, animal studies bring the concern that lies with scaling. Animal testing in small animals 
such as mice or rabbit can involve whole body exposure, whereas in the human only a small 
proportion of the total volume is exposed. The absence of human studies leaves us to pose the 
concern of potential bioeffects from ultrasound.  
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The acquisition time was somewhat long in our experiments that make it challenging for future 
tissue and animal studies. Acquisition time may be improved by optimizing the imaging method. 
The imaging method given in this study needs to be modified to achieve similar results with less 
acquisition time. From a diagnostic safety point of view, the lack of detectable contrast of 
cavitation bubbles in water at diagnostic ultrasound power and frequency may not rule out the 
cavitation bubble occurrence; however, it may only imply that the photon flux and the speed of 
the X-ray detector may have been insufficient to visualize the cavitation bubble formation. In 
terms of the safety level of ultrasound devices, one problem is how to rule out possible collateral 
effects which may have resulted from cavitation occurrence.  A null finding doesn’t necessarily 
mean that no effect exists because the null finding may be due to the insufficiently sensitive 
assay with respect to the detection of the cavitation bubbles. As such, further studies are 
recommended to refine the imaging parameters of the proposed imaging technique in this thesis 
for the detection of cavitation bubbles, if they exist, at corresponding low power and frequency 
diagnostic ultrasound exposure.  
To lower the threshold of energy needed for visualization of cavitation bubbles, the accuracy of 
the threshold determination is critically dependent on the sensitivity of the detection system. 
Although ABI is a very sensitive method for the detection of bubbles, its performance relies on 
X-ray photon flux. The detection of small cavitation bubbles corresponding to low output powers 
and high frequency of diagnostic ultrasound requires higher X-ray flux. The benefits of 
diagnostic ultrasound currently outweigh the known risks. However, continued research is 
required to confirm or refute the potential risks of diagnostic ultrasonography. For future 
research, it is also recommended to perform the experiments in a higher storage ring energy 
synchrotron which can provide higher photon flux to enable us to eventually develop a protocol 
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for safety assessment of diagnostic ultrasound using ABI method. The refinement of the ABI 
technique should not be limited to diagnostic ultrasound but be implemented to assess and 
characterize cavitation bubble formation in other clinical acoustic systems such as HIFU and 
lithotripsy.  
 
 
 
 
 
 
